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Predictors of joint disease and outcome of arthroplasty 
from patient perspective to molecular profiling. 
The average life expectancy is increasing, and it is predicted that by 2045 over 30% 
of the population in the Western World will be aged over 60 years of age. With older 
age, health deteriorates and the prevalence of most chronic diseases increases, 
however, the extend of these diseases varies between men and women.1 Loss of 
independency at higher age is most often due to problems of the musculoskeletal 
system (MSK). Out of all rheumatic diseases, osteoarthritis (OA) is the most frequent 
cause of these MSK problems, which may cause severe disability of patients. OA is 
the most prevalent chronic joint disorder worldwide, affecting the joints of hip, knee, 
hands, spine and feet and is strongly influenced by metabolic health and age.2-4 
In short, OA is characterized by deterioration of the cartilage of the joint and leads to 
narrowing of the joint space until the presence of bare bone on bone contact and the 
formation of osteophytes.5 Of the 291 conditions studied in the Global Burden of 
Disease study, OA ranks as the 11th highest contributor to global disability and has 
been found to be the leading source of morbidity (i.e. pain and functional disability) 
in industrialized countries.6,7 Incidence and prevalence vary widely depending upon 
the used definition and sampled population.8,9 Knee OA is more prevalent than hip 
OA with an estimated global prevalence of radiographically confirmed knee OA of 
3.8% (95%CI: 3.6-4.1), while for hip OA this was 0.85% (95%CI: 0.74-1.02%).10,11 In 
the Netherlands, the average prevalence of osteoarthritis is 5.7% in males and 
10.4% in females, affecting more often the knee than the hip.12   
In 2007, the health care costs of joint related diseases in the Netherlands, including 
osteoarthritis, were estimated at 2.1 billion euro, 3.6% of the national medical costs.13 
By 2015, the total direct costs attributable to osteoarthritis alone were 1.3 billion euro, 
which was 1.6% of the total healthcare costs for the Netherlands in 2015.14 Thus, 
adequate treatment and the adequate selection of patients to undergo treatment is 
paramount to keep public healthcare affordable in the near future. 
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Efficient treatment is hampered by the heterogeneity of this disease; the 
disassociation of radiographic and clinical symptoms makes the diagnosis a 
container of diverse pathological processes. Currently, no cure exists to halt the 
progression of osteoarthritis and treatment consists of pain relief and minimizing the 
impact on functioning in daily life.  
Patients will start with pain medication such as analgesics, intra articular steroids 
and/or intra articular hyaluronic in order to relieve their symptoms.15-18 As these 
medications only affect the symptoms of OA, they do not slow down the progression 
of the disease. When the symptoms have become too severe and pain medication 
is not sufficient anymore, arthroplasty will be performed. Arthroplasty is a major 
invasive surgery during which the joint is replaced by an implant.  
 
In the Netherlands, 29,937 total hip arthroplasty (THA) and 29,221 total joint 
arthroplasty (TKA) surgeries were performed in 2017.19 The procedure is very safe 
and effective with a mean survival rate of a hip or knee prosthesis of 95% at 15 years 
after surgery.20-24 Despite these excellent results with respect to revision of the knee 
or hip prostheses, patients perceived satisfaction varies. While some patients are 
very satisfied (mean 83 points out of 100 on a visual analog scale), a large group 
(up to 20%) is not satisfied with their surgery.25-28 
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Postsurgery factors associated with outcome of joint arthroplasty: prosthesis 
and physical activity. 
Reasons for this large portion of less favorable outcomes are multifactorial and can 
be related to surgical factors (i.e. surgical technique), joint status (i.e. deformity or 
degree of osteoarthritis) but also patient factors, like preoperative patient 
expectations, patient selection and baseline health status. The latter will also be 
associated with the metabolic state of the patient, thus determining recovery and 
rehabilitation after a surgical intervention, like a total joint arthroplasty, which has a 
tremendous impact on a patient. Next to this, other preoperative factors related to 
metabolic health, affecting muscle function (i.e. mitochondrial function) will also have 
an effect on postoperative recovery and thus rehabilitation after a major surgical 
procedure. 
This is underscored even more, since the majority of the patients who have total joint 
arthroplasty at the age of about 70 years have one or more comorbidities, resulting 
in higher perioperative risks with concomitant less favourable outcome of TJA 
surgery. Finally, outcome after TJR can be affected by the total joint arthroplasty 
itself, which is related to foreign body reactions to wear debris produced by the 
artificial new joint. In this thesis, we assess three main factors that are related with 
the outcome; (I) the implant, (II) physical activity and (III) baseline health of the 
patient. 
I Bearings of prostheses (implants).  
Many designs and types of hip and knee prostheses are available, not only with 
different shapes but also with different types of bearings. One of these bearings is a 
metal-on-metal bearing used in total hip replacement, with the idea that it is more 
durable (i.e. less wear) than a metal on polyethylene bearing. Since metal-on-metal 
(MOM) bearings produce metal wear debris, causing both local and systemic 
adverse effects (e.g. nephrotoxicity or cardiotoxicity), these implants are no  to be 
used.29 However, since these MOM hip prostheses are still in place thousands of 
patients, a discussion on long-term effects of these implants on patients is important. 
 
5 
II Postoperative physical activity  
One of the main hallmarks of successful total joint arthroplasty is its actual use, as 
is reflected by the level of physical activity (PA) of the patients. Postoperative 
rehabilitation is essential to have an optimal postoperative result since both muscle 
strength as well as range of motion of the joint after the arthroplasty will affect PA.30 
The literature on PA after arthroplasty up to now is conflicting and an age-matched 
comparison with the general population of postoperative PA is lacking.  
 
III  Baseline health of the patient  
Since OA is prevalent especially among elderly patients, their preoperative baseline 
health varies considerably. The heterogeneity in baseline health status can be 
measured in many different ways.31 Here we discuss to what extent the baseline 
frailty index, a standardized measurement of handgrip strength or molecular profiling 
associate with the outcome.    
 
Baseline health factors associated with outcome of joint arthroplasty: 
frailty index, handgrip strength & molecular profiling.  
III A  Frailty 
In the Netherlands, up to 83% of the THA patients and 79% of TKA patients are 60 
years and older.19 As frailty is highly prevalent in the elderly, with a prevalence of 
10.7% in this age group, it is likely that a considerable proportion of patients 
undergoing THA or TKA are frail.32 This may have an effect on recovery after a TJA 
and thus the functional outcome after such an intervention.  
Although there is not one definition for frailty, the most often used definitions include 
a combination of decrease of independence, strength, cognition, activity, energy, 
weight and walking speed.33-39 Considerable heterogeneity in the extent of frailty 
between individuals is present, with some persons accelerating fast while others are 
slowly progressing to more severe levels of frailty.40 Between persons of the same 
age, the onset of frailty differs greatly per individual. The pooled prevalence rates for 
persons aged 65-69 is less than 5%, while for those aged 80-85 this is over 15% and 








Frailty represents less resilience, with less capability to resist stressors, and thus 
reflects overall health and functional status of an individual, as simplified in figure 2. 
As such frailty might be associated with less favorable outcome after arthroplasty 
surgery (i.e. a cause for the 15-20% less favourable results after hip- and knee 
arthroplasty surgery).41,45-47 Frailty can be assessed by means of a validated 
questionnaire, and in order to assess the role of frailty in the outcome of total joint 
surgery, we used the self-reported Groningen Frailty Indicator (GFI) questionnaire to 
classify patients as frail or non-frail.48  
III B Handgrip strength 
As the GFI is a self-reported questionnaire, one can also assess the prognostic value 
of a more objective measure, handgrip strength (HGS). HGS is a proxy for overall 
muscular strength and is associated with worse general health and all-cause 
mortality.49-55 In various patient groups, HGS has been shown to be a predictor for 
disability, malnutrition and surgery complications.56-65 Also, HGS may reflect a 
degree of sarcopenia, the loss of skeletal muscle. Sarcopenia is relatively common 
in eldely, with prevalence of up to 50% in those aged over 80.66 The relation of 
preoperative HGS and changes of hip and knee function and quality of life after 




III C Metabolic Health 
Variation in the baseline health status of elderly patients is strongly determined by 
their immune and metabolic health. With the increased lifespan of the world 
population, as well as increasing levels of metabolically compromised and obese 
individuals and sedentary lifestyles, the baseline health of elderly decreases and the 
incidence and the burden on society of OA will increase as a consequence. Years 
of biomedical ageing research, predominantly in animal models, has recently made 
progress into understanding how immune and metabolic health varies and influences 
the individual ageing and disease rates (e.g. by accumulation of senescent cells, 
blood born factors and damaged proteins). 40  
This research resulted in novel treatment strategies for OA, currently being testing 
in clinical trials. The field is, however, in need of new biomarkers that may classify 
which baseline risks would require such treatment. Defining biomarkers for ageing 
and how these affect the onset and progression of diseases and of outcome of 
interventions like THA or TKA, would enhance patient specific treatment option. 
Biomarker research may also increase knowledge on the primary physiological 
processes underlying OA. For personalized medicine, it is paramount to increase our 
understanding of osteoarthritis as well as to find proper markers of predictive and 
prognostic value. 
Epidemiological studies have shown associations of OA with unfavorable metabolic 
parameters, such as high body mass index (BMI), waist hip ratio and proportion of 
fat mass, which are especially features of metabolic diseases, such as hypertension, 
obesity and diabetes mellitus.68-75 In concordance with this, weight loss reduces the 
symptoms of OA, relieves the pain and increases the physical function of people with 
OA.76-79 
For hip and knee OA, this association is partly explained by increased mechanical 
load; however, also an association of high BMI and hand OA, a non-weight bearing 
joint, has  been found.80,81 The latter suggests a connection between OA and obesity 
beyond axial loading.82,83 Furthermore, the association of OA with classical markers 
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of poor metabolic health such as LDL-cholesterol indicates that the metabolic health 
of individuals affects susceptibility for OA.84-86 Currently, more and more evidence is 
emerging linking OA to the metabolic syndrome.87-91 
To increase our understanding of the relationship of OA with baseline metabolic 
health more intense analyses of metabolism are required, for example by measuring 
metabolites in the circulation. Metabolites, the intermediate end products of 
metabolism, represent the influence of genotype, phenotype and environment on 
cell, tissues and organ functions. Novel metabolomics assays may assist in 
estimating the metabolic health of individuals. Such assays, as for example the well- 
standardized 1H-Nuclear Magnetic Resonance (NMR) based plasma metabolite 
assays, detect a fraction of the blood metabolome and can be applied to estimate 
the relation between baseline metabolic health and OA disease risk.   
Thus, a metabolite profile which differs between OA patients and healthy persons 
may reflect the aetiology of OA, the metabolites may refer to pathways that causally 
contributed to the OA process. Alternatively, such differences may reflect (be a 
biomarker of) the baseline health status of patients indicative of the resilience to 
recover from arthroplasty and may be part of the puzzle to explain the 15-25% of 
adverse outcome after a total hip- or knee arthroplasty in these OA patients. 
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Outline of this thesis 
This thesis addresses several characteristics (potential (bio)markers), tested for their 
association with outcome after a total hip or knee arthroplasty. Characteristics of 
different nature were included: material of prosthesis, physical activity, 
questionnaires, clinical measures and metabolomics. This thesis aims to evaluate 
some of these aspects related to outcome of arthroplasty, from patient perspectives 
to molecular profiling (e.g. metabolic health). 
First, in chapter 2, a meta-analysis as well as a systematic review was performed in 
order to assess the mortality in patients with metal-on-metal total hip prostheses as 
compared to patients with non-metal-on-metal total hip prostheses. Following, in 
chapter 3, the level of physical activity in hip and knee prosthesis patients was 
compared to the general population in order to get an indication of the actual ‘use’ 
of the prosthesis.  
We then focused on baseline health factors such as frailty index, handgrip strength 
and molecular profiling. In chapter 4, the Groningen Frailty Indicator (GFI) was 
validated for patients scheduled to undergo hip or knee arthroplasty. Subsequently, 
in chapter 5, the GFI was applied in order to assess whether it can be used as a 
prognostic factor for functional outcome after hip or knee arthroplasty. Since the GFI 
is a subjective questionnaire, a more objective measure such as handgrip strength 
was assessed in similar fashion in chapter 6.  
Finally, in chapter 7 metabolomics-profiling was used to identify possible biomarkers 
of OA and OA-progression. This type of biomarker may contribute to a prognostic 
tool to select patients who will benefit substantially from arthroplasty. Additionally 
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Importance: There are concerns about increased mortality in patients with metal-on-
metal bearings in total hip arthroplasty.  
Objective: To determine the mortality and the morbidity in patients with metal-on-
metal articulations (MOM THA) compared to patients with non-metal-on-metal 
articulations (non-MOM THA) after primary total hip arthroplasty. 
Data sources: Search of PubMed, MEDLINE, EMBASE, Web of Science, CINAHL, 
Cochrane, Academic Search Premier, Science Direct, Wiley and clinical trial 
registers through March 2015, augmented by a hand search of references from the 
included articles. No language restrictions were applied. 
Study selection: Two reviewers screened and identified randomised controlled trials 
and observational studies of primary total hip arthroplasty comparing MOM THA with 
non-MOM THA. Two reviewers independently extracted study data and assessed 
risk of bias. Risk differences (RD) were calculated with random effect models. Meta-
regression was used to explore modifying factors. 
Main outcomes and measures: Difference in mortality and difference in morbidity 
expressed as revisions and medical complications between patients with MOM THA 
and non-MOM THA. 
Results: There were 47 studies included, comprising 4000 THA in randomised trials 
and over 500.000 THA in observational studies.  For mortality, random effects 
analysis revealed a higher pooled RD of 0.7% (95%CI 0.0% to 2.3%); I-square 42%; 
the heterogeneity was explained by differences in follow-up. When restricted to 
studies with long-term follow-up (i.e. 10 years and more) the RD for mortality was 
8.5% (95%CI 5.8% to 11.2%); number needed to treat was 12. Further subgroup 
analyses and meta-regression random effects model revealed no evidence for other 
moderator variables (study level covariates e.g. resurfacing vs non-resurfacing 
MOM) than follow-up duration. The quality of the evidence presented in this meta-
analysis was characterized as moderate according to the CLEAR-NPT (for non-




Conclusions and Relevance:  Meta-analysis revealed an increased long-term risk of 
mortality and revision surgery for patients with MOM THA compared to patients with 
non-MOM THA. Results based on the meta-analysis have major implications on 
treatment decisions and may be used for future research directions. 
 
Introduction 
Metal-on-metal bearings have been used since the early years of total hip 
arthroplasty (THA) development, and are still used today with 2.000 procedures in 
2014 in the National Joint Registry alone.1 Early historical prostheses from the 1960's 
1970's and 1980s include the McKee-Farrar hip and Ring hip prosthesis.2 They can 
be considered the first generation of metal-on-metal THA (MOM-THA). However, a 
recent long-term follow-up study of first generation MOM-THA reported increased 
mortality in patients with metal-on-metal bearings in total hip arthroplasty compared 
to patients with non-metal-on-metal bearings.3 While this is an isolated report, metal-
on-metal bearings in THA are known to produce metallic particles due to wear and 
corrosion.4  
These metallic particles may lead to local and systemic adverse effects (e.g. 
nephrotoxicity, cardiotoxicity, carcinogenicity, and structural changes in the visual 
pathways and basal ganglia), which in turn could lead to increased mortality.5,6 
These reports are in conflict with two recent registry-based studies of modern, 
second generation MOM-THA which do not report higher mortality associated with 
metal-on-metal hips.7,8 However, there are concerns that registry-based studies in 
this setting may be subject to residual confounding.9 The purpose of this systematic 
review and meta-analysis is therefore to determine the overall mortality and 
morbidity in randomised controlled trials and observational studies for first- and 
second-generation MOM bearings compared to non-MOM bearings after primary 
THA in patients with end-stage primary and secondary osteoarthritis. 
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Methods 
The reporting of this systematic review is in accordance with the PRISMA statement 
and a protocol has been registered a priori at the Prospero registry (PROSPERO 
2014: CRD42014007417).10 After the PROSPERO protocol was registered, we also 
performed a systematic review of observational studies evaluating mortality and 
medical complications (i.e. cancer incidence, kidney failure or cardiomyopathy) for 
metal-on-metal bearings compared to non-metal-on-metal bearings in patients with 
total hip arthroplasty. 
This would allow us to compare the results from randomised controlled trials (RCTs) 
to the results from observational studies. The population of interest consisted of 
patients treated with primary total hip arthroplasty due to endstage primary and 
secondary osteoarthritis of the hip after failed conservative treatment. The 
intervention group consisted of patients who received metal-on-metal bearings, 
including total hip resurfacing with metal bearings: MOM THA. The control group 
consisted of patients with primary total hip arthroplasty with non-metal-on-metal 
bearings (e.g. metal-on-polyethylene, metal-on-ceramic, ceramic-on-ceramic, 
ceramic-on-polyethylene): non-MOM THA. The primary outcome was mortality, 
expressed as the number of patients who died within the study period. The 
secondary outcome was morbidity, expressed as the number of surgical and medical 
complications experienced by the subjects within the study period. 
Data Sources and Searches 
The search strategy was composed in collaboration with a librarian experienced in 
the field of total hip arthroplasty, and included studies, abstracts, and trial registry 
records from the date of their their inception to the end of March 2015. The 
following databases were searched: PubMed, MEDLINE, EMBASE, Web of 
Science, Cochrane, CINAHL, Academic Search Premier. The following journal 
publisher databases were also searched: ScienceDirect and Wiley. References of 
included articles were screened for relevant studies. Finally, clinical trial registers 
(clinicaltrails.org; WHO InternationalClinicalTrialsRegistryPlatform; Multi-register; 
Dutch-TrialRegistry) were searched to identify any ongoing trials that were 
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completed but not yet published. Contact persons of eligible trial registry records 
were contacted by e-mail, and at least two reminders were sent in case of no 
response. The search strategy for the RCTs consisted of the following 
components, each defined by a combination of controlled vocabulary and free text 
terms:     
   1. implant type: metal-on-metal, resurfacing and brand names 
   2. total hip arthroplasty 
   3. randomised controlled trial. 
Study Selection 
Initially, the literature was screened on title and abstract. This screening was 
performed by two reviewers (BP and JM) independently. Both reviewers recorded 
their findings in a pre-designed electronic database. Both databases were then 
compared and any disagreements were resolved by consensus or by consulting a 
referee. When the information in the abstract did not suffice, or if any doubt 
remained, the studies remained eligible. The fulltext papers of eligible studies were 
independently evaluated by two reviewers (BP and JM). Both recorded their findings 
in a pre-designed electronic database. Any disagreements were resolved by 
consensus or by consulting a referee. All bibliographic records identified through the 
electronic searches were collected in an electronic reference database and 
subjected to the following inclusion and exclusion criteria: 
Inclusion criteria: 
1) primary total hip arthroplasty 
2) comparison of metal-on-metal bearing with non-metal–on-metal bearing 
3) randomised controlled trial or quasi-randomised controlled trial (for RCTs) 
4) follow-up of at least 3 months. 
Exclusion criteria: 
1) only bilateral cases with metal-on-metal and non-metal-on-metal in the same 
patient (this would not allow us to determine mortality for the groups separately). 
2) no reporting/evaluation of mortality or morbidity. 
Data Extraction and Quality Assessment 
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Two reviewers (BP and JM) independently extracted data and appraised the risk of 
bias from included studies regarding mortality and morbidity, patient demographics, 
study characteristics, and implant specifications in a pre-defined electronic data 
sheet. The data sheet was designed during the extraction of trial data on a random 
sample of eligible studies. Any disagreements were resolved by consensus or by 
consulting a referee. 
 
Risk of bias was appraised at the level outcome using the CLEAR-NPT checklist and 
Cochrane risk of bias table.11 The CLEAR-NPT checklist was specifically designed 
to appraise the methodological quality of non-pharmacological trials and contains 
items related to the standardization of the intervention, care provider influence, and 
additional measures to minimize the potential bias from lack of blinding of 
participants, care providers, and outcome assessors.11 Any disagreements were 
resolved by consensus or by consulting a referee. 
 
Data Synthesis and Analysis 
A random effects model was employed to pool the risk difference of individual studies 
in order to estimate an overall risk difference and its associated confidence interval. 
The inverse variance method, which gives more weight to larger studies, was used 
to pool outcomes for different studies.  
The overall effects, corresponding to a random effects model, is reported in the forest 
plots along with its confidence intervals. The sizes of the square boxes on the forest 
plots are proportional to the total number of patients in the selected studies.  
An overall test on heterogeneity between studies was performed. To estimate 
between-study variance, DerSimonian-Laird’s method was employed.12 In case 
moderators are incorporated in the model, the weighted estimation gives an estimate 
of the weighted least squares relationship between the moderator variables and the 
true effect. All analyses were performed using Metafor Package R statistics.13  
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The measure of interest chosen was risk difference (RD) to account for any "empty 
cells" for mortality or morbidity corresponding to a particular study. Randomised 
controlled trials of first and second generation MOM THA and observational studies 
of first generation MOM THA (evolution of prosthesis development) were eligible for 
meta-analysis. Observational studies of second generation MOM were considered 
subject to strong selection bias, so they were not eligible for meta-analysis.7-9  
 
The amount of heterogeneity was assessed through visual inspection of forest plots 
and by calculating tau-squared statistics (which is the amount of heterogeneity in the 
true RDs) and I-squared statistics. The latter estimates how much of the total 
variability in the effect size estimates is due to heterogeneity among the true effects.  
 
In the presence of heterogeneity, and if data allowed, random effects meta-
regression on pre-defined factors (study level covariates) was employed. These 
factors were defined in the PROSPERO protocol: type of metal bearing (resurfacing 
vs. non-resurfacing), type of non-metal bearing, head size, fixation method 
(cemented vs. cementless), indication for THA (primary vs. secondary osteoarthritis), 
methodological items from CLEAR NPT and Cochrane risk of bias Table, duration of 
follow-up, mean age at operation, gender distribution (% of females and males), and 
pre-operative health (American Society of Anesthesiologist (ASA) scores).  
 
To assess for publication bias, we constructed a funnel plot for studies reporting the 
primary outcome. In the case of asymmetry in the funnel plot, or if publication bias 
was suspected based on the trial registries, a trim-and-fill method and cumulative 






The literature search yielded 686 hits and 30 studies (38 papers) published between 
1975 and 2014 were included, for a total of 1,806 patients with MOM THA and 2,151 
patients with non-MOM THA.2,14–42 Three studies were not published in peer 
reviewed journals (1 abstract, 2 trial registry reports)19,21,41 and 27 studies 2,14–18,20,22–
40,42 were published in 38 papers; 7 studies on the same RCT were published in more 
than one paper, including 1 study that was published in 3 papers. These papers were 
mostly follow-up reports. For the analyses, we used the paper with the longest follow-
up. Details of study selection and flow of the review are shown in Figure 1 and details 
of included studies are shown in Table 1. 
Fig 1. PRISMA flow chart 
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The search of the trial registry reports yielded 111 hits, of which 12 were deemed 
eligible. The contact persons of these 12 trials were approached. Four did not 
respond, even after at least 2 reminders. Eight did respond, which resulted in the 
inclusion of 2 trials. One additional trial was already included as a journal version. 
Five trial registry reports were excluded because the study was not a randomised 




The literature search yielded 288 hits and 9 studies were included, with a total of 
78,110 patients with MOM THA and 451,605 patients with non-MOM THA, published 
between 1996 and 2014.3,7,8,43–48 Details of study selection and flow of the review are 
shown in Figure 1 and details of the included studies are shown in Table 1.  
 
Mortality 
There were 25 RCTs (31 papers) that reported mortality.14,16–27,29,31–38,40–42 These 
RCTs comprised 1225 patients with MOM THA (71 mortalities) and 1486 patients 
with non-MOM THA (80 mortalities). There were five observational studies that 
reported mortality: one with first generation MOM THA and four with second 
generation MOM THA.3,7,8,43,48 Meta-analysis of RCTs and first generation MOM 
observational studies showed a difference trend towards higher mortality for MOM 
THA: RD 0.7% (95%CI: 0.0% -  2.3%), I-square equal to 42%. 
Figure 2 shows the results of three different meta-analyses, including the RD of the 
MOM vs. non-MOM studies and the 95%CI associated to each individual study. The 
overall effect for each separate meta-analysis based on a random effects model is 
shown. This heterogeneity, I-square 42%, was explained by differences in follow-up, 
as shown in Figure 2.  
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After correction for follow-up with random effects meta-regression, there was no 
residual heterogeneity, and I-square was equal to 0%. When restricted to studies 
with long term follow-up (10 years or more)3,35,36,38, the RD was 8.5%, (95%CI: 5.8% 
- 11.2%); number needed to treat was 12. This analysis used the unadjusted data 
from Visuri et al3. When using adjusted data from Visuri et al3, the RD was equal to 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































Further subgroup analyses and meta-regression revealed no evidence for other 
modifying factors (e.g. resurfacing vs. non-resurfacing MOM). Sensitivity analyses 
with “leave one out” methodology indicated that the results were not significantly 
influenced by any single study. 
 
Table 2 shows all-cause mortality and cause-specific mortality for first and second 
generation MOM observational studies. The first generation MOM observational 
study, which looked at non-resurfacing MOM in patients with primary osteoarthritis, 
showed a trend towards increased risk of mortality for patients with MOM compared 
to non-MOM THA, Incidence Rate Ratio 1.05, which is in line with the long term 
results from the RCTs.3 
The second generation MOM observational studies showed decreased risk of 
mortality for patients with MOM compared to non-MOM-THA, Hazard Ratios ranging 
from 0.51 to 0.90.7,8,43,48 This is in contrast with the long-term results from RCTs and 

































































Visuri 2010 No 1st 1.05 . 0.95-1.16 17 579 1 585 
Lubbeke 2014 No 2nd 0.90* 0.70-1.20 9.6 883 2 458 
Makela 2014 Mixed 2nd 0.78 . 0.69-0.88 4.6 10 728 18 235 
McMinn 2012a Yes 2nd 0.61* 0.50-0.75 3.6 8 352 53 409 
McMinn 2012b Yes 2nd 0.68* 0.55-0.84 3.6 8 352 50 529 
Kendal 2013a Yes 2nd 0.51* 0.45-0.59 6 7 437 22 311 










y Visuri 2010 No 1
st 1.27 . 0.98-1.63 17 579 1 585 











y Visuri 2010 No 1st 1.07 . 0.93-1.22 17 579 1 585 











Visuri 1996 No 1st 1.25 . 0.99-1.58 13.5 698 1 831 
Smith 2012 No 2nd 1.02* 0.93-1.12 3 21 264 248 995 
Lomohammed 2013 No 2nd 1.04* 0.70-1.56 3.2 988 9 714 
Makela 2012 Mixed 2nd 0.92 . 0.81-1.05 4 10 728 18 235 
Smith 2012 Yes 2nd 0.72* 0.61-0.86 3 19 312 248 995 
IRR = Incidence rate ratio, * Hazard Ratio, FU = Follow Up in years 




















































Morbidity: surgical complications 
There were 26 RCTs (30 papers), all of second generation MOM THA, that 
reported revisions.14–17, 25–40,42,49–52 These studies comprised 1546 MOM THA (49 
revisions) and 1746 non-MOM THA (24 revisions). There were more revisions in 
MOM THA compared to non-MOM THA: RD 0.8% (95%CI: -0.1% - 1.7%); I-square 
0%; random effects meta-analysis presented in Figure 3. This effect was stronger 
for cemented THA, with more revisions in MOM than non-MOM THA: RD 2.7% 
(95%CI: 0.1% - 5.3%); number needed to treat was 37. Regarding revision for 
aseptic loosening the RD was 0.6% (95%CI: -0.3% - 1.4%), and regarding revision 
for septic loosening the RD was 0.3% (95%CI: -0.3% - 0.9%). Sensitivity analyses 
with “leave one out” methodology indicated that the results were not significantly 
influenced by any single study. 
Morbidity: medical complications 
There were four RCTs, all of second generation MOM THA, that reported medical 
complications, with maximum follow-up ranging from 2 to 10 years.19,35,41,50 Since 
there were only three or fewer RCTs that reported on each medical complication 
(nephrotoxicity, cardiotoxicity, carcinogenicity, and general medical complications 
[e.g. venous thrombosis]) meta-analysis was not considered appropriate. Data from 
single studies are reported in Table 3. 
 
Table 3 – Medical complications for RCTs. 





















NCT00208494 196 2 1 4 35 194 3 3 5 37 
NCT01422564 12 1 . 1 . 12 0 . 0 . 
Desmarchelier  111 . . . 2 116 . . . 5 
Penny 18 . . . 1 15 . . . 0 
Nephro = nephrotoxicity, cardio = cardiotoxicity. 
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There were four observational studies that reported cancer incidence: one with first 
generation MOM THA and three with second generation MOM THA, see Table 2.44–
47 The first generation MOM observational study showed increased risk of cancer for 
patients with MOM compared to non-MOM THA.44 The second generation MOM 
observational studies showed no difference in risk of cancer for patients with MOM 
compared to non-MOM THA.45–47 
Risk of bias 
Risk of bias items from the CLEAR-NPT and Cochrane are presented in Figure 4. 
All studies suffered from problems with allocation concealment and blinding of 
patients, caregivers, and outcome assessors. The strong points of all studies were 
that compliance with the treatment was of course 100%, follow-up was similar for 
both MOM and non-MOM groups, and the skill/experience of the surgeons was 
similar for MOM and non-MOM THA (non-resurfacing).  
The results from observational studies of second generation MOM THA were 
different from those of first generation MOM THA and those of the RCTs, suggesting 


























































































































































Petersen 2010 + - + + ? + + - + + + + + + + - ? + +
Zagra 2013 + - + + + + + + + + + + + + + - + + +
Grubl 2006 ? - + + ? + ? - + + ? + + + ? - ? + +
Schouten 2012 ? - + + + + + + + + ? - + + +
Jensen 2011 + - + + - + + - + + - + + + + - - + +
Zijlstra 2011 ? - + + - + + - + + - + + + ? - - + +
Hanna 2012 ? - + + + + + - + + - + + + ? - - + +
Weissinger 2011 ? - + + ? + + - + + + + + + ? - ? + +
Tiusanen 2013 ? - + + - + - - + - - + + + ? - ? + +
Penny 2012 + - + + - + + - + + - + + + + - - + +
nct00208494 + -
Gauthier 2013 + - + + ? + + - + + ? + + + + - ? + +
Malviya 2011 ? - + + - + ? - + + ? + + + ? - ? + +
Brodner 2003 + - + + - + + - + + + + + + + - + + +
Macdonald 2005 + - + + + + + - + + + + + + + - + + +
Wang 2012 + - + + ? + + - + + ? + + + + - ? + +
Engh 2014 + - + + + + + - + - + + + + + - + + +
Bjorgul 2013 + - + + ? + + - + + + + + + + - + + +
Zerahn 2011 + - + + - + + - + + ? + + + + - ? + +
nct01422564 + -
Hailer 2011 + - + + - + + - + + + + + + + - + + +
Howie 2005 + - + + ? + + - + + ? + + + + - ? + +
Desmarchelier 2013 ? - + + ? + + - + + ? + + + ? - ? + +
Zijlstra 2010 + - + + ? + + - + + - + + + + - ? + +
Pabinger 2003 + - + + ? + + - + + ? + + + + - ? + +
Fig. 4 - Risk of bias assessed by means of the Clear NPT and Cochraine scoring form. 
NPT_1 Was the generation of allocation sequences adequate?
NPT_2 Was treatment allocation concealed?
NPT_3 Were details of the intervention administered to each group made available?
NPT_4 Were careproviders'experience or skill in each arm appropriate?
NPT_6 Were participants adequately blinded?
NPT_6.1 If participants were not adequately blinded; were all other treatments and care the same in each randomized group?
NPT_6.1.1 If participants were not adequately blinded; were withdrawals and lost to follow-up the same in each group?
NPT_7 Were care providers or persons caring for the participants adequately blinded?
NPT_7.1 If care providers were not adequately blinded; were all other treatments and care the same ine ach randomized group?
NPT_7.1.1 If care providers were not adequately blinded; weere withdrawels and lost to followup the same in each randomized group?
NPT_8 Were outcome assessors adequately blinded to assess the primary outcomes?
NPT_9 If outcome assessors were not adequately blinded, were specifi methods used to avoid ascertainment bias
NPT_10 Was the followup schedule the same in each group















The potential influence of publication bias is small, 
as shown by a nearly symmetrical funnel plot in 
Figure 5. Also, the trim-and-fit method and the 
cumulative meta-analysis showed small potential 
influence of publication bias that would not influence 
the results. Furthermore, the results from the non-
published RCTs (identified from the trial registries) 
were similar to those of published studies: RD for 
mortality in the non-published studies was -0.3% 
(95%CI: -1.8% - 1.1%), and in the published studies 
was 0.1% (95%CI: -1.3% - 1.5%).  
Fig 5. Funnel plots of RCTs. The red 
open boxes represent an abstract and two 





We found that when restricting to studies with long term follow-up (10 years and 
more)3 35 36 38, there was an increased risk of mortality in patients with MOM THA 
compared to patients with non-MOM THA: RD 8.5% (95%CI: 5.8% - 11.2%). This 
finding, compared to a lack of difference between MOM and non-MOM THA patients 
with less than 10 years’ follow-up, might indicate a dose-response association. The 
longer patients are exposed to MOM THA, the higher the risk of mortality is 
compared to non-MOM THA. Importantly, sensitivity analyses with meta-regression 
showed that duration of follow-up was the only effect modifier. 
Regarding surgical morbidity, there were more revisions in MOM THA compared to 
non-MOM THA: RD 0.8% (95%CI: -0.1% - 1.7%), based on 26 RCTs of second 
generation MOM THA. When restricted to cemented THA, this effect was stronger: 
RD 2.7% (95%CI: 0.1% - 5.3%). 
 
Since data on post-operative medical complications were reported in only a few 
studies, no valid meta-analysis could be done on differences between the two THA 
groups. Regarding the observational studies, one first generation MOM study 
showed an increased risk of cancer for MOM patients compared to non-MOM THA 
patients.44 The second generation MOM observational studies showed no difference 
in overall cancer risk. However, risk of soft-tissue sarcoma and basalioma was higher 
for MOM THA patients.48 The risk of mortality for MOM THA from observational 
studies of second generation MOM THA was different from those of first generation 
MOM THA and RCTs between (non) MoM THA, suggesting confounding by 
indication in studies of second generation MOM THA as previously reported by 
Kandala et al.9 In a recent review, Hartmann et al6 demonstrated that metal ion 
concentrations were persistently elevated after implantation of MOM bearings in 
whole blood, serum, plasma, erythrocytes and urine, irrespective of patient 
characteristics and study characteristics.  
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Of concern is that the same authors found very high serum cobalt concentrations in 
several of their included studies—above 50 μg/L, while the detection limit for serum 
cobalt is typically 0.3 μg/L. They found the highest metal ion concentrations in 
patients with a stemmed, large-head MOM implant and in patients with hip 
resurfacing arthroplasty. Our sensitivity analyses did not identify any association 
between MOM head size (either resurfacing or THA) and mortality or surgical 
complications. However, the number (25) and size (2700 pts) of our included RCTs 
may have been too small to detect a difference. 
 
Toxic and carcinogenic effects 
Devlin et al53 and Bradberry et al54 have shown in a systematic review that patients 
with suspected Prosthetic Hip Associated Cobalt Toxicity (PHACT) had symptoms 
that fell in three categories: neuro-ocular toxicity, cardiotoxicity and thyroid toxicity., 
The signs and symptoms developed between 3 and 72 months (median 19 months) 
after the MOM THA.53,55 The most common treatment of PHACT in literature was 
removal of the metal-containing prosthesis, which resulted in lowered cobalt 
concentration and improvement of symptoms.53-55 Of great concern is also the fact 
that the International Agency for Research on Cancer (IARC) has classified cobalt 
as group 2B, “possibly carcinogenic to humans".56  
Furthermore, Moulin et al57 have shown that metal workers exposed to cobalt have 
an increased mortality rate from lung cancer. Although most emphasis in literature 
is on cobalt toxicity (PHACT), the effects of chronic exposure to elevated chromium 
or nickel levels should not be dismissed. The International Agency for Research on 
Cancer (IARC) has classified chromium and nickel as group 1, "carcinogenic to 
humans".56 Chromium (VI) in particular is carcinogenic through direct DNA damage 
after intra-cellular reduction to chromium (III), mutation, genomic instability, 
aneuploidy, and cell transformation.56 Exposure to chromium by ingestion or 
inhalation is associated with increased risk of lung cancer, sinonasal cancer, and 
stomach cancer.56 58-61 
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The connection between chromium inhalation/ingestion and an increased risk of lung 
cancer, sinonasal cancer, stomach cancer, and possibly melanoma do not directly 
extrapolate to increased cancer risk due to increased plasma chromium levels in 
MOM THA. Briggs et al62 have shown a strong relationship between whole blood 
levels of chromium and total chromosomal aberration indices in peripheral 
lymphocytes of MOM patients. Ladon et al63 have shown an increase of both 
chromosome translocations and aneuploidy in peripheral blood lymphocytes at 6, 
12, and 24 months after MOM-THA. Therefore, the association of increased 
chromium plasma levels and increased risk of mortality through cancer warrants 
further research. The arguments for this association are the carcinogenic effect of 
chromium through direct DNA-damage, strong relationship between whole blood 
levels of chromium and total chromosomal aberration indices in patients with MOM, 
chronically increased chromium plasma levels in patients with MOM, and increased 
long-term mortality in MOM patients as shown by the present systematic 
review.6,56,62,63 Furthermore, patients with MOM THA are not only exposed to a single 
metal but to a "cocktail" of metal ions including chromium, cobalt, titanium, nickel, 
and molybdenum, of which at least two are potentially carcinogenic (chromium and 
nickel) and one is possibly carcinogenic (cobalt).6,56 
 
Strengths and limitations 
Our search strategy was thorough and complete. We included studies published 
between 1975 and 2014. Also, after contacting corresponding persons, we were able 
to include additional RCTs (both peer-reviewed papers and clinical trial reports) from 
trial registries such as clinicaltrials.org. In total, we were able to include 47 papers, 
including several with follow-up of 10 years or more. 
For non-resurfacing THA, the surgical procedure is almost identical for MOM and 
non-MOM THA. Even the implants are identical with respect to the femoral stem and 
outer shell of the cup. The only difference is the bearing (liner and femoral head) that 
is inserted during the procedure. Therefore, the surgical skill/experience is the same 
for non-resurfacing MOM and non-MOM THA. 
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The fact that the results from observational studies of first generation MOM THA 
concur with those from the RCTs reinforces the conclusion that MOM patients have 
an increased risk of mortality in the long run compared to non-MOM patients. 
We should consider some limitations. Most RCTs had problems with allocation 
concealment and blinding during follow-up. However, the primary outcome of 
mortality is an objective outcome measure and is therefore very unlikely to be 
misclassified due to problems with blinding. Lack of blinding could have resulted in 
intensified follow-up for patients with MOM THA once the issues with MOM became 
apparent. However, none of the included studies mentioned differences in follow-up. 
Also, if we were to assume intensified follow-up (due to public awareness) for 
patients with MOM, and that this follow-up would be successful in reducing mortality 
and morbidity, these effects would have led to an underestimation of the observed 
effect on mortality and surgical morbidity (revisions) in MOM THA. Thus, in this case 
the increased risk of long-term mortality for MOM THA and the increased risk of 
revision for MOM THA would even be higher. These unlikely effects would thus not 
change our conclusions. 
There was limited data from RCTs on medical complications. Future RCTs and new 
reports of existing RCTs should therefore report these complications in a systematic 
way. 
 
Comparison with other studies 
Visuri et al3,44 showed increased mortality and increased cancer incidence from 
MOM THA in an observational study of first generation MOM hip prostheses 
implanted between 1967 and 1973: the McKee-Farrar. This study is particularly 
interesting since the McKee-Farrar is part of the evolution of total hip prostheses and 
was not subject to modern marketing, nor was it labelled a "sports hip". The results 
from Visuri et al3 are in accordance with the results of the RCTs of second generation 
(modern) MOM THA, therefore reinforcing our conclusion that MOM THA is 
associated with an increased risk of mortality in the long term. Kendal et al7 found 
increased mortality in non-MOM THA in a registry based study of second generation 
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MOM THA using propensity score matching. Their results are in disagreement with 
the results of our meta-analysis, likely because registry-based studies are subject to 
residual confounding by indication. Indeed, Kandala et al9 have shown that 
confounding by indication is likely for the Kendal study, since one-fifth of the metal-
on-metal subjects are predicted to live beyond 100 years of age, making metal-on-
metal total hip replacement more beneficial for longevity than any other known 
treatment. This latter finding is highly unlikely, and confounding by indication for the 
Kendal study is the most likely reason for this predicted longevity. Mäkela et al48 
found at short-term follow-up no difference in cancer incidence and cause-specific 
mortality in patients with second generation MOM THA compared to non-MOM THA. 
For the short-term follow-up, their results are in agreement with the results of our 
meta-analysis. 
 
Conclusions and implications for clinicians and researchers 
Studies with follow-up of greater than 10 years seem to suggest an increased risk of 
mortality in MOM THA compared to non-MOM THA. Additionally there is an 
increased risk of revision in MOM THA compared to non-MOM THA. In the light of 
these results, more long-term follow-up of RCTs reporting mortality is paramount. 
Also, future observational studies should address the dose-response association of 
person/hip years exposure to MOM THA and/or levels of metal ions to the risk of 
mortality and other medical complications e.g. cancer incidence, cardiomyopathy 
and renal failure. There is currently no case for the use of MOM THA giving the 
increased risk of long-term mortality and revision without any proven major 
advantage. Considering the results discussed above, it is prudent to closely follow 
the patients that have already received a MOM THA, especially in the long-term. 
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Background: Total hip arthroplasty (THA) and total knee arthroplasty (TKA) bring 
relief of pain and functional disability to patients with end-stage osteoarthritis, 
however, the literature on their impact on patients’ level of physical activity (PA) is 
scarce.  
 
Methods: Cross-sectional study in patients who underwent THA/TKA surgery in the 
preceding 6–22 months and a random sample of persons aged >40 years from the 
Dutch general population, participating in a national survey. PA in minutes per week 
(min/week) and adherence to the Dutch recommendation for PA (NNGB yes/no) 
were measured by questionnaire to assess health-enhancing PA. Multivariable linear 
(total min/week) and logistic regression analyses (meeting recommendations PA), 
adjusting for confounders, were performed for THA and TKA separately.  
 
Results: In total, 258 THA (62.3% female, aged 69.4 (9.1)) and 221 TKA (65.7% 
female, aged 69.5 (8.9)) patients and 4373 persons from the Dutch general 
population (51.4% female, aged 58.9 (11.6)) were included. The presence of THA 
was associated, after adjusting for age, sex, BMI education and musculoskeletal 
comorbidities, with more total min/week spent on PA (THA 13.8% increase, 95%CI 
1.6–27.6%), whilst both TJA groups were associated with adhering to NNGB (THA: 
OR 1.79, 95%CI 1.26–2.56; TKA: OR 1.73, 95%CI 1.20–2.51).  
 
Discussion: As this study used questionnaires to compare the PA of THA/TKA 
patients to the general population, some recall and selection bias might have been 
induced. After surgery, overall, TJA patients are more likely to adhere NNGB than a 







Worldwide, the numbers of patients undergoing total hip or total knee arthroplasty 
(THA or TKA) for hip or knee osteoarthritis (OA) are rapidly increasing. Overall, the 
outcomes are favourable, with a large majority of patients having less pain and 
improved physical functioning after surgery.1–4 
 
Although the benefits of THA and TKA are well documented for pain and function, 
relatively little is known on their impact on one specific aspect of physical functioning,  
i.e. physical activity (PA). Just like for any other individual, achieving and maintaining 
a sufficient level of PA is important for patients with hip and knee OA with respect to 
their potential general health benefits. 
 
Moreover, in patients who undergo THA or TKA, PA may have an additional 
beneficial effect on the quality of the bone, which in turn may prevent complications 
such as early loosening.5–8 In addition, PA may have a positive effect on muscle 
strength and range of motion of the affected leg.9 
 
With respect to the literature on PA after THA or TKA, de Groot et al. demonstrated 
in 84 THA and TKA patients that 6 months post-operatively PA levels as measured 
with an activity monitor did not significantly differ from the preoperative activity 
levels.10 Harding et al11 found similar results when measuring PA by means of an 
accelerometer in 63 American THA and TKA patients before surgery and 6 months 
post-operatively. Kahn and Schwartzkopf12 found no difference in PA as measured 
with an accelerometer between those on the waiting list for TKA and those who had 
TKA 2 years earlier. By using the patient-reported University of California at Los 
Angeles (UCLA) activity questionnaire, Baumann et al13 found that both THA and 
TKA patients were regularly active on moderate to high levels after on average 6–
12 months after surgery. This finding is supported by Dahm et al14, who reported that 
5.7 years after surgery TKA patients had an average physical activity score of 7.1 
out of 10, with 10 being highly active. In contrast to these findings, Kahn and 
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Schwartzkopf12 observed, using an accelerometer, that adherence to health-
enhancing PA guidelines was only 5% in persons with TKA.  
 
In all of these studies, a comparison with the general population was lacking. Two 
Dutch studies compared patient-reported physical activity in THA15 and TKA16 
patients at 1–5 years postoperatively to that of age and gender-matched controls. It 
was found that in THA the proportion of persons reaching the Dutch Public Health 
Physical Activity guideline (the “Nederlandse Norm Gezond Bewegen”, NNGB) was 
similar to that of matched controls (51.2% (THA) vs 48.8% (controls))15, whereas in 
TKA patients the proportion of patients adhering to the guideline (54.5%) was 
significantly lower than that of the matched control population (63.7%).16 However, 
these studies did not take BMI into account, whilst BMI is one of the determinants of 
physical activity.17 
 
Given the lack of knowledge on post-operative PA levels after total joint arthroplasty 
(TJA) compared to the general population, the aim of the present study was to 
compare the minutes of PA and proportion meeting the public health guidelines of 
THA and TKA patients to those of the general Dutch population.  Moreover, factors 







This cross-sectional, multicentre study concerned a comparison of PA levels of THA 
and TKA patients approximately one year after surgery with those of the general 
Dutch population. The data from the population of patients with THA and TKA were 
obtained from a study primarily aiming to make an inventory of the use of physical 
therapy and the presence of comorbidity18, whereas the data from the general 
population were obtained from the Dutch National Bureau of Statistics (in Dutch: 
Centraal Bureau voor de Statistiek, CBS).  
Since the survey had to be filled in only once by patients, it was judged to fall outside 
the remit of the law for Medical Research Involving Human Subjects Act; MO [in 
Dutch; Wet medisch wetenschappelijk onderzoek met mensen (WMO)]. An 
exemption for medical ethical review was therefore given by the Medical Ethical 
Committee of the Leiden University Medical Center. The health monitoring 
conducted by the CBS commissioned by the Dutch Government also falls outside 
the remit of the WMO. The study was conducted in accordance with the Handbook 
for Good Clinical Research Practice of the World Health Organization19 and the 
Declaration of Helsinki principles.20 
 
Patients with THA or TKA 
The patient data were obtained from a cross-sectional study performed in 2012, 
including patients who underwent THA or TKA for hip or knee OA in 2011 in four 
different hospitals in the Leiden region (Leiden University Medical Center in Leiden, 
Rijnland Hospital in Leiderdorp, Groene Hart Hospital in Gouda and Reinier de Graaf 
Hospital in Delft, the Netherlands). Patients receiving THA or TKA for reasons other 
than end-stage OA (such as fracture or rheumatoid arthritis) were excluded from the 
study, as well as patients undergoing revision surgery. Between July 2012 and 
October 2012, all patients operated in 2011 were approached by mail by their 
orthopaedic surgeon, resulting in a range of post-surgery time of 7–22 months. The 
orthopaedic surgeon sent all eligible persons an invitation letter, information leaflet, 
informed consent form, survey and pre-stamped return envelope. Patients who 
returned the envelope with a completed survey and signed informed consent were 
included in the study. 
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Data general population 
Data from the Dutch general population were provided by the CBS and were derived 
from a nationwide survey on general health (Gezondheids-enquête).21 This 
questionnaire is annually administered to a representative sample of ±8.000 Dutch 
inhabitants and is the prime health monitor tool of the Dutch government.22 The 
selection of participants is drawn from municipality registers. Persons living in 
institutionalized homes (e.g. nursing homes) are excluded. For the present study on 
physical activity, only data were selected from 2011, i.e. the same year as the data 
from patients with THA or TKA, and from respondents who were over 40 years of 
age, as none of the persons with arthroplasty was aged below 40. 
 
Assessments 
Included in both surveys were the following variables or questionnaires: 
 
 Socio-demographic and basic health characteristics  
Demographic variables included: age, gender and marital status (split into either 
married or not married). The height and weight of the patient were asked in order to 
calculate the body mass index (BMI). Smoking status (non-smoker, ex-smoker and 
smoker) and educational level (low (elementary school, lower secondary education), 
medium (secondary school or college) or high (higher secondary education or 
university)) were recorded. 
 
 Physical activity (PA) 
PA was assessed using the validated Dutch version of the short questionnaire to 
assess health (SQUASH).23,24 The SQUASH records the total amount of minutes per 
week (min/week) spent on PA in an average week in the past 12 months regarding 
eight different domains of active life: commuting, work activities, walking, cycling, 
gardening, odd jobs, household and sports. With the aid of the compendium of 
Ainsworth25, PA can subsequently be categorized into light, moderate or vigorous 
intensity. Using this information, it is possible to define whether an individual adhered 
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to the Dutch Public Health recommendation (NNGB) for PA (30 min of moderate 
intensity PA on at least 5 days per week).26 
 
 Quality of life (QoL) 
QoL of the persons with a THA/TKA was assessed with the Short Form 36 (SF36) 
questionnaire, whilst the QoL of the general Dutch population was assessed with the 
Short Form 12 (SF12).27,28 The SF36 outcomes of the THA/TKA patients were 
transformed to SF12 outcomes.  
From the SF12, two summary scales were derived: the physical component scale 
(PCS) and the mental component scale (MCS). The higher the score on these 
scales, the better the physical or mental functioning. 
 
 Comorbidity 
The presence of comorbidity was assessed by means of a self-reported 
questionnaire of the CBS which comprised 19 different comorbidities.29 For every 
comorbidity, the participants of the survey were asked to respond with either yes or 
no to the question “Have you received any treatment for [condition] in the past year”. 
 
The included diseases were clustered into three groups:  
● Musculoskeletal comorbidities: Severe back pain (including slipped disc), 
severe neck or shoulder pain, severe elbow wrist or hand pain, inflammatory 
arthritis or other joint conditions. 
● Non-musculoskeletal comorbidities: Asthma or COPD (chronic obstructive 
pulmonary disease), (severe) cardiac disorder or coronary disease, 
arteriosclerosis (abdomen or legs), hypertension, (consequences of) stroke, 
severe bowel disorder, diabetes mellitus, migraine, psoriasis, chronic 
eczema, cancer and urine incontinence. 
● Sensory comorbidities: Hearing impairments (group and face-to-face 
conversation), vision impairments (short and long distance) and dizziness in 




The demographic and health characteristics of patients undergoing THA or TKA 
were each compared with those of the general Dutch population by means of two 
sample t-tests or Chi-square tests, where appropriate. Mann–Whitney tests were 
conducted to compare the min/week spent on PA for each of four different age 
groups (aged under 65, 65–69, 70–74 and 75+).  
The min/week of PA was log-transformed to reach a normal distribution. 
Multivariable linear regression models were used to assess whether having had a 
joint replacement was associated with min/week spent on PA. Each analysis was 
done separately for THA versus the general Dutch population and TKA versus the 
general Dutch population. The antilog of the effect sizes (beta’s) is reported for both 
the analyses with the 95% confidence interval (CI).  
Multivariable logistic regression was used to assess the association between the 
presence of a joint replacement and adherence to the Dutch public health physical 
activity guideline. These results are presented as odds ratio (OR) with the 95% CI. 
The analyses were done separately for THA versus the general Dutch population 
and TKA and the general Dutch population. 
 
All models (multivariable linear and multivariable logistic regression analyses) were 
constructed using a stepwise method. Potential confounders for the level of physical 
activity, i.e. sex, BMI, age and education level, were included in the models.  
The determinants of minutes per week spent on activities categorized according to 
the three different levels of intensity of physical activity were determined for the 
arthroplasty groups and the Dutch population separately, by means of linear 
regression models including the variable of interest and correcting for age and sex. 
These analyses were performed including the variables age, sex, BMI, education, 
non-musculoskeletal comorbidities, musculoskeletal comorbidities, sensory 
comorbidities, MCS, PCS and time since surgery.  
 
The level of statistical significance was set at P< 0.05, and analyses were performed 






Of the 545 THA and 465 TKA patients of the 4 hospitals who were invited to 
participate, 258 THA patients (response rate 47.3%) and 221 TKA patients 
(response rate 47.5%) completed the questionnaires.  The selection of data from the 
general Dutch population from the year 2011 yielded 4373 surveys completed by 
people aged 40 years or older. Of those, 568 persons (13%) replied positively to the 
question “Have you received any treatment for osteo- or rheumatic arthritis in the 
past year?”.  
The arthroplasty groups comprised statistically significantly more females, and the 
patients had a higher mean age and higher BMI than the general Dutch population. 
The PCS and MCS were statistically significantly lower in both the THA and the TKA 
groups than in the general population. There was no difference in the presence of 
sensory comorbidities between the arthroplasty groups and the general population. 
However, both musculoskeletal and non-musculoskeletal comorbidity were more 
present in the arthroplasty patients as compared to the general population (see also 
Table 1).  
Table 1 - Characteristics of patients with Total Joint Arthroplasty and the general Dutch population 









Total 4373 258 
 
221   
Female 2248 (51.4%) 159 (62.3%) 0.01 144 (65.7%) <0.01 
Age (year) 59 ± 11.6 69 ± 9.1 <0.01 70 ± 8.9 <0.01 
Body Mass Index 26 ± 5.0 27 ± 4.1 <0.01 29 ± 5.0 <0.01 
Education  
level 
Low 653 (15.6%) 75 (37.3%) 
<0.01 
72 (41.1%) 
<0.01 Medium 2391 (57.0%) 86 (42.8%) 81 (46.3%) 
High 1150 (27.4%) 40 (19.9%) 23 (12.6%) 
SF-12 
PCS 53.9 ± 9.4 47.6 ± 11.2 <0.01 46.6 ± 10.8 <0.01 
MCS 44.1 ± 5.0 39.8 ± 5.2 <0.01 40.6 ± 5.1 <0.01 
Comorbidities 
≥ 1 Non-MSK 2465 (57.4%) 142 (72.8%) <0.01 138 (84.1%) <0.01 
≥1 MSKl 1224 (27.9%) 93 (39.7%) <0.01 84 (40.7%) <0.01 
≥1 Sensory 400 (9.3%) 21 (8.4%) 0.736 21 (9.9%) 0.717 
Variables reported as mean±SD or N(%).  
*P - P-value for two sample T test or Chi2 between hip/knee arthroplasty and the general population 
MSK – Musculoskeletal comorbidities, PCS/MCS – Physical /Mental Component Score 
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Table 2 - Total minutes per week spent on physical activity by, age group for hip or knee 
arthroplasty or the general Dutch population 
    
General Dutch 
population 
Total hip arthroplasty Total knee arthroplasty 
Gender Aged N Mean ± SD N Mean ± SD P* N Mean ± SD P* 
Men 
<65 2521 2846 ± 1543 32 2722 ± 1252 0,692 21 2924 ± 1468 0,959 
65-69 414 1976 ± 1474 23 2315 ± 1336 0,052 20 2079 ± 1316 0,640 
70-74 313 1784 ± 1330 20 2130 ± 843 0,003 12 1968 ± 1667 0,912 
≥75 372 1461 ± 1209 21 1443 ± 1065 0,840 22 2193 ± 1477 0,018 
Female 
<65 2761 2845 ± 1530 38 2745 ± 1148 0,857 46 2883 ± 1695 0,956 
65-69 401 2075 ± 1412 34 2480 ± 1908 0,364 25 2048 ± 1539 0,764 
70-74 286 1967 ± 1273 33 1867 ± 1071 0,888 28 1944 ± 2122 0,239 
≥75 525 1449 ± 1173 53 1703 ± 1453 0,350 45 1284 ± 912 0,577 
    N  Count (%) N  Count (%) P* N  Count (%) P* 
Adherence to 
NGBB 
4373 2954 (67,6%) 258 195 (75,6%) 0,007 221 161 (72,9%) 0,105 
* P-value for Mann-Whitney or Chi2 as compared to the general population 
 
Table 2 shows the crude number of minutes spent per week on PA, stratified for age 
and gender. As can be seen in Figure 1, male arthroplasty patients spend more 
minutes per week physically active in the higher age groups as compared to the 
general Dutch population. The proportion of persons adhering to the NNGB guideline 
is in the arthroplasty groups higher than in the general Dutch population (THA 76%, 
TKA 73% and general Dutch population 68%).  
 
Fig. 1 - Stratified representation of total minutes per week physical activity per 
age group and gender 
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Association between TJA and minutes per week spent on total physical activity 
Univariately, both THA and TKA were significantly associated with more minutes per 
week physical activity when compared to the general population. As there were 
major differences between the groups, it was needed to correct for potential 
confounders. When correcting for age, gender, BMI, education and musculoskeletal 
comorbidities a statistically significant association was for THA, not TKA. With the 
adjustments, persons with a THA spend 13.8% more minutes per week on physical 
activity compared to the general population (see Table 3).  
 
 
Table 3 – Regression analyses of min/week physical activity and adherence to NNGB. 
Total min/week Physical Activity 
  Total Hip Arthroplasty Total Knee Arthroplasty 
 Beta 95% CI P* Beta 95% CI P* 
UnivariateA 1.229 1.099-1.352 <0.001 1.324 1.186-1.483 <0.001 
Multivariate 1B 1.140 1.023-1.274 0.018 1.122 0.998-1.262 0.055 
Multivariate 2C 1.138 1.016-1.276 0.024 1.112 0.986-1.256 0.084 
Adherence to NNGB 
  Total Hip Arthroplasty Total Knee Arthroplasty 
 OR 95% CI P* OR 95% CI P* 
UnivariateA 1.487 1.111-1.989 0.008 1.289 0.952-1.745 0.101 
Multivariate 1B 1.750 1.243-2.465 0.001 1.750 1.219-2.512 0.002 
Multivariate 2C 1.789 1.253-2.556 0.001 1.731 1.195-2.507 0.004 
A – Univariate analysis 
B – adjusted for age, sex, BMI and education 




Association between TJA and meeting public health recommendation 
The multivariable logistic regression models showed that, adjusted for age, gender, 
BMI, education and muscular comorbidities, both THA and TKA patients had a 
significantly higher likelihood of meeting public health recommendations for healthy 
PA as compared to the general population (THA: OR 1.79 (95%CI 1.25–2.55); TKA: 
OR 1.73 (95%CI 1.20–2.51)). See also Table 3. 
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Determinants of physical activity 
Regarding the determinants of physical activity in the general population, age, sex, 
PCS and education were found to be statistically significantly associated with total 
minutes per week spent on PA and per category of intensity (see Table 4). 
 
In the general population, BMI was associated with the number of min/week of 
moderate and vigorous intensity PA, but not with light intensity PA. Within both the 
arthroplasty groups, it was found that age was a significant determinant of total 
min/week of PA and the min/week of light intensity PA. Within the THA group, age 
was also a determinant for the min/week of moderately intensive PA. Sex was 
associated with the min/week of moderate and vigorous intensity PA in both 
arthroplasty groups and also with the min/week of light intensity PA in the THA group.  
 
In the general population, comorbidities were only found to be a determinant of total 
minutes per week of PA, but not of the min/week in the three categories of PA 
intensity. In THA patients only the presence of sensory comorbidities was associated 
with the total min/week of PA, whereas in TKA the presence of comorbidities was 
not associated with PA.  
 
Although the association of a number of potential determinants with PA in the TKA 
and TJA groups did not reach statistical significance, overall the directions of the 




Table 4 – Variables statistically significantly associated with min/week physical activity after 






















Age 0.973 <0.001 0.966 <0.001 0.966 <0.001 
SexA 0.953 0.037     
BMI 0.995 0.022 0.960 0.005   
Physical Component Score 1.016 <0.001     
Low educationB 0.774 <0.001     
Non-musculoskeletal comorbiditiesC 1.076 0.002     
MusculoskeletalS comorbiditiesC 1.052 0.046     













Age 0.966 <0.001 0.604 <0.001 0.973 <0.001 
SexA 0.748 <0.001 0.604 <0.001   
BMI     0.759 0.044 
Physical Component Score 1.007 <0.001     
Low education B 0.809 <0.001     
















Age 0.991 <0.001 0.984 0.031   
SexA 1.084 0.020 1.596 0.01 1.538 0.009 
BMI 0.912 0.022   0.964 0.027 
Physical Component Score 1.016 <0.001     
Mental Component Score 0.989 0.001     
Low education B 1.180 0.006     
















Age 1.026 <0.001     
SexA 1.189 <0.001 1.489 0.005 1.432 0.022 
BMI 0.986 0.003     
Physical Component Score 1.014 <0.001   1.021 0.027 
Mental Component Score     0.957 0.008 
Medium education B 1.151 0.002     
A – Females were reference 
B – High education as reference 




This study demonstrated that the presence of a THA was associated with more 
min/week spent on PA as well as better adherence to public health recommendations 
for PA (NNGB) when compared to the general population. TKA was found to only be 
associated with adhering to the NNGB when compared to the general Dutch 
population.  
Overall, it seems the Dutch population spends more minutes per week on physical 
activity, but since the patient group differs from the general population the 
comparison between these groups should be adjusted. When adjusting for age, sex, 
BMI and education it is found that persons with THA do spend more minutes per 
week on physical activity and that persons with a THA and TKA are more likely to 
adhere to the Dutch guideline on physical activity, NNGB.  
 
That TKA is associated with the NNGB but not to the minutes per week activity can 
be explained by the level of intensity of the physical activity performed. In the general 
population, more associations between potential determinants of physical activity 
and the actual numbers of PA reached statistical significance than in the arthroplasty 
groups. The lack of significance is probably due to the relatively small sample sizes 
in the arthroplasty groups, limiting the statistical power.  
 
Our groups spent more min/week on PA than reported by two other Dutch studies 
(for THA in this study 2183 min/week PA, THA in Wagenmakers et al15 1601 
min/week, for TKA in this study 2153 min/week PA, TKA in Kersten et al16 1347 
min/week PA). In parallel, regarding the proportion of patients adhering to the Dutch 
recommendation for physical activity, the outcomes were more favourable in the 
present study (THA in this study 75.6% and THA in Wagenmakers et al15 51.2%; 
TKA in this study 72.8% and TKA in Kersten et al16 55%).  
 
Both these latter two studies were done at 1–5 years post-surgery, and our study 
included patients within the first 22 months after surgery. As reported earlier by our 
group (Peter et al30), 43.5% of the THA patients and 50.5% of the TKA patients had 
post-operative physiotherapy for more than 3 months. This implies that a vast 
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amount of our patients might still have intense training with aid of physiotherapists, 
motivating patients to adhere to the PA. As for the other two studies (Kersten, 
Wagenmakers), no data on prolonged post-operative physiotherapy are present, and 
thus, these patients might resume easier into their old, less active activity level.  
 
A recent systematic review on physical activity after THA or TKA measured with 
accelerometers showed that the post-operative PA levels were lower in the 
arthroplasty groups as compared to healthy control participants.31 The differences in 
outcome could be because our sample of the general population might not be totally 
healthy and be less active than selected healthy persons. Also, as this study used a 
questionnaire whilst the systematic review concerned objective measures, 
participants might have caused some recall bias.  
 
The general population in our study had an adherence rate to the Dutch PA of 67.5% 
which is comparable to reports from CBS published (Dutch adult population, 66% 
adhered to the Dutch public health physical activity guideline in 2012).32 The minutes 
per week spent on PA in our study was also consistent with the numbers reported 
by CBS (2589 min per week in 2012 and 2525 min per week in our study for overall 
physical activity for the Dutch population).33  
 
Factors we identified as influencing the level of PA of persons with hip or knee 
arthroplasty (BMI, increased age, physical component score) are in line with the 
findings in a systematic review by Stubbs et al34 regarding PA in patients with hip or 
knee OA. The inverse association of BMI on the level of PA shows that it is an 
important factor, as well as age and gender, to include in any case–control study.17 
Low-impact activities like walking or cycling seem to protect against function loss 
and experienced pain from OA, in contrast heavy load activities might be a risk factor 
for the development of osteoarthritis, but also early implant failure although debate 
exists on the latter.35-38 Since contradictory evidence exists on this topic, research 
into this field is necessary. 
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Current post-operative rehabilitation after a hip or knee arthroplasty is focussed at 
independent ambulation and regaining a normal walking pattern, which was 
deteriorated in the years before surgery due to the slowly progressing osteoarthritis. 
Secondary to this it aims at getting the patient physically active. As mentioned 
before, about half of our patients reported to receive physiotherapy for more than 3 
months after surgery.30 This might imply that these patients are more motivated to 
be active than the general population. 
 
 Another reason for the higher levels of PA in the arthroplasty groups might be the 
fact that PA is a risk factor for TJA.39 As shown by de Groot et al10, the post-operative 
levels of PA did not significantly differ from preoperative levels, suggesting that PA 
levels of TJA were probably higher than those of the general population before 
surgery as well. Finally, the patients filling in the questionnaire knew that the subject 
of the study was PA, whilst the Dutch general population had to fill in an elaborate 
list of questions including all aspects of life, with only a subset on PA. Thus, the 
patients in our study might have overestimated their PA.  
 
The limitations of this study are potential overestimation of outcome measures and 
recall bias, due to using the SQUASH questionnaire, more objective measures like 
accelerometers should be used in future studies. Furthermore, the preoperative 
levels of PA should be taken into account as an important confounder for outcome 
as well. Thus, more valid comparisons with the general population are possible. 
 Also, patients in our study who refused to fill in the questionnaires were not asked 
about their reasons as to why they declined to participate, and therefore, we have 
no information about any possible self-selection bias. In addition, the comorbidities 
of participants were all self-reported and we were unable to confirm the presence of 
comorbidities both in the general Dutch population and the arthroplasty groups. 
 
The findings of this study give insights into the movement patterns of arthroplasty 
patients compared to the general Dutch population. Findings show that although a 
part of the arthroplasty patients adhere to the Dutch public health guideline, there is 
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Background/Objective: Frailty is highly prevalent in the elderly, increasing the risk of 
poor health outcomes. The Groningen Frailty Indicator (GFI) is a 15-item validated 
questionnaire for the elderly. Its value in patients with end-stage hip or knee 
osteoarthritis (OA) has not yet been determined. This study assesses the validity of 
the GFI in this patient-group.  
Methods: End-stage hip or knee OA patients completed the GFI (range 0-15, ≥4 is 
frail) before arthroplasty surgery. Convergent validity was determined by Spearman-
rank correlation between the SF12 physical (PCS) and mental (MCS) component 
scores and the physical and mental GFI-domains, respectively. Discriminant validity 
was assessed by means of overall GFI-score and the pain-domain of the Hip/Knee 
Osteoarthritis Outcome Score (HOOS/KOOS). 
Results: 3275 patients were included of whom 2957 (90.3%) completed the GFI. 
Mean GFI-scores were 2.78(2.41) and 2.28(1.99) in hip and knee OA-patients, 
respectively, with 570(35.9%) of hip and 344(24.1%) of knee patients considered 
frail. The convergent validity was moderate to strong (physical domain R=-0.4, 
mental domain R=-0.6) and discriminant validity low (R HOOS/KOOS-pain domain=-
0.2), confirming the validity of the GFI-questionnaire in this population.  
Conclusion: With 90% of participants completing the GFI, it is a feasible and valid 
questionnaire to assess frailty in end-stage hip and knee OA-patients. One-third 
(33.3%) of the patients undergoing hip arthroplasty and a quarter (24.1%) of those 
undergoing knee arthroplasty are frail. Whether this is associated with worse 






Osteoarthritis (OA) is a degenerative joint disease which often leads to disability and 
pain. A highly effective treatment for end stage OA is arthroplasty surgery.1,2 Over 
202,500 total hip and 402,100 total knee arthroplasties (THA and TKA) are 
performed annually in the United States of America alone, with the volume expected 
to increase up to 6-fold by 2030.3 
At present, 83% of the patients receiving THA and 79% of patients receiving TKA 
are older than 60 years of age.4 As frailty is highly prevalent in the elderly, it is likely 
that a considerable proportion of patients undergoing THA or TKA are frail.5 Although 
there is not one definition for frailty, the most often used definitions include a 
combination of decrease of independence, strength, cognition, activity, energy, 
weight and walking speed.6-12 Literature shows that there is considerable 
heterogeneity in the extent of frailty individuals may experience, with some persons 
accelerating fast while others are slowly progressing to higher levels of frailty.13 
Within persons of the same age, also the onset of frailty differs per individual.14-17 
It is generally acknowledged that frailty hampers the ability to resist stressors, 
leading to vulnerability for adverse outcomes after surgery.6, 16-19 As such, it is of 
importance to have more insight into frailty in the group of patients undergoing THA 
or TKA. As a first step into the exploration of the role of frailty in the outcomes of total 
joint surgery, an appropriate instrument for frailty is needed 
The Groningen Frailty Indicator (GFI) is a frequently used questionnaire in the elderly 
to assess frailty. The advantage of the GFI is that it is a self-reported score, 
furthermore, this questionnaire has been validated specifically for elderly (mean age 
81 years). In these elderly (both community dwelling and institutionalized), it was 
found that the GFI is feasible, reliable and valid.20 However, it is not known yet how 
feasible the GFI is in a clinical setting as well as the validity of the GFI amongst the 
somewhat younger patients with end stage hip or knee OA waiting for arthroplasty 
surgery. Therefore, in this study we aimed to assess the feasibility and validity of the 
GFI as a tool to measure frailty in end stage hip or knee osteoarthritis patients 
scheduled to undergo arthroplasty surgery.   
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Methods 
Study design                                                           . 
This study is part of the Longitudinal Leiden Orthopaedics Outcomes of Osteo-
Arthritis study (LOAS). The LOAS study is an ongoing, multi-center, longitudinal 
prospective cohort study including patients undergoing primary total hip or knee 
arthroplasty (THA or TKA). Participants are recruited in 7 participating hospitals (the 
Leiden University Medical Center, Leiden; Alrijne Hospital, Leiden/Leiderdorp 
(former Diaconessenhuis and Rijnland Hospital); Groene Hart Hospital, Gouda; 
LangeLand Hospital, Zoetermeer; Reinier de Graaf Gasthuis, Delft; Albert 
Schweitzer Hospital, Dordrecht; Waterland Hospital, Purmerend). The LOAS study 
(Trial ID NTR3348) started in June 2012. The present study is only concerned with 
data gathered preoperatively from June 2012 – June 2016.21 
Patients 
All patients who were able to complete questionnaires in Dutch and who were 18 
years or older were eligible for participation. Excluded were patients who did not 
provide informed consent, had insufficient Dutch language skills or of whom the 
physical or mental status did not allow participation. Eligible patients were informed 
about the study through written and oral information by their treating surgeon at the 
outpatient clinic. Only patients who agreed to be approached by the researcher 
received additional written information about the study by regular mail or e-mail, as 
well as a questionnaire, a stamped return envelope and a consent form.  
Patients were included in the study once written informed consent was obtained 
according to the Declaration of Helsinki.22 For the purpose of the present analysis 
only data from patients who returned the preoperative questionnaire between the 
start of the study in June 2012 until June 2016 were included. Ethical approval was 
obtained by the Medial Ethics Committee of the Leiden University Medical Center 
(registration number P12.047) and funding was received from the Dutch Arthritis 
Foundation (LLP13).  
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The questionnaires were incorporated in current clinical setting of the included 
hospitals which all participate in the collection of patient reported outcome measures 
(PROMs) for the national Dutch Arthroplasty Register (LROI).  
Assessments 
Frailty: Frailty was assessed by the Groningen Frailty Indicator (GFI). This 
questionnaire consists of 15 questions covering several aspects of life, such as 
independence in daily tasks, involuntary weight loss, medication use, mental state, 
vision and hearing. Together these questions lead to a score between 0 and 15, a 
score of ≥4 is considered to be frail. The GFI is specifically directed to elderly persons 
both living at home as well as in institutions.20,23,24 
Overall health: Quality of life was measured using the validated Dutch version of the 
Short Form (SF)-12.25 The SF-12 comprises 12 items on generic measurement of 
the overall health-related-quality of life. Scores range from 0 to 100, with 0 being 
lowest possible score and 100 the highest. From the SF12, 2 subscales can be 
calculated, the physical component score (PCS) and mental component score 
(MCS). These subdomains were assessed separately in the analyses.26  
Hip / Knee Symptoms: The Hip disability/Knee injury Osteoarthritis Outcome Score 
(HOOS/KOOS) questionnaires are validated questionnaires to measure the function 
of patients with end-stage osteoarthritis for hip or knee respectively.27,28 These 
questionnaires comprise five domains (activities of daily living, quality of life, sports, 
symptoms and pain). For the current study the validated Dutch version was used.29,30 
Statistical Analyses                                                  . 
Patient characteristics were analysed using descriptive statistics. Rates of patients 
who did not, partially or completely filled out the GFI were computed. Comparisons 
between patients who filled in the GFI completely and those who did not or partially 
were done by means of either Chi-Square tests for categorical variables and t-tests 
for continuous variables. In addition, for each GFI item the proportion of missing 
values was determined.  
To explore determinants for completing the questionnaire a binary variable 
“completion of questionnaire” was constructed. This variable was used in a logistic 
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regression analysis to see if age, sex, BMI and comorbidities are of significant 
influence on the completion of the questionnaire.  
The internal consistency of the GFI in this patient population was assessed by means 
of Cronbach’s alpha, with an alpha of >0.7 being considered as good consistency 
[31]. Convergent validity of the GFI was determined by computing correlations 
between the physical domain of GFI (questions 1-9) and the PCS of the SF-12. The 
mental domain of the GFI (question 14 and 15) was correlated with the MCS of the 
SF-12. Correlations were computed using a Spearman rank correlation coefficients. 
As the corresponding subscales of the GFI and SF12 aim to measure similar 
constructs it was hypothesized that the correlation between the subscales of the GFI 
and SF12 will be high. 
Discriminant validity of the questionnaire was assessed by correlating the physical 
domain of the GFI to the MCS and the mental domain of the GFI to the PCS. Also, 
a Spearman rank correlation analysis including the total GFI-score and pain as 
measured by the HOOS/KOOS questionnaire was performed. As the correlated 
constructs are conceptually different, we hypothesized the correlation between these 
domains would be low. 
For those THA and TKA patients who completed the GFI the prevalence of frailty 
was calculated, based on the cut-off score of four.24 The demographic variables of 
those assigned frail and those not designated as frail were compared by means of a 
t-test or Chi-square test, whichever was appropriate.  




Within the time frame of the present analysis 3275 patients with end-stage hip OA 
(N=1691) and knee OA (N=1584) were included in the cohort study. For both end 
stage hip and knee OA, 90.3% of the participants completed the questionnaire. In 
Table 1 the socio-demographic variables of patients returning the questionnaire that 
did and did not complete it fully were compared. In hip OA, those who did not fully 
complete the questionnaire were significantly older, whereas in knee OA those who 
did not complete the questionnaire fully were more often female and had a lower 
score on the HOOS/KOOS-activities of daily life domain. In both end stage hip and 
knee OA those who did not complete the questionnaire had a significantly lower 
score on the MCS.  
 
Table 1 – Characteristics of patients with end stage OA who did and did not complete the 
Groningen Frailty Indicator questionnaire.  
















Female 925 (61.5%) 107 (67.3%) 0.155 911 (64.2%) 119 (77.3%) 0.001 
Age 67.8 ± 9.8 70.9 ± 9.4 <0.001 67.4 ± 8.9 67.6 ± 9.1 0.818 
BMI 27.2 ± 4.3 27.0 ± 5.4 0.529 29.4 ± 4.7 29.0 ± 4.4 0.373 
Not living alone 1187 (77.7%) 118 (71.9%) 0.097 1095 (76.5%) 115 (75.7%) 0.598 
Musculoskeletal 
Comorbidities 
259 (17.8%) 29 (20.9%) 0.370 326 (24.1%) 39 (26.5%) 0.522 
Other Comorbidities 942 (70.7%) 80 (69.0%) 0.692 900 (74.7%) 85 (73.9%) 0.855 
SF12 
Physical  32.2 ± 9.4 32.4 ± 9.2 0.821 32.3 ± 9.1 32.4 ± 9.7 0.918 











Pain 37.9 ± 18.6 39.8 ± 20.0 0.244 38.9 ± 17.6 36.4 ± 18.8 0.124 
Symptoms 39.8 ± 18.5 41.9 ± 20.6 0.252 43.7 ± 13.5 42.0 ± 12.4 0.178 
Activities 
of daily life 
39.9 ± 19.2 41.8 ± 21.6 0.324 45.0 ± 18.2 40.8 ± 20.9 0.026 
Sport 18.1 ± 18.4 21.6 ± 21.7 0.200 10.7 ± 14.3 11.2 ± 15.5 0.852 
Quality  
of Life 
33.4 ± 10.8 35.2 ± 12.1 0.083 33.6 ± 10.4 34.6 ± 11.8 0.327 
* Charcteristics of patients who completed and did not complete the GFI were tested by means of a 
T-test (normal distribution), Mann-Whitney test (not normal distribution) or Chi-square test (discrete 
variables). 
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On a total of 15 items, the median number of missing items for both joint locations 
was 0 (range 0 to 15), whereas the mean (SD) was 0.4 (1.9) (hip OA: 0.4 (2.0), knee 
OA: 0.3 (1.8)). Of the 164 patients with hip OA who did not complete all questions, 
29 did not fill in any question whereas 99 missed only one question. Of the 154 
patients with knee OA who did not complete all questions, 21 did not fill in any 
question and 102 persons had only one missing question.  
Table 2 shows the percentage of missing values per question. Most frequently 
missed was question 15 “How would you rate your physical fitness on a scale of 1 to 
10?” for both hip and knee (hip 4.4% missing, knee 4.2% missing). This was the only 
question with no predefined answering options; instead patients had to write down 
the number themselves. In addition, in patients with hip OA question 2 “Are you able 
to walk independently outside?” (2.8% missing) and question 3 “Are you able to 
(un)dress yourself?” (2.7% missing) were relatively often missing, while in knee OA 
patients question 6 “Do you encounter problems in daily life because of impaired 
hearing?” (2.6% missing) and question 2 “Are you able to walk independently 
outside?” (2.3% missing) were relatively often missing. 
Table 2 – Percentage of missing per question for the Groningen Frailty Indicator Hip Knee 
1 Are you able to do groceries by yourself? 2.5% 1.9% 
2 Are you able to walk independently outside? 2.8% 2.3% 
3 Are you able to (un)dress yourself? 2.7% 2.2% 
4 Are you able to use the bathroom by yourself? 2.7% 2.0% 
5 Do you encounter problems in daily life because of impaired vision? 2.5% 2.6% 
6 Do you encounter problems in daily life because of impaired hearing? 2.4% 1.8% 
7 Did you unintentionally lose weight over the past 6 months? 2.4% 1.8% 
8 Do you use 4 or more types of medication 2.7% 1.8% 
9 Do you have any complaints of your memory? 2.1% 1.8% 
10 Do you experience emptiness around you? 2.2% 1.8% 
11 Do you miss the presence of other people around you? 2.4% 2.0% 
12 Do you feel left alone? 2.7% 1.8% 
13 Have you felt down or depressed lately? 2.5% 2.0% 
14 Have you felt nervous or anxious lately? 2.5% 2.0% 




To assess determinants for completing the GFI questionnaire a logistic regression 
model was build including age, sex, BMI, musculoskeletal and other comorbidities. 
Table 3 shows the odds ratio’s associated to this model.  It was found that age and 
sex are statistically significant determinants for completing the questionnaire in 
persons with end-stage OA of the lower limb corrected for BMI and comorbidities.    
 
Table 3 – Odds ratio’s for demographic characteristics associated with completing the GFI. 
 Odds Ratio 95% CI P-value 
Age 0.981 0.966-0.997 0.020 
Sex 1.497 1.100-2.038 0.010 
BMI 1.006 0.974-1.039 0.714 
Musculoskeletal comorbidities 0.946 0.661-1.354 0.762 
Other comorbidities 0.890 0.644-1.230 0.481 
Characteristics were included in logistic regression analysis to assess their association with 
completing the GFI questionnaire (yes/no). 
 
Older age is, independent of gender, BMI and comorbidities, associated to lower 
odds for completing the questionnaire (OR: 0.98, P-value 0.020) while for gender it 
was found that, when correcting for age, BMI, musculoskeletal and other 
comorbidities, females have higher odds for completing the questionnaire as 
compared to males (OR: 1.50, P-value; 0.010). BMI and having musculoskeletal or 
other comorbidities were not statistically significant associated to the completing of 
the GFI questionnaire for persons with end-stage hip or knee OA.  
The internal consistency of the GFI in patients scheduled to undergo arthroplasty 
was 0.69, just below the threshold of 0.7 of good internal consistency [31]. Regarding 
the validity of the GFI questionnaire the mental and physical domains of GFI were 
strongly to moderately correlated with the MCS of the SF12 (R = -0.59, P<0.001) 
and the PCS (R = -0.39, P<0.001), respectively, confirming the validity of the 
questionnaire. When performing cross-over analysis by correlating the mental 
domain of the GFI to the PCS of the SF-12 discriminatory validity was confirmed with 
a very weak correlation (R= -0.08; P<0.001).  
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In addition, the correlation of the physical domain of the GFI and MCS had a low 
correlation of R= -0.28 (P<0.001). The correlation of the GFI with the HOOS/KOOS-
pain score was, as hypothesized, low and also confirmed its discriminatory value to 
distinguish between pain and frailty (R = -0.23, P<0.001).  
Of the 2957 patients with end stage hip or knee OA who did complete the 
questionnaire, 853 (28.8%) were considered frail (a score of ≥4 on GFI). Patients 
with hip OA scored on average higher on the GFI (mean (SD) score: 2.78 (2.41) 
versus 2.28 (1.99)) and were more often considered frail as compared to persons 
with knee OA (33.3% versus 24.1%). Table 4 shows that frail persons were 
statistically significantly more often female, older and had a higher BMI as compared 
to those who are not frail. Also, frail persons scored statistically significantly lower 
on all scales of physical functioning of the HOOS/KOOS as well as on the physical 
and mental component scale of the SF-12 before arthroplasty surgery.  
Table 4 – Comparison of demographic characteristics of frail and non-frail end stage OA patients 








End stage hip OA 1018 (66.7%) 509 (33.3%) 
< 0.001 
End stage knee OA 1086 (75.9%) 344 (24.1%) 
Female 1216 (58.4%) 620 (73.6%) < 0.001 
Age 67.07 ± 9.02 68.99 ± 9.97 < 0.001 
BMI 28.07 ± 4.41 28.69 ± 5.14 0.002 
Musculoskeletal comorbidities 351 (17.5%) 234 (29.4%) < 0.001 
Other comorbidities 1248 (68.1%) 594 (84.4%) < 0.001 
SF12 
Physical  33.38 ± 9.52 29.33 ± 7.80 < 0.001 
Mental 58.33 ± 6.79 47.01 ± 11.06 < 0.001 
HOOS  
/ KOOS 
Pain 40.56 ± 17.53 32.96 ± 18.45 < 0.001 
Symptoms 43.05 ± 16.25 38.19 ± 16.34 < 0.001 
Activities of daily life 45.36 ± 18.22 34.97 ± 18.51 < 0.001 
Sport 16.07 ± 17.54 10.64 ± 14.57 < 0.001 
Quality of Life 34.49 ± 10.79 31.06 ± 9.75 < 0.001 
* Charcteristics frail and non-frail patients were tested by means of a T-test (normal distribution), 
Mann-Whitney test (not normal distribution) or Chi-square test (discrete variables). A score of ≥4 





The GFI is a valid questionnaire to assess frailty in end stage hip or knee OA patients 
by means of a self-reported postal questionnaire. According to the GFI, using the 
cut-off of 4, about one-third of the patients undergoing THA and a quarter of the 
persons undergoing TKA are frail.  
The feasibility of the use of the GFI within the current clinical setting for patients with 
end stage hip or knee OA is good, as 90% of the participants completed the 
questionnaire. In a study by Metzelthin et al. in older community dwelling persons 
showed that 77.4% of the persons completed the questionnaire.32  
Those who did not complete the questionnaire were more often male and older. The 
open question (question 15) was most often left empty, indicating that it is probably 
easier for patients to have closed questions with predefined answer options. Further 
research is needed to reconsider the format of this question aiming to obtain higher 
response rates.  
Although the Cronbach’s alpha of 0.69 is just below the threshold of good internal 
consistency of 0.7, it does indicate that the internal consistency of the GFI in our 
patient group is satisfactory and it is comparable to the alpha of 0.68 as found by 
Peters et al in home dwelling elderly in the Netherlands.20,31 
With respect to the convergent and discriminatory validity of the GFI for this specific 
patient group, the magnitude of the observed associations was in line with our 
hypotheses. Our convergent validity (range -0.6 –0.4) was comparable to the 
findings of Peters et al (range 0.4-0.61) [20]. The discriminatory validity in our patient 
group (range -0.08 - -0.3) was even stronger as compared to the elderly of Peters et 
al (range 0.08 - 0.5).20 
Significantly more patients with end stage hip OA were considered to be frail as 
compared to end stage knee OA (hip; 33%, knee; 24%, P<0.001). However, both 
these numbers are lower as compared to the study of Peters et al20 who found 60% 
of the independent living elderly in their study to be frail as measured by the GFI, but 
the average age in that study was 81 years, much higher than in the present study 
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(mean age 68 years). In a study among Romanian home-dwelling elderly (mean age 
75), 75% of the participants were considered frail by the GFI.33 These studies show 
that the presence of frailty shows wide variability depending on country, social status, 
diagnosis and age. The median and mean scores of the GFI in our patient group 
(2.00 and 2.54, respectively) were lower than the averages in independent living old 
persons found by Peters et al20 (median 3) or reported by Metzelhin et al32 and 
Drubbel et al34 (means 3.8 and 3.2, respectively).  
In both the latter studies the mean age was higher than in our study (77 and 73 years 
respectively). The lower frailty score in our patient groups can, apart from age, be 
explained by the fact that all patients were selected by an orthopaedic surgeon to 
receive arthroplasty surgery and were thus considered to be fit enough for major 
surgery. 
The rates of persons with OA classified as being frail in our study are not easy to 
compare with other studies, as different methods to ascertain frailty were employed. 
Using Fried’s Frailty Phenotype, Mandl et al35 found that 8% of persons scheduled 
for knee arthroplasty were considered frail (although 17% reported difficulty with 
activities of daily life) with a similar rate found in men with hip osteoarthritis (8%) and 
in a study of persons with knee, hip or hand OA from 6 different European cohorts 
(10.2% considered frail). 6,36,37 
A larger proportion, i.e. 22.4% of persons with hip or knee OA, was considered frail 
using Fried’s Frailty Phenotype in a Brazilian study.38 With the interpretation of these 
proportions it must be taken into account that the criteria of Fried’s Frailty Phenotype 
are to be ascertained by a physician and do not include activities of daily life. 6  
 
Dent et al39 have published an overview of the most commonly used frailty-
questionnaires including, besides the GFI, three other self-reported frailty 
assessments: the Tilburg Frailty Index, the PRISMA-7 and the SPQ. However, none 
of these other three self-reported questionnaires have to our knowledge been used 




Since a large proportion, about one third, of the patients scheduled to undergo major 
implant surgery are considered frail as scored by the self-reported GFI, the effects 
of frailty on their postoperative outcome should be assessed in future studies. This 
study has shown that the use of the GFI to discriminate between frail and non-frail 
total joint arthroplasty patients is appropriate. 
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Introduction: Up to 33% and 25% of end-stage hip and knee osteoarthritis (OA) 
patients are considered frail by the Groningen Frailty Indicator (GFI).1 This study 
aims to assess whether frail patients have lower functional gains after arthroplasty 
and to assess GFI as a tool to discriminate between good or adverse change-score. 
Materials and Methods: End-stage hip/knee OA patients scheduled for arthroplasty 
were recruited from the LOAS-study. Functional outcome was measured as change-
score on the Hip/Knee Osteoarthritis Outcome Score (HOOS/KOOS), by subtracting 
pre-operative score from 1-year post-surgery score and then dichotomised based on 
a cut-off of 20 points. For each HOOS/KOOS-subscale 3 models were estimated: 
GFI univariate (model 1), GFI and baseline-score (model 2) and baseline-score 
univariate (model 3). A ROC-analysis was performed to assess the discriminative 
ability of each model. 
Results: 805 end-stage hip (31.4% frail) and 640 end-stage knee OA patients 
(25.4% frail) were included. Frail patients were older, had a higher BMI, more 
comorbidities and lived more often alone. Persons considered frail by GFI had 
significant lower baseline-score; however, except for “function in sports & recreation” 
and “quality of life” change-scores were similar in frail and non-frail persons. 
The discriminatory value of GFI was negligible for all HOOS/KOOS-subscales. 
Baseline score, however, was adequate to discriminate between TKA patients with 
more or less than twice the minimal clinical important difference (MCID) on KOOS-
symptoms-subscale (AUC=0.802) 
Conclusion: Although frail OA patients have lower functioning scores at baseline, 






Osteoarthritis (OA) is a common, degenerative, disabling joint disease, affecting up 
to 23.1% of persons aged over 70 years.2 These numbers are likely to increase due 
to population ageing and the epidemic proportions of obesity in the general 
population.3,4 Thus far no cure for OA has been found; instead when pain relief is not 
sufficient anymore, the final treatment option is Total Joint Arthroplasty (TJA) in hip 
(THA) or knee (TKA). In the Netherlands, 28,798 THAs and 24,107 TKAs were 
performed in 2015 with up to 50% of the THA and 42% of TKA in persons aged ≥70.5 
Despite these large numbers, about 10-20% of all THA and TKA patients are not 
satisfied with their post-operative results.6,7 One of the reasons might be pre-
operative state of the patient, reflected by frailty. 
Frailty is a common syndrome in the elderly, with an overall prevalence of frailty 
amongst people aged ≥65 of 10.7%.8,9 Frailty, as a representative of health and 
functional status, hampers the capacity to resist stressors, which in turn leads to 
increased susceptibility for adverse outcomes after surgery.9-13 Reported levels of 
frailty vary greatly amongst age groups, with the pooled prevalence rates for persons 
aged between 65-69 being below 5% while for those aged 80-85 this is over 15% 
and even over 25% for persons aged ≥85.8 Within persons of the same age group, 
substantial heterogeneity is present to the levels of frailty an individual might 
experience.10,11,14-16 
Previously we have shown that the Groningen Frailty Indicator (GFI) is a feasible 
and validated questionnaire in persons with end stage hip or knee OA.1 Using the 
GFI with a cut-off value of 4, we demonstrated that up to one third of the end stage 
OA-patients scheduled to undergo THA and a quarter of those scheduled for TKA 
are considered to be frail.1 
Mandl et al17 have addressed adverse events after TJA in 241 frail and non-frail 
patients and found that there was only an association between activities of daily life 
and adverse events after TJA. However, this study had a follow-up period of only 30 
days and is not representative for the long-term functional outcome of TJA in patients 
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with end stage hip or knee OA. A study by McIsaac et al18 (follow-up 1 year) in 
125163 TJA-patients studied healthcare resource usage but not functional 
outcomes. They found frail patients to have increased mortality, increased length of 
stay in hospital, higher chance of re-admission and higher rates of discharge to 
institutional care after TJA as compared to non-frail TJA patients. A study on the 
impact of frailty on the long-term postoperative function has, to our knowledge, not 
yet been performed. 
In this study, we aim to assess whether frail persons (cut-off value GFI≥4) have lower 
gain in post-operative function and quality of life. We also assess by means of ROC-
curves whether the pre-operative GFI is valuable tool to discriminate between THA 





This analysis was performed in the longitudinal prospective cohort study 
“Longitudinal Leiden Orthopaedics Outcomes of Osteo-Arthritis Study (LOAS, Trial 
ID NTR3348)” which consists of patients undergoing total hip or knee arthroplasty 
for primary osteoarthritis. Participants were selected from 7 participating hospitals 
(the Leiden University Medical Center, Leiden; Alrijne Hospital, Leiden/Leiderdorp 
(former Diaconessenhuis and Rijnland Hospital); Groene Hart Hospital, Gouda; 
LangeLand Hospital, Zoetermeer; Reinier de Graaf Gasthuis, Delft; Albert 
Schweitzer Hospital, Dordrecht; Waterland Hospital, Purmerend). 
Patients 
 All TJA patients aged over 18 years able to complete questionnaires in Dutch were 
eligible for participation. Patients were excluded if the physical or mental status did 
not allow participation or in case they did not sign the informed consent. Written and 
oral information about the study was given by the treating medical specialist at the 
outpatient clinic. Patients willing to be approached by the researcher received 
additional written information about the study by regular mail or e-mail, as well as a 
questionnaire, a stamped return envelope and a consent form. Patients were 
included once written informed consent was obtained according to the Declaration 
of Helsinki.19 
For the purpose of the present analysis only data from patients who returned both 
the preoperative and the 12 month follow-up questionnaires was included. Ethical 
approval was obtained from the Medial Ethics Committee of the Leiden University 
Medical Center (registration number P12.047) and funding was received from the 
Dutch Arthritis Foundation (LLP13). 
Assessments 
Demographic variables: The collected socio- and demographic characteristics of the 
patients included: age (years); sex and length (cm) and weight (kg) to calculate the 
Body Mass Index (BMI). Living situation was also collected and divided in ‘living 
alone’ or ‘living together’, the latter category included persons living with family 
members as well as persons living in community housing. 
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Comorbidities: The presence of comorbidities was assessed by means of a self-
reported questionnaire comprised of 19 different comorbidities. Patients were asked 
to respond with either yes or no to the question “Have you received any treatment 
for [disease] in the past year”. The included diseases were then clustered in two 
groups: musculoskeletal comorbidities (severe back pain, severe neck or shoulder 
pain, severe elbow wrist or hand pain, inflammatory arthritis or other joint conditions) 
or other comorbidities (asthma or COPD, cardiac disorder or coronary disease, 
arteriosclerosis, hypertension, stroke, severe bowel disorder, diabetes mellitus, 
migraine, psoriasis, chronic eczema, cancer and urine incontinence, hearing or 
visual impairments and dizziness in combination with falling). 
Groningen Frailty Indicator: The presence of frailty was analysed by means of the 
Groningen Frailty Indicator (GFI). The GFI is a 15 item validated questionnaire based 
on many aspects of life: activities of daily life, medication use, mental state, vision 
and hearing. Each item can give one point, resulting in a maximum score of 15. A 
patient with a score of ≥4 was considered frail.20-23 The GFI has been validated to be 
used in patients with end-stage OA scheduled to undergo arthroplasty surgery.1 
Functional outcome (HOOS/KOOS): Patient function was assessed by the validated 
Hip disability/Knee injury Osteoarthritis Outcome Score (HOOS/KOOS) 
questionnaires for hip and knee patients respectively. Both questionnaires comprise 
five domains: activities of daily living (ADL), quality of life (QoL), sports (SP), 
symptoms (SYM) and pain (P).24,25 For the current study the validated Dutch versions 




Demographic characteristics of frail and non-frail patients were compared for hip and 
knee arthroplasty separately by means of Student’s T-test (continue, normally 
distributed variables), Mann-Whitney U-test (continue, not normally distributed 
variables) or Chi-square (categorical variables), whichever was appropriate; per joint 
site. 
Functional outcomes were assessed by means of the 5 subscales of the 
HOOS/KOOS questionnaire (pain (P), symptoms (S), activity limitations of daily 
living (A), sport and recreation functioning (SP) and joint related quality of life (QoL)). 
Scores were compared between frail and non-frail patients by means of Mann-
Whitney U-test for each time point (baseline and 12 months) separately. In addition, 
for each of these scores a change-score was calculated by subtracting pre-surgery 
score from the 1-year follow-up scores. These were compared between frail and 
non-frail patients (cut-off value GFI≥4) by means of Mann-Whitney U-test. 
Adverse outcome was defined as improving less than twice the Minimal Clinically 
Important Difference (MCID), meaning an improvement of less than 20 points on the 
HOOS/KOOS in the year after surgery.24 This binary score (more or less than twice 
MCID) was calculated for each subscale of the HOOS/KOOS. For each subscale a 
logistic regression model was estimated with the binary outcome score and GFI as 
continue independent risk factor (Model1). Then a multivariable logistic regression 
model with GFI and baseline HOOS/KOOS score as prognostic factor was estimated 
(Model 2). Finally, a univariate logistic regression model was estimated to assess 
the association of baseline HOOS/KOOS score on GFI (Model 3). AUC was 
estimated to assess the discriminatory ability of the logistic regression models.28 
All analyses were performed separately for THA and TKA patients. Data were 
analysed using the SPSS statistical package (version 20.0, SPSS, Chicago, Illinois). 
The level of statistical significance was set at P ≤ 0.05 for all analyses.  
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Results 
Among the 3,190 patients that were included in the LOAS-cohort, 1,570 (873 THA 
and 697 TKA) completed the HOOS/KOOS questionnaires at baseline and at 12 
months follow-up. Of these, 92% also completed the GFI, resulting in 1445 persons 
in our analyses (805 THA and 640 TKA), see also Figure 1. Patients who did not 
complete the GFI were significantly older than those who did (mean (SD) age in 
years completed 66 (9.1), mean (SD) age not completed 69 (8.6), P=0.008) and 
female (72.8% female not completed, 63.5% female completed, P=0.04). No 
significant differences for BMI, musculoskeletal or other comorbidities were 
observed. 
Figure 1 – Flowchart of patients included in the study and their final outcome. 
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Upon comparing frail patients to non-frail patients, significant differences were found 
for almost all the socio-demographic characteristics included in the analyses. Frail 
persons were more often female, older, had more comorbidities, a higher BMI and 
were more often living alone as compared to non-frail end-stage hip or knee OA 
patients (see also Table 1). Within the group of frail patients, frail patients with knee 
OA had significant higher BMI as compared to frail hip OA patients (results not 
shown).  
Table 2 shows the crude baseline and the 12-month follow-up scores on each of the 
HOOS/KOOS subscales as well as the change score. Except for the KOOS-
symptoms subscale, all baseline and 12 months scores of the HOOS/KOOS 
subscales were statistically significantly different in the frail persons as compared to 
non-frail patients. However, the significant difference between frail and non-frail is 
only clinically relevant at baseline in the subscale pain for hip and subscale ADL for 
both hip and knee. At 12 months the MCID-threshold of 10 is only reached in ADL 
for hip patients and in the subscale sports for hip and knee patients.24  
Table 1 - Demographic characteristics of frail and non-frail (as defined by the Groningen Frailty 
Indicator (GFI)) end-stage osteoarthritis patients. 
  Hip Knee 
Non-Frail Frail (GFI≥4) Non-Frail Frail (GFI≥4) 
N=552 N=253 P* N=477 N=163 P* 
Female N(%) 312 56.5% 187 74.2% <0.001 291 61.5% 125 76.7% <0.001 
Age mean (SD) 66.2 9.1 68.3 10.3 0.004 66.1 8.6 68.2 8.7 0.010 
BMI mean (SD) 26.6 3.8 28.1 5.3 <0.001 28.9 4.4 30.0 5.2 0.022 
MSK comorbA N(%) 64 12.0% 60 25.0% <0.001 98 21.6% 44 29.3% 0.054 
Other comorbB N(%) 321 65.0% 185 84.1% <0.001 294 70.5% 117 84.2% 0.001 
Living alone N(%)  66 12.0% 88 34.8% <0.001 78 16.4% 66 40.5% <0.001 
*P-value corresponding to Chi-square (discrete variables) or t-test (normally distributed continue variables) 
for differences between frail and non-frail persons within joint-specific group. 
A MSK cormob. - Musculoskeletal comorbidities include severe back pain, severe neck or shoulder pain, 
severe elbow wrist or hand pain, inflammatory arthritis or other joint conditions. 
B Other comorb _ Other comorbidities include asthma or COPD, cardiac disorder or coronary disease, 
arteriosclerosis, hypertension, stroke, severe bowel disorder, diabetes mellitus, migraine, psoriasis, chronic 













































































































































































































































































































































































































































































































































































































































































































































































The change-score for the Sports subscale was lower in frail as compared to non-frail 
in both hip (P=0.002) and knee (P<0.001). Also for the Quality of Life-subscale in 
knee a lower outcome change-score was found for frail persons (P=0.02). This 
suggests that the development over time, i.e. the change-score, in most subscales 
is similar in frail and non-frail persons. Only in Sports and QoL, non-frail persons 





Using the continuous scores of GFI (range 0-15, Figure 2); the potential of the GFI 
to discriminate between outcomes was assessed by constructing three models and 
the AUC for each model was estimated (Table 3). The model that included only GFI 
had poor discriminatory value (maximum AUC was 0.643 for Sports subscale in 
THA). The AUC for the model with GFI and baseline score as risk factors was equal 
to 0.804 for Symptoms in TKA while the model with only baseline score as risk factor 
had an AUC equal to 0.802 for Symptoms in TKA (Table 3).  
Finally, we assessed the number of reoperations that were performed in the first 12 
months post primary hip or knee arthroplasty and compared the rates of frail to the 
rate in the non-frail patients (Figure 1).  Of the 163 frail patients with a knee 
replacement, 6 (3.7%) had to be re-operated on the same knee within 12 months, 
this rate was lower in the non-frail knee patients (2.1%, P=0.278). For persons with 
a hip replacement we did see a significant lower rate of re-operations in the non-frail 
patients (2.4%) as compared to the frail patients (6.4% P=0.005). 
 
Table 3 – Discriminatory power between more or less than twice the MCID increase for various 
models in- and excluding Groningen Frailty Indicator (GFI). 
  Hip Knee 












Pain 0.498 0.712 0.697 0.543 0.730 0.705 
Symptoms 0.549 0.797 0.767 0.510 0.804 0.802 
Activities of Daily Life 0.532 0.795 0.753 0.539 0.734 0.708 
Sport  0.643 0.705 0.573 0.588 0.597 0.557 
Quality of Life 0.575 0.623 0.623 0.561 0.611 0.582 
Area under the estimated ROC curve corresponding to different models.   
A - Model 1: Univariate analysis with Groningen Frailty Indicator (GFI) score as prognostic factor. 
B - Model 2: Multivariate analysis with GFI and baseline score as prognostic factor. 




Although obvious preoperative (i.e. baseline) differences in values for the 
HOOS/KOOS subscales existed between frail and non-frail patients who undergo 
TJA, frailty did not discriminate between good or adverse outcome.  
A model for TKA including GFI and pre-operative Symptoms-baseline score has an 
AUC equal to 80.4% for distinguishing between patients with a twofold MCID change 
on the symptoms subscale of the HOOS/KOOS. When only the pre-operative score 
was used, a similar AUC was found (80.2%), indicating that frailty has only a 
marginal additional value to increase this discriminatory value of post-surgery 
outcome in THA and TKA patients. 
One reason might be the presence of selection bias, since only persons who are 
scheduled to undergo arthroplasty were included. This also explains skewed 
distribution of the continuous GFI scores. These persons have all undergone 
selection by the orthopaedic surgeon and those not considered fit to have surgery 
were excluded. The levels of frailty in this rejected group were unknown. However, 
amongst those undergoing surgery still 31.4% in hip and 25.4% in knee are 
considered frail by GFI (cut-off value of 4). Another problem may be the selection 
bias which is induced by excluding patients who, based on their mental or physical 
status, could not complete the questionnaires. Exactly these patients may be those 
who are most frail. Unfortunately, we did not have data to assess exactly how many 
patients were not capable to complete the questionnaires.   
A study by O’Neill et al29 demonstrated that the initial clinical impression by a 
physician of a patient is a useful screening tool to predict for mortality in patients 
undergoing major surgery. Also, a study conducted by Gerdhem et al30 has 
demonstrated the subjective estimate of physicians of biological age is appropriate. 
Our results support these studies in the sense that improving outcome within the 
current selection of the physician, who apparently allowed GFI-indicated frail 
patients, is not possible by GFI since both frail and non-frail profited almost equally 
from the operation. 
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In our study we did find that persons who are considered frail by GFI have more 
often comorbidities and higher BMI, however, this is not a strong prognostic factor 
for postoperative functional outcomes. This might be due to selection bias by the 
treating orthopaedic surgeon (i.e. more severe comorbid patients or patients with 
even higher BMI were not selected). However, our results are in line with a study in 
head and neck cancer patients, showing that frailty as measured by the GFI is not 
predictive for postoperative complications after surgery.31 In contrast, a study by 
Baitar et al32 found that GFI is able to separate patients with cancer with normal and 
abnormal Comprehensive Geriatric Assessment. 
We did find a higher reoperation rate in the frail patients as compared to the non-frail 
patients, confirming previous studies that found that frailty is a predictor for adverse 
events such as complications, readmission and reoperation.33-35 This could be 
related to the increased number of comorbidities as we saw in our frail population; 
however, this should be further assessed in future studies.  
For functional recovery after arthroplasty surgery, we have now shown that GFI is 
not a strong prognostic factor. We found that the functional baseline score is a strong 
prognostic score which can fairly well discriminate between good and adverse 
functional outcomes. In addition, we found that frail persons have significant lower 
functional baseline scores than non-frail persons. Therefore, baseline score seems 
a better measurement to give any indication about the to-be-expected outcome of 
surgery over frailty score when focusing on functionality, not necessarily when 
focusing on QoL or health care use. Jiang et al33 have also identified that worse 
baseline scores of OKS are associated with worse post-surgery OKS up to 10 years 
after TKA. Exploring what other health assessments apart from functional 
parameters would predict post-surgery functionality, such as metabolic and 
inflammatory conditions at baseline, might improve patient-specific outcome 
prediction. 
The cut-off of more or less than twice the MCID to assess the effect of GFI was 
arbitrarily, however, if we set the threshold at once the MCID (i.e. 10-point increase) 
similar results were found.  
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A limitation of this study is the aforementioned selection bias, as we only assessed 
persons selected by their treating surgeon to undergo surgery and did not have 
information of patients who were not selected to undergo surgery. These latter 
patients are most likely to be frail. Nevertheless, up to one-third of the patients who 
do undergo surgery are considered frail as measured by the GFI. 
Among the patients selected for THA and TKA, baseline frailty assessed by the GFI 
did not provide added value in distinguishing between patients with more or less than 
twice the MCID change on functional outcome score by the HOOS/KOOS index, one 
year post-operative. Theoretically, it may be possible that more frail patients, 
currently not admitted to surgery, would profit functionally from THA/TKA surgery. 
However, as we do see higher reoperation rates in the frail patients, further research 
is needed before broadening the indication for arthroplasty surgery.  
We conclude that although frail OA patients have lower functioning scores at 
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Background: About 33% of the osteoarthritis patients undergoing total hip/knee 
arthroplasty are not satisfied with the outcome, warranting the need to improve 
patient selection and to improve management of patient expectations. Previous 
research has found that quadriceps strength is related to outcome of arthroplasty 
and handgrip strength has been suggested as a proxy for overall muscle strength. 
This study aims to assess whether preoperative handgrip strength is associated with 
gain in hip/knee function and quality of life in arthroplasty patients. 
Materials & Methods: 226 hip and 246 knee arthroplasty-patients were selected 
from a prospective cohort study, including patients from October 2010 to September 
2012. Preoperative handgrip strength was assessed with a dynamometer and the 
HOOS/KOOS and SF-36 questionnaires were collected before arthroplasty and one 
year thereafter. The association of handgrip strength with the outcome change was 
assessed by linear regression models, including age, sex, body mass index and 
baseline score. 
Results: Handgrip strength was strongly associated with change score on “sport & 
recreation”-domain in hip and moderately to “sport & recreation”-domain in knee and 
“symptoms”-domain in hip.  
Conclusions: Handgrip strength can be used as a tool to provide patients with 







Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) are effective 
procedures to improve pain and functioning in osteoarthritis (OA) patients.1,2  Despite 
high success rates, up to one-third of persons undergoing arthroplasty are not 
satisfied with the outcome of surgery, warranting the need to improve the selection 
of patients who may and may not benefit and manage expectations in this patient 
group. 3-5  
Besides age, gender, physical and mental status, poor quadriceps strength was 
associated with worse outcomes of knee arthroplasty.6-8 Handgrip strength (HGS) is 
a proxy for overall muscular strength, with only a small number of measurements 
with a handgrip dynamometer considered necessary to characterize an individual’s 
overall strength status.9-11 
HGS has been demonstrated to associate with worse general health in the elderly 
as well as being a predictor for all-cause mortality in elderly.12-18 In various patient 
groups, HGS has been shown to be predictor for disability, malnutrition and surgery 
complications.19-29 To our knowledge, only one study focused on HGS in hip and 
knee arthroplasty patients, showing that a lower HGS is associated with increased 
length of hospital stay after hip or knee replacement while correcting for age.30 
Hence, the value of HGS as a predictor for long-term outcomes after lower limb 
arthroplasty surgery is currently unknown.  
The purpose of this study is to assess the association of preoperative HGS with 
postoperative changes of hip and knee function and quality of life one year after total 
hip or knee arthroplasty as measured on the various subscales of the Hip disability 
and Osteoarthritis Outcome Score (HOOS) and Knee Injury and Osteoarthritis 




Materials & Methods 
This study on HGS as an indicator for THA and TKA outcome was part of a 
prospective observational cohort study on the outcomes of THA and TKA performed 
at the Department of Orthopedics of the Alrijne Hospital, Leiderdorp, the 
Netherlands, from October 2010 to September 2013 (inclusion of patients until 
September 2012).  
The study protocol was in concordance with the Declaration of Helsinki31 and was 
reviewed and approved by the local hospital Review Board of the Alrijne Hospital 
(registration number 11/02), which is supervised by the Medical Ethics Committee of 
the Leiden University Medical Center, Leiden, the Netherlands. 
 
This prospective cohort study aimed to include all consecutive patients undergoing 
a primary THA or TKA because of OA, aged 18 years or older, able to read and 
understand Dutch and being mentally and physically able to complete 
questionnaires.  
Excluded were patients with revision of a THA or TKA, undergoing a hemi-
arthroplasty of the hip and undergoing a THA or TKA because of a tumor or 
rheumatoid arthritis. All assessments were done preoperatively and 12 months 
thereafter and consisted of HGS measurement at the hospital and the collection of 
questionnaires, administered personally (preoperative assessment) and by regular 
mail (follow-up).  
 
One day preoperatively, before being admitted to the hospital, information about the 
study was provided to all eligible patients. Patients received a response form as well 
as a set of questionnaires. The response form comprised statements for both 
patients who wished to participate (including signature) and those who did not want 
to participate. Each patient was asked to return the questionnaires and informed 





Socio-demographic characteristics were recorded preoperative and included: age 
(years); gender and length (cm) and weight (kg) to calculate the Body Mass Index 
(BMI). Age was categorized into three groups; <60 years, 60-70 years and aged >70. 
 
Isometric HGS was measured before arthroplasty using the JAMAR® hydraulic hand 
dynamometer (Patterson medical, Mississauga, Canada).32 Results were expressed 
in kilograms. Patients were shown the correct operation of the dynamometer prior to 
measurements. They were instructed to keep their shoulders adducted and neutrally 
rotated, their forearm in a vertical position, and wrist in a neutral position and to 
squeeze the grip with maximal strength. The highest result of two grip strength trials 
with the dominant hand in a seated or semi-seated position was used. 
 
Patient reported outcome scores were collected before arthroplasty surgery and at 
one year follow-up. The SF-36 questionnaire was used to assess overall quality of 
life and the HOOS/KOOS for joint specific PROMS measurements. The SF-36 is 
composed of 36 questions and standardized response choices. Summary 
component scores for physical health (PCS) and mental health (MCS) can be 
calculated from this questionnaire. In this study, scores of the Dutch general 
population were used to standardize our scores in order to apply norm-based 
scoring.33 
 
In patients undergoing THA, the HOOS was used to assess functioning. This 
questionnaire consists of 40 items divided over 5 dimensions: pain (P); symptoms 
(S); activity limitations-daily living (ADL); function in sport and recreation (SP) and 
hip related quality of life (QoL). Persons with end stage knee OA received the similar 
KOOS questionnaire which comprises 42 items and uses the same 5 subscales as 
the HOOS. For the present study, validated Dutch versions of the HOOS and KOOS 






Patients’ socio-demographic characteristics were compared between those who did 
and did not complete the one year follow-up assessment by using unpaired Student’s 
t-test (for continue variables) or Chi Square test (for categorical variables).  
 
The SF-36 PCS and MCS subscales were included as outcome score as well as the 
five subscales from the HOOS/KOOS questionnaire: pain (P), symptoms (S), activity 
limitations of daily living (ADL), function in sport and recreation (SP) and quality of 
life (QoL). For each of these subscales a change score was calculated by subtracting 
the pre-surgery scores from the 1-year follow-up score.  
 
Normality of the change scores was assessed by means of histograms, Q-Q-plot 
and Kolmogorov-Smirnov test. Multiple regression models for hip and knee patients 
were used to study the association between HGS and change scores adjusted for 
age group, gender, BMI and preoperative values of outcome measures. An 
interaction term between gender and age group was incorporated in the model to 
investigate possible additional different effects between males and females. These 
analyses were performed for THA and TKA separately.  
 
The strength of the association of HGS to the outcome change score was quantified 
by assigning the unstandardized effect sizes to one of the categories: 0-0.19 very 
weak, 0.2-0.39 weak, 0.4-0.59 moderate, 0.6-0.79 strong, 0.8-1.00 very strong.36 
 
All data was analyzed using the SPSS statistical package (version 20.0, SPSS, 






341 persons undergoing THA surgery completed the preoperative assessment of 
which 226 (66.3%) persons completed the one year follow-up. Among the 315 TKA 
patients, 246 (78.1%) completed the one year follow-up. 
Demographic characteristics of patients with end stage OA, scheduled for either total 
hip or total knee arthroplasty are shown in Table 1. There were no statistically 
significant differences in age, gender and BMI between those who did and did not 
complete follow-up. Among those who completed the questionnaire, TKA patients 
were significantly more often female than those who underwent THA (P=0.001) and 
had a higher BMI (P<0.001), there was no significant difference in age between THA 
or TKA patients (P=0.605).  
Table 1 - Demographic characteristics of patients with end stage OA, scheduled for either total hip 
or total knee arthroplasty. 










Sex %Female 127 (56.1%) 75 (65.2%) 0.109 176 (71.5%) 52 (75.3%) 0.531 
Age (Years) 66.4 (9.5) 67.8 (10.8) 0.243 66.9 (9.2) 68.1 (11.5) 0.359 
BMI 26.9 (4.4) 27.8 (4.8) 0.082 29.4 (4.5) 29.7 (4.7) 0.675 
* P-value for differences between patients with end stage hip or knee OA who did and did not 
complete follow-up. Difference was calculated by means of Chi-Square or unpaired Student’s T-
test, where was appropriate. 
 
Mean HGS was 26 kg for end stage hip OA and 24 kg (SD=10) in end stage knee 
OA patients, with males having higher scores than females in both hip (mean (SD) 
HGS males: 34(10) kg, females: 21(6) kg) and knee (mean(SD) HGS males: 34(10) 
kg, females 19(7) kg).  
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As can be seen in Table 2, for each outcome score except MCS a significant 
difference in pre- and post-surgery outcome score was found. In both hip and knee 
the change in outcome for PCS was higher than the minimal clinically important 
difference (MCID) of 10 points. However, for MCS the change scores were not 
significant, neither clinically relevant.37,38 The smallest change score on the 
HOOS/KOOS subscales was 10.8, (KOOS-S) which is just above the MCID cut-off 
of 10.39,40 Interestingly, the final scores on the “Function in sport and recreation” and 
“Symptoms” subscales of the HOOS/KOOS were significantly (both P<0.001) higher 
in the THA groups than the TKA group.  
 
Table 2 – Outcome score at baseline and one year follow-up. 
  
  
Total Hip Arthroplasty 
N= 226 












PCS b 40.2  (7.5) 53.3 (7.7) <0,001 40.6 (7.3) 52.1 (8.9) <0,001 




ADLe 45.2 (17.8) 84.8 (16.9) <0,001 50.1 (18.1) 84.2 (16.4) <0,001 
Pain 43.2 (18.5) 88.2 (14.7) <0,001 43.0 (16.5) 85.0 (17.0) <0,001 
QoLf 35.7 (10.3) 54.8 (17.1) <0,001 35.2 (9.9) 54.2 (17.1) <0,001 
SPg 21.6 (19.3) 63.8 (26.6) <0,001 14.0 (16.0) 47.1 (28.8) <0,001 
Symptoms 38.2 (18.9) 80.5 (19.8) <0,001 45.0 (13.5) 55.8 (12.0) <0,001 
* P-value for Wilcoxon test assessing outcome score at baseline and one year follow-up. 
a SF-36: Short Form 36 Questionnaire. 
b PCS: Physical Component Score of the SF-36 questionnaire 
c MCS: Mental Component Score of the SF-36 questionnaire 
d HOOS/KOOS: Hip disability / Knee injury Osteoarthritis Outcome Score.  
e ADL: Activities of Daily Life – domain of the HOOS/KOOS Questionnaire 
f QoL: Quality of Life – domain of the HOOS/KOOS Questionnaire 




The unstandardized adjusted coefficients, showing the effect of preoperative HGS 
and the change on the postoperative PROMS outcome-variable, are shown in table 
3 where the effect is quantified by the coefficient (coef). In both arthroplasty groups 
a significant effect of HGS on “function in sport and recreation”-scale of the 
HOOS/KOOS (THA: coef=0.68, P=0.005; TKA coef =0.52, P=0.049) was found. 
Some evidence for an effect of HGS on the “symptoms” subscale was seen in THA 
(coef=0.56, P=0.001), but not in the TKA group (coef=0.16, P=0.146). A small effect 
of HGS to “quality of life” as measured by HOOS/KOOS was seen on THA 
(coef=0.32, P=0.047) and TKA (coef=0.33, P=0.033). A significant effect of HGS was 
found on PCS for TKA (coef=0.31, P=0.001) but not in THA (coef=0.14, P=0.052). 
No evidence of effect of HGS on the MCS of the SF-36 on both THA and TKA group 
was found.  
All observed statistically significant effects were positive, indicating that with 
increasing handgrip strength a positive change in the outcome measures occurs 
after arthroplasty surgery. 
Table 3 – Outcome of multiple regression models for HGS and change score.  
Total Hip Arthroplasty 
N= 226 
Total Knee Arthroplasty 
N=246 
Coef (SE) 95% CI P* Coef (SE) 95% CI P* 
SF-36a 
PCS b 0,136 (0,07) [-0,001 - 0,273] 0,052 0,305 (0,09) [0,135-0,476] 0,001 




ADLe 0,253 (0,15) [-0,037 - 0,543] 0,087 0,308 (0,15) [0,012-0,604] 0,042 
Pain 0,270 (0,13) [0,015 - 0,524] 0,038 0,188 (0,16) [-0,119-0,496] 0,229 
QoLf 0,317 (0,16) [0,005-0,630] 0,047 0,327 (0,15) [0,026-0,628] 0,033 
SPg 0,681 (0,24) [0,209-1,153] 0,005 0,520 (0,26) [0,001-1,039] 0,049 
Symh 0,564 (0,17) [0,228-0,900] 0,001 0,159 (0,11) [-0,056-0,373] 0,146 
* P-value; potential confounder age group, sex, BMI and baseline-outcome. 
a SF-36: Short Form 36 Questionnaire 
b PCS: Physical Component Score of the SF-36 questionnaire 
c MCS: Mental Component Score of the SF-36 questionnaire 
d HOOS/KOOS: Hip disability / Knee injury Osteoarthritis Outcome Score 
e ADL: Activities of Daily Life domain of the HOOS/KOOS  
f QoL: Quality of Life domain of the HOOS/KOOS 
g SP: Function in sport and recreation domain of the HOOS/KOOS 





This study shows that preoperative hand grip strength of total hip or knee 
arthroplasty patients is strongly associated to the change in outcome on the “function 
in sport & recreation”-subscale of the HOOS/KOOS in both the THA and TKA groups, 
a strong positive association was also found on the “symptoms”-subscale and some 
evidence for a smaller effect on “quality of life” of the HOOS in THA patients.  
Our findings are in agreement with current research where low HGS before surgery 
is associated to adverse outcome scores. The associations of HGS with the increase 
in score for physical measures (reflected in “function in sports and recreation”, 
“symptoms” and PCS) post-surgery is also discussed in Savino et al., the authors 
show that HGS is associated to walking recovery after hip fracture surgery.41 In the 
same type of patients, Visser et al42 have shown that a decline in HGS post-surgery 
is associated to less recovery of mobility and Beloosesky43 has demonstrated that 
HGS can be used to predict motor functioning at 6 months post-surgery. Although 
we measure a more generic outcome measure in a different patient group with a 
longer follow-up, these findings are in line with published literature.  
The association of HGS with “function in sport and recreation” was more pronounced 
in THA patients than TKA patients and the “symptoms”-subscale was only 
associated with HGS in THA patients, not in TKA patients. A systematic review by 
Skoffer et al44 found that muscle strength training in THA is effective to improve QoL 
after surgery, whereas for TKA this is not demonstrated.  
These outcomes, together with the present study, suggest that the association of 
muscle strength with surgery outcome is dependent on the joint site, however, the 
mechanism has yet to be elucidated. TKA patients were, at baseline, more 
overweight than THA patients, which may play a role. Indeed, it has been reported 
that obesity is negatively associated with functional score and quality of life after TKA 
but not in THA.45 However, our results were corrected for BMI, nevertheless, we do 
find different results for both joints. 
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The mean HGS values found in our study (THA: males: 34, females: 21; TKA: males: 
34, females 19) were lower than the reference values as reported by Leong et al46 
for males (HGS=42) and females (HGS=26) aged 61-70 from North America and 
Europe. These lower values are explained by the fact that our patients all have end-
stage osteoarthritis, while the reference values were obtained in healthy adults.  
This study suffers from a high rate of loss to follow-up (THA: 33.7% and  TKA: 
21.9%), although we did not find any statistically significant differences in age, sex 
or BMI distribution, those who did not complete follow-up tend to be older and have 
a higher BMI. As increased age and BMI are associated with worse outcomes, this 
is a major limitation to our study. 
Since the guidelines on indication for hip and knee arthroplasty are based on limited 
evidence, the application of HGS as a tool to identify patients who may experience 
lower outcome changes may contribute to optimize patient specific care.47,48 HGS 
could be applied to manage patients expectations and include patients in the shared 
decision making process.  
In conclusion, a rather easily applicable clinical measurement such as HGS could 
contribute to the assessment of the postoperative outcome of THA and TKA, 
providing the orthopedic surgeon as well as patients an easy preoperative tool on 
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Objective: Higher body mass index (BMI) is associated with osteoarthritis (OA) in 
both weight-bearing and non-weight-bearing joints, suggesting a link between OA 
and poor metabolic health beyond mechanical loading. This risk may be influenced 
by systemic factors accompanying BMI. We hypothesize that differences in 
metabolic state contribute to development of OA. This study explores the association 
of metabolites with radiographic knee/hip OA (HOA/KOA) prevalence and 
progression. 
Methods: A 1H-NMR-metabolomics assay was performed on plasma samples of 
1564 cases for prevalent OA and 2125 controls collected from the Rotterdam Study, 
CHECK, GARP/NORREF and LUMC-arthroplasty cohorts. HOA/KOA was assessed 
by means of Kellgren-Lawrence (KL) score and the OARSI-atlas. End-stage 
knee/hip OA was defined as indication for arthroplasty surgery (TKA/THA). OA-
progression was defined as an increase in KL-score, to at least ≥2. Controls did not 
have KOA/HOA at baseline or follow-up. Principal component analysis of 227 
metabolites demonstrated 23 factors, of which 19 remained interpretable after 
quality-control. Associations of factor scores with OA definitions were investigated 
with logistic regression resulting in odds ratio’s (OR) per SD. 
Results: Two factors showed consistent associations with prevalence and 
progression of KOA/HOA and TKA/THA. The “Glutamine and Histidine” factor 
showed negative associations (HOA: OR=0.7,P<0.001; THA: OR=0.7,P<0.001; 
KOA: OR=0.8,P=0.004; KOA progression: OR=0.8,P=0.020). The “Fatty-acids 
make-up” factor, representing chain length, ratio of saturated fatty acids and degree 
of unsaturation, showed positive associations (THA: OR=1.4,P<0.001; TKA: 
OR=1.6,P<0.001; HOA-progression: OR=1.2,P=0.047). 
Conclusion: Fatty acid-make-up, histidine and glutamine serum levels associate with 





Osteoarthritis (OA) is a common, age-related, progressive degenerative disease of 
articular joints and one of the leading causes of disability and pain worldwide. Due 
to ageing, increased longevity, and increasing obesity of the population, the OA 
incidence is expected to rise in the near future.1-3 Epidemiological studies have 
shown systemic effects including associations of OA with unfavourable metabolic 
parameters, such as high body mass index (BMI), waist hip ratio and proportion of 
fat mass with metabolic diseases, such as hypertension, obesity and diabetes 
mellitus4-10 Conversely, weight loss reduces the risk, as well as, relieve the pain and 
increase the physical function of people with OA.11-14 
Associations with BMI have been found for OA in both weight-bearing and non-
weight bearing joints, suggesting a connection between OA and obesity beyond axial 
loading.15-17 In line with this view, OA associates with classical markers of poor 
metabolic health such as increased circulating levels of (LDL) cholesterol.18,19 
Together these data indicate that the metabolic health of individuals likely affects 
susceptibility to OA.16,20-25  
In addition to classical metabolic parameters, such as cholesterol and glucose levels, 
metabolic health can be assessed by a range of serum metabolites. In the current 
study we investigated whether prevalence and progression of radiographic knee and 
hip OA is associated with 1H-NMR based plasma metabolite levels. A well 
standardized and affordable is that of NightingaleLtd Finland. The Nightingale 
platform provides data on 231 metabolites, representing a comprehensive and highly 
correlated spectrum of amino acids, keton-bodies, lipids, lipoproteins and composite 
scores such as fatty acid chain length and previously reported to be associated with 
metabolic syndrome, diabetes and cardiovascular disease.26,27 
In the current study, we have analysed associations of the Nightingale 1H-NMR 
based metabolites with prevalent radiographic hip and knee OA, and progression of 
radiographic knee and hip OA in multiple cohorts participating in the Biobanking and 
BioMolecular resources Research Infrastructure consortium (BBMRI metabolomics 
consortium).28 Identifying an OA-specific metabolite profile independent of BMI 
would provide further insight into the characteristics of the link between poor 
metabolism and OA and may eventually help clinicians to better identify those knee 





CHECK study: CHECK (Cohort Hip & Cohort Knee) is a prospective, 10-year follow-
up, observational cohort study of 1002 people aged between 45 and 65 years at the 
time of inclusion, with pain in their knee(s) and/or hip(s), who had never or not longer 
than 6 months ago visited a general physician for these complaints.29 Blood samples 
were taken non-fasted. Hip and knee radiographs were scored pairwise according 
to the Kellgren & Lawrence (KL) scoring system. When scored pairwise, these 
people did not have obvious radiographic knee or hip OA at baseline (i.e. KL=0 or 
1). As such, these persons were considered controls for the cross-sectional analyses 
on OA prevalence at baseline. Those who did not develop OA during follow-up were 
included as controls in the progression analyses. 
 
GARP study: The GARP cohort (N=217) consists of patients with advanced 
radiographic OA at two or more joint sites of hand, spine, knee or hip. Follow-up was 
performed at 5 years, at which radiographs for hip, knee and hand were scored 
pairwise using the OARSI Atlas and the KL scoring system. Matched to the GARP 
study, a normal reference control group (NORREF) was collected using the same 
protocol and included in this study as controls.30-32 Blood was collected non-fasted. 
 
LUMC Arthroplasty studies: The LUMC arthroplasty studies (N=462) consist of 
participants of the RAAK, TacTics (NTR309) and TOMaat (NTR303) studies.33,34 
These cross-sectional studies included OA patients who received THA or TKA. Since 
all participants underwent THA/TKA, all patients are considered as end-stage OA 
and included in the cross-sectional OA prevalence analysis. Blood samples were 
collected during surgery while patients were fasted. 
 
Rotterdam Study: The Rotterdam Study (RS) is a large prospective population-
based cohort study of men and women aged 55 years and older in the municipality 
of Rotterdam, the Netherlands. The study design and rationale are described 
elsewhere in detail.35 In summary, the objective of the study is to investigate the 
determinants, incidence and progression of chronic disabling diseases in the elderly. 
Baseline measurements were obtained through a home interview and visits to the 
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research centre for physical examinations and imaging and laboratory assessments, 
blood samples were taken while patient was fasted. The present study includes 2802 
participants from RS-I (Ergo 4) who were followed for 7 years. The study included 
both individuals with and without OA at baseline with mean follow-up time of 6.51 
(0.41) year. 
 
Informed consent was obtained from all included participants according to the 
Declaration of Helsinki (WHO) and good clinical practise.36 In addition, approval by 
the local Medical Ethics Committee was obtained. 
 
Definitions of OA 
Prevalent radiographic OA was defined as either having a KL score of ≥2 in hip 
and/or knee at baseline or having THA or TKA for primary OA.37 THA/TKA patients 
were also assessed separately. Controls (N=2125) had no radiographic hip and knee 
OA (KL<2) and were selected from the Rotterdam Study, CHECK and NORREF as 
described above. 
 
Data on radiographic OA progression were available for GARP, CHECK, and the 
Rotterdam Study. For GARP, progression of radiographic OA was defined as 
progression of joint space narrowing (JSN) and/or osteophyte size above the 
smallest detectable change.32 For CHECK and the Rotterdam Study, this was 
defined as an increase in KL-score, resulting in a KL score of ≥2 at follow-up. Thus, 
both incidence (KL score of 0 or 1 at baseline and ≥2 at follow-up) and progression 
(increase at KL score with a baseline of ≥2) were defined as progression in our 
analyses.  
 
Controls were selected from CHECK and the Rotterdam Study and had neither 






EDTA plasma samples were taken either at the time of TKA/THA in the LUMC-
arthroplasty-studies or at baseline for the cohort studies. Samples were shipped to 
Nightingale to perform standardized metabolomics analyses on a high throughput 
platform (Nightingale Ltd, Helsinki, Finland). The 1H-NMR technique used by 
Nightingale provides simultaneous quantification of routine lipids, lipoprotein 
subclass profiling with lipid concentration units, resulting in 231 measurements. 
Details of the techniques have been described before.38-40 
 
Statistical Analyses 
Analyses were performed per joint (hip or knee) and are also depicted in a flowchart 
(Figure 1). Since most distributions of metabolites were skewed, metabolite levels 
were LN-transformed to obtain normal distribution. Metabolite levels below the 
detection limit were considered missing. Metabolites with more than 5% missing 
were removed from analysis. Principal component analysis (PCA) was applied to 
reduce the data dimension of correlated metabolites. Factors were examined by 
means of scree plots and factors with an eigenvalue above 1 after Varimax rotation 
with Kaiser Normalization were included in analyses. A metabolite was said to load 
on a given factor if its factor loading was >0.4 or <-0.4. For each subject, a score 
was computed for the measures loaded on the factor, representing the linear 
relationship (Pearson correlation under Varimax rotation) between a factor and 
variable. 
Since some of the used cohorts consist of only controls (NORREF and CHECK at 
baseline) the presence of cohort effects among controls was assessed by relating 
each factor to cohort while adjusting for age, sex, BMI and fasting status. Factors 
with significant cohort effects were removed from the analyses. 
The remaining factors were included in logistic regression analyses to assess their 
association with OA, adjusting for age, sex, BMI and fasting status. Results are 
expressed as odds ratios per standard deviation and were corrected for multiple 
testing according to Bonferroni. To assess the modifying role of BMI and fasting, 
analyses were also performed without an adjustment for BMI or fasting. 
Since follow-up was performed at different time points, the progression analyses 
were done by means of meta-analysis. To increase power by reaching substantial 
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cases and controls in the analysis, CHECK and GARP were combined. The 
summary statistics (regression coefficients and standard errors) of GARP+CHECK 
were then combined with the summary statistics of the Rotterdam Study in a random 
effects meta-analysis using the “meta package” for R. The individual metabolitesof 
factors who associate to both cross-sectional OA and progression of OA were LN-
transformed and Z-standardized before being included in regression analyses for 



























Of the 231 metabolites measured on the Nightingale platform, 4 metabolites had 
more than 5% of the measurements below the detection limit and were removed 
from analysis. These were conjugated linoleic acid (CLA), the ratio of CLA to total 
fatty acids (CLAFA), diglycerids (DAG) and ratio DAG to triglycerids (DAG/TG). See 
Supplementary Table 1 for complete list of assessed metabolites. 
 
Principal component analysis 
As shown in Supplementary Table 2, PCA revealed 23 factors with an eigenvalue of 
≥1, accounting for 91,4% of the total variance. Notably, the first 2 components 
explained 56.4% of the variance. Based on the characteristics of the metabolites 
loading on each of the factors, we distinguished groups of metabolites representing 
low density lipids (LDL), very low density lipids (VLDL), high density lipids (HDL), 
fatty acids, and amino acids, se Supplementary Table 1. 
Prior to analyses, quality control was performed within the control group with respect 
to cohort effects and led to removal of factor 2 (representing mostly VLDL-related 
metabolites), factor 10 and 13 (both representing HDL-related metabolites), and 
factor 16 (representing triglycerides in large HDL particles), accounting for 28.06% 
of the variance in the original dataset (see Supplementary Table 3). 
 
Table 1 - Baseline characteristics of subjects in the cross-sectional analyses. 
 HOA THA KOA TKA Controls 
Age,            mean (SD) 69,6 (11,9) 68,0 (13,13) 72,5 (8,63) 71,0 (9,26) 66,1 (10,13) 
Female,      N (%) 482 (65,6%) 313 (70,2%) 700 (70,8%) 142 (71,7%) 1301 (61,4%) 
BMI,           mean (SD) 27,5 (4,4) 27,6 (4,6) 28,7 (4,53) 29,8 (4,1) 26,5 (3,9) 
CHECK,                   N 0 0 0 0 864 
GARP/NORREF,     N 108 34 150 7 34 
LUMC-cohorts,        N 302 302 153 153 0 
Rotterdam Study,    N 326 111 687 39 1227 
Total,                       N 736 447 990 199 2125 
HOA - Prevalent Radiographic Hip Osteoarthritis                    THA – Total Hip Arthroplasty 




Cross-sectional analyses of factors 1, 3-9, 11, 12, 14, 15 and 17-23. 
As depicted in Table 1, 736 cases with radiographic hip OA, 990 cases with 
radiographic knee OA, and 2125 controls without radiographic knee or hip OA at 
baseline were included in the cross-sectional analysis. These subpopulations 
differed with regard to age, gender and BMI. Therefore, all analyses were adjusted 
for age, sex and BMI. 
 
As shown in Table 2, cross-sectional analyses with the remaining 19 factors 
(explaining 64.1% of variance) showed 3 factors that were positively associated with 
total joint arthroplasty of both the hip (THA) and knee (TKA) as compared to controls; 
factor 17 (THA: OR=1.38, 95%CI=1.20-1.59, P=0.002; TKA: OR=1.49, 95%CI=1.21-
1.83, P=0.003), factor 22 (THA: OR=1.41, 95%CI=1.23-1.63, P=1.90E-5; TKA: 
OR=1.61, 95%CI=1.33-1.95, P=1.73E-5) and factor 23 (THA: OR=1.31, 
95%CI=1.13-1.51, P=0.005; TKA: OR=1.71, 95%CI=1.40-2.09, P=2.66E-6).  
Factor 1 showed a statistically significant association with TKA (OR=0.70, 
95%CI=0.58-0.85, P=0.005), but, despite the similar effect size, did not reach 
statistical significance after correcting for multiple testing for THA (OR=0.85, 
95%CI=0.74-0.99, P=0.646).  
Three additional factors showed associations with THA, as well as, radiographic hip 
OA being; factor 4 (HOA: OR=1.37, 95%CI=1.23-1.53, P=4.17E-7; THA: OR=1.33, 
95%CI=1.14-1.55, P=0.005), factor 11 (HOA: OR=0.82, 95%CI=0.74-0.91, P=0.002; 
THA: OR=0.77, 95%CI=0.67-0.88, P=2.00E-4) and factor 19 (HOA: OR=0.68, 
95%CI=0.60-0.76, P=3.69E-10; THA: OR=0.65, 95%CI=0.55-0.75, P=5.93E-7). 
Concurrent to factor 1, effect sizes of these factors in the association with OA in the 




































































































































































































































































































































































































































































































































































































































































































Factors 1, 4, 11, 17, 19, 22 & 23 and progression of radiographic hip and knee OA. 
Subsequently, we investigated whether the observed associations of factors 1, 4, 
11, 17, 19, 22, 23 with prevalent hip and/or knee OA also contributed to OA 
progression. Progression data were available for the participants of the CHECK, 
GARP and Rotterdam Study. In total, 282 individuals experienced progression of OA 
in hip and 463 persons experienced progression of OA in knee and 1244 persons 
did not have any incidence of OA after 5 to 7 years of follow-up, see Table 3. 
 
 
A meta-analysis was performed to combine the results of the Rotterdam Study and 
CHECK and GARP cohorts (see also Table 4, corresponding forrestplots are 
depicted in Figure 2). Factor 19 associates to lower odds for knee OA (OR=0.84, 
95%CI=0.73-0.97, P=0.020). Factor 22, as in the cross-sectional analyses, 
associates with increased odds for progression of hip OA (OR=1.16, 95%CI=1.00-
1.34, P=0.047).  
 
Notably, factor 17 had an inverse effect on progression of hip OA as compared to 
the cross-sectional analyses (hip progression: OR=0.87, 95%CI=0.75-1.00, 
P=0.047; cross-sectional hip OA: OR=1.38, 95%CI=1.20-1.59, P=0.002).  
 
  
Table 3 – Baseline characteristics of subjects in progression analyses. 






CHECK/GARP N 125 292 523 
Age mean (SD) 58.9 (5.5) 57.4 (5.7) 55.4 (5.2) 
Female N (%) 89 (71.2%) 241 (82.5%) 410 (78.4%) 
Body mass index mean (SD) 26.0 (3.7) 28.0 (5.0) 25.7 (3.8) 
Rotterdam Study N 157 171 721 
Age mean (SD)  72.8 (5.0)  73.13 (5.1)  71.99 (4.6) 
Female N (%)  60.5%  66.1%  53.8% 
Body mass index mean (SD)  27.8 (4.4)  29.09 (4.3)  26.74 (3.5) 
Total N 282 463 1244 
Baseline characteristics of persons with radiographic hip and knee progression as well as the 





Assessment of individual metabolites of factors 17, 19 and 22. 
Successively, we explored whether individual metabolites of the factors which go 
both with cross-sectional OA and progression of OA, drive any of the found 
associations. As shown in Supplementary Table 3, for Factor 17 the strongest effect 
was found in Pyruvate in any OA, whereas this effect got even stronger in 
arthroplasty (OR=1.21, 95%CI= 1.12-1.30, P=<0.001 and OR=1.93, 95%CI=1.72-
2.16, P<0.001, respectively). Factor 19 appears to be mainly driven by Glutamine, 
which was negatively associated with both OA and TJA (OR=0.70, 95%CI=0.64-
0.76, P<0.001 and OR=0.65, 95%CI=0.58-0.74, P<0.001, respectively). Of factor 22 
was FALen consequently associated with both OA and arthroplasty (OR=1.26, 
95%CI=1.16-1.36, P<0.001 and OR=1.83, 95%CI=1.64-2.05, P<0.001, 
respectively). 
Assessment of individual metabolites of factors 17, 19 and 22 with OA-progression 
did not result in an obvious independent effect of any of the metabolites, nonetheless 
again the effect size of FALen was relatively large, albeit not statistically significant 
(Supplementary Table 4). 
 
Table 4 - Results of meta-analysis for the progression of radiographic hip/knee OA. 
    OR 95% CI P-Value 
Factor 1 (LDL) hip 0,878 0,757-1,017 0,083 
knee 0,910 0,805-1,029 0,134 
Factor 4 (LDL) hip 1,064 0,872-1,298 0,541 
knee 0,963 0,849-1,093 0,560 
Factor 11 (Fatty Acids) hip 0,948 0,818-1,098 0,476 
knee 1,042 0,917-1,184 0,527 
Factor 17 (Amino Acids) hip 0,855 0,749-0,998 0,047 
knee 0,870 0,694-1,091 0,228 
Factor  19 (Amino Acids) hip 0,916 0,653-1,286 0,614 
knee 0,844 0,732-0,973 0,020 
Factor  22 (Fatty Acids) hip 1,156 1,002-1,334 0,047 
knee 1,045 0,925-1,180 0,483 
Factor  23 (Amino Acids) hip 0,962 0,828-1,119 0,617 
knee 0,918 0,806-1,046 0,201 
Meta-analysis combining the results for the relation of factor to progression of hip/ knee 
OA from the Rotterdam Study and CHECK+GARP cohorts. Factors were studied when 
they had significant associations with prevalent radiographic hip or knee osteoarthritis. 
OR= odds ratio, 95%CI=95% confidence interval. 
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The effects of BMI and statins for factor 17, 19 & 22 
 
To explore possible 
confounding effects of BMI in 
the associations observed, 
we performed analyses with 
and without adjustment for 
BMI. As shown in 
Supplementary Table 5, the 
effect sizes got slightly larger 
when omitting an adjustment 
for BMI.  
 
Moreover, as statins might 
affect the concentrations of 
metabolites, we performed 
sensitivity analyses to assess 
their influence on our 
outcomes.41 The use of 
statins was known for all 
included studies except CHECK. Sensitivity analysis with subjects that did not use 
statins revealed only minor changes in the effect sizes (results not shown). 
 
The modifying effect of fasting on associations of factor 17, 19 and 22 with OA 
As some cohorts were fasted and others were unfasted, we also assessed in similar 
fashion the effects of fasting on the outcomes. Supplementary Table 6 shows the 
outcomes for the cross-sectional analyses for factors 17, 19 and 22 with and without 
the addition of fasting to the analysis. Although fasting had a strong significant effect 
in the analyses, the odds ratio’s for factor and OA-phenotype were only marginally 




Serum metabolomics assay of hip and knee OA cases and controls were assessed 
by means of the Nightingale 1H-NMR platform, resulting in 227 different metabolite 
measurements. These metabolites were included in PCA-analyses which identified 
19 factors explaining 71.9% of variance eligible for further regression analyses. Of 
these, seven factors (1, 4, 11, 17, 19, 22 and 23) were associated with cross-
sectional OA and three factors (17, 19 and 22) were found to be associated with 
cross-sectional hip or knee OA, as well as its progression. All associations were 
assessed independent of age, sex, fasting and BMI. As such, this study places 
composite scores of fatty acid-make-up, energy balance, histidine and glutamine at 
the heart of the link of osteoarthritis and metabolites. 
 
Factor 19, composed of 2 amino acids: glutamine and histidine showed a consistent 
association with a decreased risk for hip and knee OA in the cross-sectional analysis 
(radiographic hip OA: OR=0.68, 95%CI=0.60-0.76, radiographic knee OA: OR=0.83, 
95%CI=0.75-0.91 and THA OR=0.65, 95%CI=0.55-0.75) as well as for the knee 
progression analyses (OR=0.84, 95%CI=0.73-0.97). These findings are consistent 
with a previously performed NMR-based urine metabolomics study which found that 
low levels of histidine are associated to OA.42 Another study by Loeser et al43 
identified that histidine (as well as alanine) measured in urine is an important 
metabolite to discriminate between persons with knee OA progression as compared 
to BMI matched controls. However, the exact nature of the underlying 
pathophysiological mechanism of the association between OA and histidine and 
glutamine remains to be elucidated.  
 
Factor 22 represents measures of the make-up of fatty acids: fatty acid chain length, 
saturated fatty acids to total fatty acids ratio and the level of unsaturation. The latter 
2 measures contributed in opposite fashion to the factor score. Factor 22 was 
associated with a higher risk for end stage hip (OR=1.41, 95%CI=1.23-1.63) and 
knee OA (OR=1.61, 95%CI=1.33-1.95), as well as a higher risk for hip OA 
progression (OR=1.16, 95%CI=1.00-1.34). Notably, fatty acid chain length is, in the 
analysis of individual metabolites, independent and strongly associated to the 
prevalent cross-sectional OA-phenotypes and seems to drive factor 22. 
 
113 
Nevertheless, in the OA-progression analyses this was less clear. A recent study 
has shown that longer-chain dietary fatty acids in rats induce both metabolic 
syndrome and OA like knee changes.44 Fatty acids are known to play a role in a 
broad range of cardiovascular diseases as well as to the immune system, which 
might hint that there is a more generic pathway underlying the association of OA and 
fatty acid make up.45,46 
 
Open for discussion is factor 17, representing alanine, lactate and pyruvate, which 
are produced during glycolysis in cells in aerobic and anaerobic conditions.47-49 
Factor 17 is associated with a higher risk for cross sectional hip OA (OR=1.38, 
95%CI=1.20-1.59), knee OA (OR=1.49, 95%CI=1.21-1.83) and arthroplasty but with 
a decreased risk for hip OA progression (OR=0.86, 95%CI=0.75-0.99). This 
association of factor 17 with OA may be a reflection of different types of energy 
consumption in play as chondrocytes in OA switch from oxidative phosphorylation to 
glycolysis as their main source of energy metabolism.50 Nevertheless, the opposite 
relation in the cross sectional and progression analyses is a result that we currently 
cannot explain. The association of factor 17 could therefore also be spurious and 
needs confirmation in additional cohorts. 
 
In this study we choose to differentiate between patients who underwent total hip or 
knee arthroplasty from patients with radiographic signs of OA. This because THA 
and TKA patients are essentially in a different stage of the disease, their OA-
symptoms were clinically assessed and severe enough to undergo arthroplasty 
surgery. In contrast, patients with radiological OA represent a range of patients who 
may not (yet) be severe enough for an indication for arthroplasty. The fact that we 
observed more consistent associations with arthroplasty patients justifies this 
approach. Although we found significant associations between some factors and 
knee or hip OA progression, none of the individual metabolites reached a statistically 
significant level for progression. This indicates that the baseline level of individual 
metabolites might be less informative then a complete metabolite profile. 
A strength of our study was that this study comprises a large sample size of which a 
subset was followed overtime, enabling us to follow progression over time. The 
combination of different studies to reach more power also meant that we 
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incorporated some studies with only cases or controls, raising the chance of cohort 
effects. However, we did assess the presence of cohort effects within the control 
phenotype, where no differences should be present between the cohorts as all 
samples are the exact same phenotype. The factors which were free of cohort effects 
were included in our analyses.  
 
We adjusted our analyses for BMI measured at baseline, however we cannot 
exclude the bias in our findings due to the effect of weight loss or gain right before 
blood collection. To obtain more insight in the modifying / confounding role of BMI in 
our analyses, we compared analyses with and without adjustment for BMI 
(Supplementary Table 5). The odds ratios between these analyses were only 
marginally altered, with the biggest change found for TKA in factor 19, where the 
odds ratio went from 0.791 (adjusted for age, sex, fasting and BMI) to 0.565 
(adjusted for age, sex and fasting). As such we concluded that the observed 
metabolite associations with OA were independent or only slightly modified by BMI. 
 
Moreover, the fact that our study included both fasted and nonfasted samples and 
metabolites are very sensitive to fasting status, the adjustment for fasting status may 
not have been sufficient to properly correct for dietary influences. To obtain more 
insight in the modifying role of fasting status, our metabolite factors and OA, we 
performed analyses with and without fasting adjustment. As shown in 
Supplementary Table 6, the odds ratios for OA in the two analyses showed only 
marginally changes i.e. effect sizes were very similar. Analyses were stratified by 
fasting status for HOA and factor 19, we found that the effect size was larger in the 
non-fasted samples as compared to the fasted samples (fasted samples: HOA 
OR=0.77, 95%CI=0.68-0.88, P=0.003; non-fasted samples: HOA OR=0.49, 
95%CI=0.37-0.63, P<0.001).  
 
The current paper is to our knowledge the first large scale hypothesis free approach 
in search for metabolites that associate to OA in a cross-sectional as well as a follow-
up design. Future research should particularly focus on replication of the found 
results and, if this succeeds, further elucidate the mechanisms behind the 
association of the identified metabolites and OA should be performed.  
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Eventually, these studies could lead up to the identification of lifestyle changes which 
might alter the predisposition for OA. Identifying lifestyle changes such as different 
levels of fatty acid intake or physical training to improve the switch between 
aerobe/anaerobe metabolism may lessen the burden of OA. In conclusion, the 
current study identified a number of metabolic factors associated with OA, 
independent of BMI. This indicates that there is an altered metabolic state in patients 
with OA as compared to controls without OA. This is another token that OA should 
be seen as a component of poor metabolic health. 
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Supplementary Table 1 
Metabolite  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 
AcetoAcetate AcAce 








                
0,62 
      
Albumine Alb 
                 
0,69 
     
3-hydroxybutyrate bOHBut 






                   
0,60 
   
Creatinine Crea 
                       
Glucose Glc 
                       
Glutamine Gln 
                  
0,77 




                     
Histidine His 
                  
0,67 




     
0,73 
               
Lactate Lac 
                
0,82 
      
Leucine Leu 
       
0,86 
               
Phenylalanine Phe 
       
0,70 
               
Pyruvate Pyr 
                
0,81 
      
Tyrosine Tyr 
       
0,71 
               
Valine Val 
       
0,83 
               
Metabolite  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 
Esterified Cholesterol EstC 0,91 
                      
Free Cholesterol FreeC 0,89 
                      
HDL2-C hdl2 cholesterol particle density  HDL2C 
 
-0,43 0,80 
                    
HDL3-C hdl3 cholesterol particle density  HDL3C 0,73 
                      
HDL-C hdl cholesterol HDLC 
  
0,79 
                    
Rem t-C non-hdl / ldl cholesterol RemtC 0,79 0,58 
                     
Serum-C cholesterol SerumC 0,91 








Metabolite  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 





                  
Apolipoprotein B ApoB 0,77 0,60 
                     
ApoB / ApoA1 ApoB/ApoA1 0,56 0,62 -0,48 
                    
Docosahexaenoic acid 22:6  DHA 
      
0,86 
                
DHA / total fatty acids   DHA FA 
      
0,94 
                
Estimated fatty chain length Falen -0,52 
                    
0,46 
 
omega 3 fatty acid FAw3 
      
0,81 
                
FAw3 / total fatty acids   FAw3 fa 
      
0,94 
                
omega 6 fatty acid FAw6 0,74 
         
0,46 
            
FAw6 / total fatty acids   FAw6 FA 
 
-0,59 
        
0,61 
            
Linoleic acid 18:2 LA 0,69 
         
0,55 
            
LA / total fatty acids   LA FA 
 
-0,42 
        
0,67 
            
Monounsaturated fatty acids 16:1 18:1 MUFA 
 
0,80 
                     
MUFA / total fatty acids   MUFAFA 
 
0,60 
        
-0,58 
            
Phosphatidycholine and other cholines PC 0,52 
 
0,59 
                    
polyunsaturated fatty acids PUFA 0,74 
         
0,42 
            
PUFA / total fatty acids   PUFA FA 
 
-0,62 
        
0,58 
            
Saturated fatty acids SFA 0,48 0,70 
                     
SFA / total fatty acids   SFA FA 
                     
-0,83 
 
sphingomyelines  SM 0,71 
                      
  triglycerides / phosphoglycerides TG PG 
 
0,81 -0,40 
                    
cholines TotCho 0,63 
 
0,58 
                    
total fatty acids  TotFA 0,56 0,69 
                     
phosphoglycerides  TotPG 0,55 
 
0,56 
                    
estimated degree of unsaturaization UnsatDeg 
 
-0,54 
    
0,45 






1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 
HDL mean diameter hdl particle HDL-D 
 
-0,43 0,87 
                    





                   
XL-HDL Total Cholesterol  XL HDL C 
  
0,81 
                    
XL-HDL Total Choleseterol to total Lipids XL HDL C % 
  
-0,67 
           
0,43 
        
XL-HDL Cholesterol Esters  XL HDL CE 
  
0,78 
                    
XL-HDL CholesterolEsters to total Lipids XL HDL CE % 
  
-0,72 
                    
XL-HDL Free Cholesterol  XL HDL FC 
  
0,85 
                    
XL-HDL Free Cholesterol to total lipids  XL HDL FC % 
         
-0,58 
             
XL-HDL Total lipids  XL HDLL 
  
0,89 
                    
XL-HDL Particle concent n  XL HDL P 
  
0,89 
                    
XL-HDL Phospholipids XL HDL PL 
 
-0,44 0,85 
                    
XL-HDL Phospholipids to total Lipids   XL HDL PL % 
 
-0,47 0,64 
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XL-HDL Triglycerids XL HDL TG 
 
0,57 0,50 
                    
XL-HDL TriGlycerides to total Lipids   XL HDL TG % 
 
0,78 
                     
L-HDL Total Cholesterol  L HDL C  -0,49 0,80                     
L-HDL Total Choleseterol to total Lipids    L HDL C % 
 
-0,42 
      
0,78 
              
L-HDL Cholesterol Esters  L HDL CE 
 
-0,48 0,79 
                    
L-HDL CholesterolEsters to total Lipids    L HDL CE % 
        
0,81 
              
L-HDL Free Cholesterol  L HDL FC 
 
-0,49 0,78 
                    
L-HDL Free Cholesterol to total lipids    L HDL FC % 
 
-0,45 0,50 
     
0,48 
              
L-HDL Total lipids  L HDLL 
 
-0,46 0,83 
                    
L-HDL Particle concent n  L HDL P 
 
-0,45 0,83 
                    
L-HDL Phospholipids   L HDL PL 
 
-0,44 0,81 
                    
L-HDL Phospholipids to total Lipids    L HDL PL % 
        
-0,70 
              
L-HDL Triglycerids   L HDL TG 
  
0,58 
            
0,42 
       
L-HDL TriGlycerides to total Lipids    L HDL TG % 
 
0,59 
                     





                  
M-HDL Total Choleseterol to total Lipids    M HDL C % 
 
-0,52 
          
-0,72 
          





                  





        
-0,65 
          





                  
M-HDL Free Cholesterol to total lipids    M HDL FC % 0,41 
                      





                  





                  





                  
M-HDL Phospholipids to total Lipids    M HDL PL % 
            
0,91 
          
M-HDLTriglycerids   M HDL TG 
 
0,76 
                     
M-HDLTriGlycerides to total Lipids    M HDL TG % 
 
0,77 
                     
S-HDL Total Cholesterol   S HDL C 0,62 
   
0,44 
                  
S-HDL Total Choleseterol to total Lipids    S HDL C % 0,68 
                      
S-HDL Cholesterol Esters   S HDL CE 0,68 
                      
S-HDL CholesterolEsters to total Lipids    S HDL CE % 0,69 
                      
S-HDL Free Cholesterol   S HDL FC 
    
0,80 
                  
S-HDL Free Cholesterol to total lipids    S HDL FC % 
              
0,50 
        
S-HDL Total lipids   S HDLL 
    
0,91 
                  
S-HDL Particle concent n mol / L  S HDL P 
    
0,89 
                  
S-HDL Phospholipids   S HDL PL -0,43 
   
0,78 
                  
S-HDL Phospholipids to total Lipids    S HDL PL % -0,69 
                      





                   









1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 
LDL cholestrol  LDL C 0,99 
                      
LDL mean diameter ldl particle  LDL D 
         
0,63 
             
LDL triglycerides   LDL TG 0,48 
  
0,77 
                   
L-LDL Total Cholesterol   LLDL C 0,98 
                      
L-LDL Total Choleseterol to total Lipids    LLDL C % 0,79 
  
-0,55 
                   
L-LDL Cholesterol Esters   LLDL CE 0,98 
                      
L-LDL CholesterolEsters to total Lipids    LLDL CE % 0,87 
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L-LDLFree Cholesterol   LLDL FC 0,97 
                      





                   
L-LDL Total lipids   LLDLL 0,98 
                      
L-LDL Particle concent n mol / L  LLDL P 0,97 
                      
L-LDL Phospholipids   LLDL PL 0,97 
                      
L-LDL Phospholipids to total Lipids    LLDL PL % -0,95 
                      
L-LDL Triglycerids   LLDL TG 0,52 
  
0,77 
                   
L-LDL TriGlycerides to total Lipids    LLDL TG % -0,41 
  
0,86 
                   
M-LDL Total Cholesterol   MLDL C 0,99                       
M-LDL Total Choleseterol to total Lipids    MLDL C % 0,83 
                      
M-LDL Cholesterol Esters   MLDL CE 0,99 
                      
M-LDL CholesterolEsters to total Lipids    MLDL CE % 0,90 
                      
M-LDL Free Cholesterol   MLDL FC 0,95 
                      
M-LDL Free Cholesterol to total lipids    MLDL FC % -0,85 
                      
M-LDL Total lipids   MLDLL 0,97 
                      
M-LDL Particle concent n mol / L  MLDL P 0,97 
                      
M-LDL Phospholipids   MLDL PL 0,89 
                      
M-LDL Phospholipids to total Lipids    MLDL PL % -0,92 
                      
M-LDL Triglycerids   MLDL TG 0,47 
  
0,79 
                   
M-LDL TriGlycerides to total Lipids    MLDL TG % 
   
0,89 
                   
S-LDL Total Cholesterol   SLDL C 0,98 
                      
S-LDL Total Choleseterol to total Lipids    SLDL C % 0,84 
                      
S-LDL Cholesterol Esters   SLDL CE 0,99 
                      
S-LDL CholesterolEsters to total Lipids    SLDL CE % 0,90 
                      
S-LDL Free Cholesterol   SLDL FC 0,90 
                      
S-LDL Free Cholesterol to total lipids    SLDL FC % -0,78 
                      
S-LDL Total lipids   SLDLL 0,95 
                      
S-LDL Particle concent n mol / L  SLDL P 0,94 
                      
S-LDL Phospholipids   SLDL PL 0,82 
                      
S-LDL Phospholipids to total Lipids    SLDL PL % -0,94 
                      





                   





                   
 
Metabolite  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 
IDL Total Cholesterol   IDL C 0,96 
                      
IDL Total Choleseterol to total Lipids    IDL C % 0,45 
  
-0,83 
                   
IDL Cholesterol Esters   IDL CE 0,94 
                      
IDL CholesterolEsters to total Lipids    IDL CE % 
   
-0,81 
                   
IDL Free Cholesterol   IDL FC 0,96 
                      
IDL Free Cholesterol to total lipids    IDL FC % 0,56 -0,54 
                     
IDL Total lipids   IDLL 0,96 
                      
IDL Particle concent n mol / L  IDL P 0,96 
                      
IDL Phospholipids   IDL PL 0,98 
                      
IDL Phospholipids to total Lipids    IDL PL % 
 
-0,78 
                     
IDL Triglycerids   IDL TG 0,44 0,43 
 
0,76 
                   
IDL TriGlycerides to total Lipids    IDL TG % -0,41 
  
0,81 






1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 
VLDLCholesterol VLDL C 0,55 0,80 
                     
VLDL mean diameter vldl particles VLDL D 
 
0,90 
                     
VLDLTriglycerides  VLDL TG 
 
0,91 
                     
XXL-VLDL Total Cholesterol  XXLVLDL C 
 
0,93 
                     
XXL-VLDL Total Choleseterol to total Lipids   XXLVLDL C % 
     
0,54 
     
0,68 
           
XXL-VLDL Cholesterol Esters  XXLVLDL CE 
 
0,87 
                     
XXL-VLDL CholesterolEsters to total Lipids   XXLVLDL CE % 
     
0,62 
     
0,44 
           
XXL-VLDL Free Cholesterol  XXLVLDL FC 
 
0,95 
                     
XXL-VLDL Free Cholesterol to total lipids   XXLVLDL FC % 
           
0,68 
           
XXL-VLDL Total lipids  XXLVLDLL 
 
0,93 
                     
XXL-VLDL Particle concent n mol / L XXLVLDL P 
 
0,93 
                     
XXL-VLDL Phospholipids  XXLVLDL PL 
 
0,92 
                     
XXL-VLDL Phospholipids to total Lipids   XXLVLDL PL % 
           
0,44 
           
XXL-VLDL Triglycerids  XXLVLDL TG 
 
0,92 
                     
XXL-VLDL TriGlycerides to total Lipids   XXLVLDL TG % 
           
-0,81 
           
XL-VLDL Total Cholesterol  XLVLDL C  0,96                      
XL-VLDL Total Choleseterol to total Lipids   XLVLDL C % 
 
-0,54 
   
0,73 
                 
XL-VLDL Cholesterol Esters  XLVLDL CE 
 
0,95 
                     
XL-VLDL CholesterolEsters to total Lipids   XLVLDL CE % 
 
-0,46 
   
0,71 
                 
XL-VLDL Free Cholesterol  XLVLDL FC 
 
0,94 
                     
XL-VLDL Free Cholesterol to total lipids   XLVLDL FC % 
 
-0,46 
   
0,61 
                 
XL-VLDL Total lipids  XLVLDLL 
 
0,96 
                     
XL-VLDL Particle concent n mol / L XLVLDL P 
 
0,96 
                     
XL-VLDL Phospholipids  XLVLDL PL 
 
0,93 
                     
XL-VLDL Phospholipids to total Lipids   XLVLDL PL % 
             
0,46 
         
XL-VLDL Triglycerids  XLVLDL TG 
 
0,93 
                     
XL VLDL TG % XLVLDL TG % 
     
-0,68 
                 
L-VLDL Total Cholesterol   LVLDL C 
 
0,96 
                     
L-VLDL Total Choleseterol to total Lipids    LVLDL C % 
     
0,69 
                 
L-VLDL Cholesterol Esters   LVLDL CE 
 
0,95 
                     
L-VLDL CholesterolEsters to total Lipids    LVLDL CE % 
     
0,72 
                 
L-VLDL Free Cholesterol   LVLDL FC 
 
0,94 
                     
L-VLDL Free Cholesterol to total lipids    LVLDL FC % 
             
0,69 
         
L-VLDL Total lipids   LVLDLL 
 
0,94 
                     
L-VLDL Particle concent n mol / L  LVLDL P 
 
0,93 
                     
L-VLDL Phospholipids   LVLDL PL 
 
0,92 
                     
L-VLDL Phospholipids to total Lipids    LVLDL PL % 
 
0,41 
                  
0,63 
  
L-VLDL Triglycerids   LVLDL TG 
 
0,91 
                     
L-VLDL TriGlycerides to total Lipids    LVLDL TG % 
     
-0,52 
       
-0,47 




Metabolite  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 
M-VLDL Total Cholesterol   MVLDL C 
 
0,91 
                     
M-VLDL Total Choleseterol to total Lipids    MVLDL C % 0,49 
    
0,55 
                 
M-VLDL Cholesterol Esters   MVLDL CE 0,43 0,86 
                     
M-VLDL CholesterolEsters to total Lipids    MVLDL CE % 0,48 -0,41 
   
0,55 
                 
M-VLDL Free Cholesterol   MVLDL FC 
 
0,92 
                     
M-VLDL Free Cholesterol to total lipids    MVLDL FC % 
             
0,45 
         
M-VLDL Total lipids   MVLDLL 
 
0,93 
                     
M-VLDL Particle concent n mol / L  MVLDL P 
 
0,92 
                     
M-VLDL Phospholipids   MVLDL PL 
 
0,92 
                     
M-VLDL Phospholipids to total Lipids    MVLDL PL % 
                    
0,75 
  
M-VLDL Triglycerids   MVLDL TG 
 
0,89 
                     
M-VLDL TriGlycerides to total Lipids    MVLDL TG % -0,44 
    
-0,54 
                 
 
Metabolite  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 
S-VLDL Total Cholesterol   SVLDL C 0,69 0,65 
                     
S-VLDL Total Choleseterol to total Lipids    SVLDL C % 0,51 -0,58 
                     
S-VLDL Cholesterol Esters   SVLDL CE 0,78 0,52 
                     
S-VLDL Cholesterol Esters to total Lipids    SVLDL CE % 0,50 -0,56 
                     
S-VLDL  Free Cholesterol   SVLDL FC 0,48 0,77 
                     
S-VLDL Free Cholesterol to total lipids    SVLDL FC % 
 
-0,50 
                     
S-VLDL Total lipids   SVLDLL 
 
0,83 
                     
S-VLDL Particle concent n mol / L  SVLDL P 
 
0,84 
                     
S-VLDL Phospholipids   SVLDL PL 
 
0,80 
                     
S-VLDL Phospholipids to total Lipids    SVLDL PL % 
    
0,45 
               
0,41 
  
S-VLDL Triglycerids   SVLDL TG 
 
0,85 
                     
S-VLDL TriGlycerides to total Lipids    SVLDL TG % -0,41 0,63 
                     
XS-VLDL Total Cholesterol   XSVLDL C 0,89 
                      





                   
XS-VLDL Cholesterol Esters   XSVLDL CE 0,85 
                      





                   
XS-VLDL Free Cholesterol   XSVLDL FC 0,89 
                      
XS-VLDL Free Cholesterol to total lipids    XSVLDL FC % 
 
-0,48 
                     
XS-VLDL Total lipids   XSVLDLL 0,84 0,42 
                     
XS-VLDL Particle concent n mol / L  XSVLDL P 0,81 0,47 
                     
XS-VLDL Phospholipids   XSVLDL PL 0,93 
                      
XS-VLDL Phospholipids to total Lipids    XSVLDL PL % 0,79 
                      





                   
XS-VLDL TriGlycerides to total Lipids    XSVLDL TG %   0,62   0,53                                     
 






Supplementary Table 2 –  
Variance explained by factors. 
 Supplementary Table 3 – Assessment of cohort 
effects in controls. 
Factor Eigenvalue % of Variance 
 Explained 
 Factor Effect 
size 
95% CI P-value* 
1 70.95 31.26  1 -0,453 -0,846 - -0.060 0,552 
2 57.17 25.19  2 0,607 0,220 – 0.994 0,046 
3 19.79 8.71  3 0,382 0,025 – 0.740 0,828 
4 11.08 4.88  4 0,113 -0,262 – 0.489 >1 
5 8.55 3.77  5 0,328 -0,059 – 0.715 >1 
6 4.75 2.09  6 -0,094 -0,484 – 0.296 >1 
7 4.08 1.80  7 -0,418 -0,827 - -0.009 >1 
8 3.67 1.62  8 0,139 -0,230 – 0.507 >1 
9 3.04 1.34  9 0,157 -0,208 – 0.523 >1 
10 2.85 1.25  10 -0,796 -1,177 - -0.415 0,001 
11 2.72 1.20  11 -0,200 -0,589 – 0.189 0,314 
12 2.50 1.10  12 0,075 -0,292 – 0.441 >1 
13 2.05 0.90  13 -0,649 -1,034 - -0.265 0,023 
14 1.87 0.82  14 0,106 -0,304 – 0.517 >1 
15 1.85 0.81  15 -0,530 -0,917 - -0.143 0,161 
16 1.63 0.72  16 1,225 0,858 – 1.592 1,64x10-9 
17 1.60 0.70  17 0,249 -0,141 – 0.639 >1 
18 1.48 0.65  18 -0,474 -0,831 - -0.117 0,207 
19 1.38 0.61  19 -0,371 -0,708 - -0.033 0,713 
20 1.25 0.55  20 -0,255 -0,626 – 0.116 >1 
21 1.16 0.51  21 -0,560 -0,934 - -0.187 0,069 
22 1.11 0.49  22 -0,236 -0,619 – 0.147 >1 
23 1.00 0.44  23 -0,111 -0,489 – 0.268 >1 
Eigenvalues and percentage of 
variance explained by the factors 
identified by principal component 
analysis on the included metabolites. 
The total variance explained by the 23 
factors with an eigenvalue of >1 was 
91,4%. 
 Association of cohort with the factor within controls. 
After adjusting for age, sex, BMI and fasting, four 
factors had a significant cohort effect and were 
removed from further analyses. 
* Pvalue Bonferroni corrected 
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Supplementary Table 4: Individual metabolites and cross-sectional outcomes 
Factor Metabolite 
Hip or knee OA  Hip or Knee arthroplasty 
OR 95%CI P*  OR 95%CI P* 
17 
Alanine 0.91 0.84-0.98 0.088  0.82 0.72-0.93 0.008 
Lactate 1.00 0.92-1.08 >1  1.47 1.31-1.65 7.0x10-10 
Pyruvate 1.21 1.12-1.30 5.1x10-6  1.93 1.72-2.16 8.0x10-20 
19 
Glutamine 0.70 0.64-0.76 8.8x10-15  0.65 0.58-0.74 2.0x10-11 
Histidine 0.91 0.84-0.98 0.120  0.92 0.81-1.04 >1 
22 
Fatty Acid Chain Length 1.26 1.16-1.36 4.8x10-8  1.83 1.64-2.05 8.0x10-20 
Saturated Fatty Acids Ratio 1.01 0.93-1.08 >1  0.95 0.84-1.07 >1 
Degree of Unsaturation 1.05 0.97-1.14 >1  1.12 0.99-1.28 0.560 
* Pvalue Bonferroni corrected 
 
 
Supplementary Table 5 – Individual metabolites and progression 
Factor Metabolite 
Hip Progression  Knee Progression 
Beta SE P*  Beta SE P* 
17 
Alanine -0,126 0,334 >1  -0,609 0,27 0,192 
Lactate -0,605 0,247 0,120  -0,569 0,448 >1 
Pyruvate -0,518 0,393 >1  -0,307 0,168 0,544 
19 
Glutamine -0,452 0,991 >1  -0,488 0,798 >1 
Histidine -0,411 0,339 >1  -0,295 0,29 >1 
22 
Fatty Acid Chain Length 7,97 3,742 0,264  4,123 4,309 >1 
Saturated Fatty Acids Ratio -1,907 1,593 >1  -0,102 1,377 >1 
 Degree of Unsaturation -0,028 1,432 >1  1,047 1,314 >1 





Supplementary Table 6 – with and without adjustment for BMI or fasting 
Factor 17 
  
OA ~ Factor + age + sex + fasting + BMI   Excluding BMI  Excluding fasting 
OR 95%CI P-value*  OR  95%CI P-value*  OR  95%CI P-value* 
HOA 1,15 1,04-1,27 0.171  1.25 1.14-1.37 0.008  1,14 1,03 - 1,26 0.228 
THA 1,38 1,20-1,59 1.5x10-4  1.52 1.35-1.72 2.28x10-10  1,34 1,17 - 1,55 7.4x10-4 
KOA 0,98 0,89-1,07 >1  1.04 0.96-1.14 >1  0,97 0,89 - 1,06 >1 
TKA 1,49 1,21-1,83 0.003  1.56 1.31-1.85 9.69x10-6  1,42 1,16 - 1,74 0.019 
Factor 19 
  
OA ~ Factor + age + sex + fasting + BMI   Excluding BMI  Excluding fasting 
OR 95%CI P-value*  OR  95%CI P-value*  OR  95%CI P-value* 
HOA 0,68 0,60-0,76 3.6x10-10  0,59 0,53-0,65 2.30x10-24  0,67 0,60 - 0,75 1.0x10-10 
THA 0,65 0,55-0,75 5.9x10-7  0,52 0,46-0,59 6.8x10-24  0,62 0,53 - 0,72 5.6x10-9 
KOA 0,83 0,75-0,91 0.004  0,71 0,65-0,78 1.7x10-11  0,82 0,74 - 0,91 0.003 
TKA 0,79 0,63-0,99 0.817  0,57 0,48-0,67 3.2x10-10  0,76 0,61 - 0,95 0.266 
Factor 22 
  
OA ~ Factor + age + sex + fasting + BMI   Excluding BMI  Excluding fasting 
OR 95%CI P-value*  OR  95%CI P-value*  OR  95%CI P-value* 
HOA 1,13 1,02-1,25 0.494  1,20 1,09-1,32 0.004  1.13 1.02-1.26 0.380 
THA 1,41 1,23-1,63 1.9x10-5  1,45 1,29-1,63 3.1x10-8  1.44 1.25-1.65 7.0x10-6 
KOA 1,06 0,96-1,16 >1  1,06 0,97-1,16 >1  1.06 0.97-1.16 >1 
TKA 1,61 1,33-1,95 1.7x10-5  1,46 1,24-1,72 7.6x10-5  1.67 1.38-2.02 1.8x10-6 
Analyses performed with logistic regression analyse relating factor-score to the OA-phenotype. Standard analyse was adjusted for age, sex, fasting and BMI, whereas 
the extra analyse was adjusted for age, sex either BMI or fasting. 
* Pvalue Bonferroni corrected. 






With increasing life expectancy, the incidence and burden of osteoarthritis on society 
will increase. Currently, no treatment of end-stage symptomatic osteoarthritis is 
available and when symptoms become too severe a total joint arthroplasty (TJA) will 
be performed, replacing the affected joint with a prosthesis. Although replacement 
surgery of the hip (THA) or knee (TKA) is safe and commonly performed, up to 20% 
of the patients are unsatisfied with the outcome.1-3 The exact reasons for this 
dissatisfaction are unknown but may vary from the type of surgical procedure itself, 
expectancy of the outcome of arthroplasty surgery to the patient’s preoperative state 
of overall metabolic health. 
This thesis aimed to evaluate some of these aspects related to outcome of TJA, from 
patient perspectives to molecular profiling (e.g. metabolic health). Characteristics of 
different nature were included: material of prosthesis, physical activity, 
questionnaires, clinical measures and metabolomics. This holistic approach enables 
the assessment of more patient specific targets such as advices on treatment 
modalities. Ultimately, selection of patients, both from a patient’s as well as 
orthopaedic surgeon’s perspective, will be optimised for the best intervention (either 
conservative or surgical) for a specific patient. Since osteoarthritis is currently the 
major driver for performing TJA, the conclusion of this thesis will spark future studies 
into OA and its overall effect on disability. 
Post-surgery factors associated with outcome of joint arthroplasty: prosthesis 
and physical activity. 
I  Bearings of prostheses 
Arthroplasty surgery with an implant aims to create a functional painless joint which 
has been destructed by a degenerative disease or even trauma. The overall success 
rate at 10 year follow-up show a mean hip or knee implant survival of 95%, resulting 
in the classification of total hip prosthesis as the operation of  century.4 There are 
many types of implants and within each type a multitude on designs of implants or 
prostheses are on the market. Each design claims to have their own specific benefits. 
One such type of hip-prosthesis is the metal-on-metal bearing total hip prosthesis 
(MoM THA), as with any artificial joint replacement, wear is present upon moving the 
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joint. The wear particles of the MoM THA are submicron metal debris particles 
(mostly chromium and cobalt particles), causing not only local, but also systematic 
reactions. For those reasons, the Netherlands Orthopaedic Association advised 
against its use since 2012, whilst further research was done. 
The overall systematic effect, defined as mortality, of these metal particles was 
assessed by means of a meta-analysis of articles on metal-on-metal total hip 
prostheses, including 47 papers. The overall methodological quality of these papers 
was moderate. All studies suffered from allocation concealment problems and often 
patients, caregivers and outcome assessors were not blinded to the treatment. In 
addition, the observational studies clearly suffered from confounding by indication.  
However, all studies had a 100% compliance with the treatment as is inevitable with 
any implanted joint, as well as high levels of skills and experience by the surgeons. 
As shown in Chapter 2, at 10 year follow-up, there is an increased risk of mortality 
in patients with MoM THA as compared to patients with non-MoM THA: 8.5% risk 
difference (95%CI: 5.8% - 11.2%). The fact that for patients with less than 10-year 
follow-up we did not observe this mortality difference indicates a probable dose-
response association for exposure to metal particles. This dose-response 
association is supported by a meta-regression analysis showing that the duration of 
follow-up was the only effect modifier. 
This severe adverse effect of metal-on-metal prostheses has been demonstrated by 
studies describing cobalt-poisoning in patients with MOM prostheses, of whom the 
symptoms were relieved upon removal of the prosthesis.5-7 On top of this, the 
International Agency for Research on Cancer (IARC) classified chromium as 
“carcinogenic to humans” and cobalt as “possibly-carcinogenic to humans”.8 Surely, 
exposure to chromium has been demonstrated to elevate the risk to develop lung, 
sinonasal and stomach cancer.9-11 Unfortunately, we did not have any information 
on the cause of death of patients with MOM prosthesis in our systematic review.  
The exact effects of the exposure to the metal-ions-cocktail of chromium and cobalt 
for MOM patients are not clear yet, warranting further research into the dose-
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response association of person/hip years exposure to MOM THA.12 In addition, close 
monitoring of patients with a MOM THA prosthesis implanted is paramount. 
II  Postoperative physical activity  
A successful total joint arthroplasty indicates that patients experience an extensive 
reduction in pain, have a better mobility of the joint and consequently experience 
more functionality (e.g. improved daily activities). How this relates to their peers in 
the general population was evaluated in Chapter 3. The functionality of THA and 
TKA patients was compared with the general population, using the level of physical 
activity (PA), as a measure of functionality.  
We assessed both the minutes per week spent on a particular type of physical 
activity as well as the overall adherence to the Dutch guideline for physical activity 
(NNGB, 5 days per week more than 30 minutes of moderate intensity physical 
activity) between both groups.  
Interestingly, THA and TKA patients adhere more often to the NNGB than the 
general Dutch population, when correcting for age, sex, BMI and education level 
(THA: OR 1.79, 95%CI: 1.26-2.56; TKA: OR 1.73, 95%CI: 1.20-2.51). Even more, 
patients who had a hip arthroplasty in the preceding 6-22 months spent more 
minutes on overall physical activity as compared to the general Dutch population 
(13.8% increase, 95%CI: 1.60-27.6%, P=0.024). For TKA, also an increase in the 
min/week on physical activity was observed, however this did not reach statistical 
significance (11.2% increase, 95%CI: -1.4 – 25.6%, P=0.084). 
The increased level of PA in THA and TKA patients may be explained by 
postoperative physiotherapy, making them more prone to adhere to a more active 
lifestyle or may be to the memory of lost mobility in the preoperative state, thus 
underscoring the importance of maintaining mobility for overall functionality. Low-
impact sports such as hiking or cycling are protective against function loss and pain 
associated with OA whereas heavy loading sports may be risk factors for developing 
OA as well as early implant failure.13-17 More studies into the impact of physical 
activity on the development and prevention of OA as well as the recovery of joint 
replacement surgery are necessary to optimize patient care.  
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The level of physical activity in this study was based on validated self-reported 
questionnaires. As is known from several studies, a discrepancy exists between 
outcomes of questionnaires and more objective measures such as accelerometers. 
Indeed a systematic review on physical activity after THA or TKA measured by 
accelerometers found that arthroplasty patients were less physically active than our 
findings which were assessed by questionnaires.18   
A study by Sabia et al.19 found that this discrepancy between self-reported activity 
and accelerometer registered activity is dependent on socio-economic status (SES), 
with persons with a higher SES having a greater correlation between self-reported 
and accelerometer measured level of physical activity. Budget constrains science to 
rely on self-reported physical activity, however with increasing technological 
progress, data on physical activity may in the near future be collected by means of 
apps at the patient’s mobile devices.  
III  Baseline health of the patient  
As the life expectancy is increasing, the prevalence of OA will increase and 
subsequently also the number of performed total joint arthroplasties will increase. In 
the Netherlands, total hip arthroplasty has increased from 23.000 in 2010 to almost 
30.000 primary hips in 2017 and primary total knee arthroplasty has increased from 
20.000 to almost 30.000 implants in 7 years. These numbers underscore the 
importance of discriminating preoperatively which patients will benefit and who will 
not benefit from TJA. The latter improves not only patient care (i.e. optimise non-
surgical treatment) but also reduces unnecessary surgery with subsequent 
unsatisfied patients and health care costs.  
Baseline health factors associated with outcome of joint arthroplasty or OA 
disease status: frailty index, handgrip strength and molecular profiling. 
Since the musculoskeletal system is a high energy-consuming organ, analysis into 
metabolic health of patients is important. We have assessed baseline health status 
in three different ways: first, by a questionnaire focussed on frailty (Chapter 4 and 
Chapter 5), second by means of a physiological measure of muscle quality (Chapter 
6) and third by evaluating blood metabolites in patients (Chapter 7).  
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III A Frailty  
The Groningen Frailty Indicator (GFI) was developed for elderly (aged ≥ 65 years) to 
assess the level of frailty based on the following characteristics; mobility, cognition, 
perception, nutrition, poly-pharma, social status and depression. A first step to use 
it in end stage hip or knee OA patients was to assess the validity and feasibility in a 
population of over 3000 end stage OA patients on a waiting list for arthroplasty 
surgery. The GFI convergent and discriminatory validity in these patients was 
comparable to that in elderly. Using the GFI in our population showed in Chapter 4 
that about one-third of the patients undergoing THA (33%) and a quarter of the 
persons undergoing TKA (24%) are frail (GFI score ≥ 4). 
Using the Frieds Frailty Phenotype (FFP) scoring system, Mandl et al20, found that 
8% of the end-stage knee OA patients experienced frailty. However, this scoring 
system does not include a domain on activities of daily life, which the GFI does 
include. Mandl et al did record the number of patients who report difficulties with 
activity of daily life, this was an additional 17%. Combining these percentages give 
comparable numbers of persons who experience frailty as found by our study using 
the GFI.   
Chapter 5 demonstrated that GFI-determined frail patients scored preoperatively 
lower on each domain of the HOOS/KOOS as compared to the non-frail patients. 
However, both frail and non-frail patients improved similarly after surgery. Therefore, 
not the GFI but the functional level of the patient before surgery was the best 
predictor of functional outcomes after surgery.  
Although the GFI does not preoperatively distinguish between the to be expected 
functional outcomes, frail THA patients did have a significantly higher reoperation 
rate in the year following their primary operation (6.4% in frail THA patients and 2.1% 
in non-frail patients, P=0.005). In TKA the reoperation rate in frail patients was also 
higher, albeit not statistically significant (3.7% in frail patients vs 2.1% in non-frail 
patients, P=0.278). The GFI may not predict functionality after surgery, it does give 
an indication of the success of surgery.  
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The importance of the pre-operative functional score as predictor for postoperative 
outcome raises new questions, such as ‘what is the optimal timing to perform 
arthroplasty surgery’? The longer arthroplasty is postponed by means of pain-
(pain)medication; the functional status of the patient will further decline. Currently 
there are no succinct guidelines for the timing of arthroplasty.21 Optimisation of timing 
of surgery with respect to preoperative health status may improve outcomes. 
Preoperative physiotherapy may boost the functional scores before undergoing 
arthroplasty surgery. Moreover, physiotherapy may change the patient’s lifestyle and 
making him/her more prone to pursue a more active lifestyle after surgery. Although 
preoperative pain levels may prevent physical activity or physiotherapy, it is 
important to assess the patients’ functional state before surgery, and prime patients 
to have an optimal musculoskeletal status before undergoing arthroplasty. 
The fact that the GFI was not predictive for the postoperative outcome score may be 
due to selection bias by the orthopaedic surgeon during the preoperative period. 
Patients who at face value were deemed too frail by the surgeon are most probably 
not selected for TJA surgery and thus not included in this study. Though a surgeon 
does not use a frailty questionnaire, studies have shown that the ‘initial clinical 
impression’ of a physician gives a fair indication to assess the risk of mortality as 
well as of patient’s biological age.22,23 
III B Handgrip Strength 
Although the GFI distinguished to some extend preoperatively between patients with 
good and less favourable outcome after TJA, a more objective clinical measure, such 
as handgrip strength (HGS) may be of better use (Chapter 6). HGS has been 
associated with adverse surgery outcomes and represents overall patient’s strength 
and as such it may be a proxy for frailty.24-26 
The HGS in end stage hip or knee OA patients (i.e. patients indicated for TJA 
surgery) was 34 kg for males and 20 kg for females, which is lower than the reference 
values of 42 kg for healthy males and 26 kg for healthy females of similar age.27 
Preoperative HGS was associated with the majority of the included outcome scores. 
The largest effect was seen for both THA and TKA patients for the domain ‘function 
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in sport and recreation’ of the HOOS/KOOS questionnaire into functional outcomes, 
independent of gender, age, BMI and preoperative score (THA: 0.681, P=0.005; 
TKA: 0.520, P=0.049). For the THA patients, also a moderate effect was found for 
the domain “symptoms” (coefficient 0.564, P=0.001) of these scores. 
This study had only one pre-operative HGS measurement, no measurements were 
made over time in the preoperative period nor post-surgery. However, although only 
one measurement was available, we did find that the pre-operative HGS was 
associated with some specific domains of functional outcome scores. This predictive 
power of HGS for postoperative outcome may improve if multiple preoperative 
measures were available. For that matter, a decline of the HGS, determined by 
multiple measurements, may be a stronger predictor of frailty compared to just one 
measurement. Nevertheless, also one time measurements of HGS, readily 
applicable in clinic, will provide the orthopaedic surgeon as well as the patient 
information on the to be expected outcome of THA and TKA. More accurate 
measurements into muscle mass and muscle quality may lead to better predictions 
of surgery outcomes, however, the measurement of HGS is fairly simple and feasible 
within the current clinical practise.  
III C Metabolites 
Recovering after major surgery like TJA, requires a strong ability to resist stressors. 
A lower ability to resist stressors, i.e. frailty, is reflected by poor metabolic health. 
There may be metabolic profiles that may reflect the susceptibility of a person to 
develop OA, their progression rate and may be key in their response to joint 
replacement surgery. To assess whether specific baseline metabolic profiles 
associate to prevalent OA and may eventually predict patients’ outcome in terms of 
progression of disease, we performed a metabolomics analysis among OA patients 
in both a cross-sectional and a follow-up design. Over 200 different metabolites were 
assessed in 1564 OA cases of whom half had radiographic progression of OA over 
time. Many of the metabolomics parameters are correlated, therefore a principal 
component analysis was used to combine the metabolites into 23 different composite 
scores (i.e. groups of highly correlated metabolites). These composite scores were 
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linked to the different OA-phenotypes (hip OA, end-stage hip OA, hip OA 
progression, knee OA, end stage knee OA and knee OA progression), independent 
of age, sex, fasting status and BMI.  
Three composite scores were found to be associated with both cross-sectional OA 
and OA progression. First, a lower level of a composite score of Histidine and 
Glutamine was associated with both prevalence of hip OA, end-stage hip OA and 
knee OA as well as with OA progression in the knee. This association has not been 
reported earlier.  
Secondly, a composite score of fatty acid make-up was associated with end stage 
hip and knee OA and with progression of hip OA. This composite score consists of 
the fatty acid chain length, the saturated fatty acids ratio and the level of unsaturation 
of fatty acids. This finding is in line with observations in rats showing that long chain 
fatty acids induce both a metabolic syndrome as well as knee OA.28-30  
Finally, we found a composite score of alanine, pyruvate and lactate, markers of 
energy metabolism, to be associated with end stage hip and knee OA and 
progression of hip OA. However, this association was positive in the cross-sectional 
analysis, but was inversely associated with progression of OA. The mechanisms of 
these associations are most probably driven through the energy consumption of 
chondrocytes, which are known to switch from oxidative phosphorylation to 
glycolysis in OA, provided that such a switch is in some way reflected by the 
metabolite profile in the circulation.31 The inverse association for progression of hip 
OA, however, warrants further investigation.  
This metabolomics study places composite scores of fatty acid make-up and energy 
balance, histidine and glutamine at the heart of the link of osteoarthritis and the 
metabolic syndrome. Future research should be aimed at replicating our findings, 
comparing them to OA markers currently used in the clinic and epidemiological 
studies and subsequently further elucidate the mechanisms behind these 
associations. Evidence for a causal link between the observed metabolites and OA 
may be explored by Mendelian Randomization studies in which genetic variants 
associated to the metabolites are tested for association with OA related endpoints.  
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Alternatively, metabolite levels and their relation to OA progression may be explored 
by intervention studies focused on histidine, fatty acid chain length and saturation. 
Physical exercise has well known effects on metabolic switches in the muscle and 
other basic aspects of ageing relevant for OA, such as cellular senescence. Such 
intervention studies may include also OA measures and cartilage tissue which is not 
regularly done.   
The metabolites which were identified in Chapter 7 may not be specific risk factors 
for developing OA, rather they may be markers of an overall state of vulnerability of 
the whole system. This vulnerable state may allow for the development of 
progression in chronic diseases such as OA.  
The analyses presented in this thesis were all performed on previously collected 
data, either by performing a meta-analysis on available literature or by combining 
collected data from different prospective cohorts. Thus these “old” data gave a new 
impulse to research. The latter also stress the importance of making data collected 
for specific research questions available for new research questions. And to combine 
data from different groups to fill in the bigger picture on health related problems as 
well as principles on vitality.  
This thesis stressed the importance of an overall integrated longitudinal study on 
patients, including repeated blood samples as well as patient reported outcome 
questionnaires, HGS and accelerometer measures as well as clinical measures at 
the start of the diagnosis of OA until years after their arthroplasty surgery. Such a 
study may identify markers that can help to distinguish patients with good and less 
favorable outcome and even the likelihood of adverse events after either 
conservative or surgical interventions, but will also give clues on preventive 
measures.  
Conclusions 
The current study is an exhaustive effort to elucidate predictors of outcome 
measures in surgically treated patients with end-stage osteoarthritis, ranging from 
patient reported outcome measures to molecular profiling. Some conclusions can be 
drawn:   
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 Metal-on-metal prostheses have an increased long-term risk of mortality 
(Chapter 2) and require close monitoring. 
 
 Patients with hip or knee prostheses in situ adhere more often to the Dutch 
guideline for physical activity as compared to the general Dutch population 
(Chapter 3).   
 
 The self-reported frailty as measured by Groningen Frailty Indicator is a valid 
questionnaire for end stage hip and knee osteoarthritis patients (Chapter 4), 
however, it does not have value in predicting the functional outcome of 
arthroplasty (Chapter 5). 
 
 Frail patients have lower functional scores before arthroplasty, which may 
influence their functional outcome score after arthroplasty (Chapter 5). 
 
 Handgrip strength is of value in predicting the outcome score on certain 
scales of the functional assessment questionnaire (Chapter 6). 
 
 Osteoarthritis prevalence and progression is associated with certain 
composite scores of blood metabolites emphasizing the metabolic 





The future from a patients’ perspective 
As patients are becoming increasingly more interested in participating in the medical 
decision making process, the orthopedic surgeon needs tools to accurately inform 
patients on what to expect from surgery. The tools presented in this thesis (frailty 
questionnaire, handgrip strength and metabolic profiling) may give a patient and the 
treating orthopedic surgeon more specific individualized data which are associated 
with outcome. These data can be used in the complex process of pre-intervention 
(both conservative as well as surgical) counseling between patient and his/her 
orthopedic surgeon. It will improve the shared-decision-making-process, deciding 
whether it is best to opt for a surgical intervention or first do a serious effort for a 
conservative (physiotherapy / lifestyle interventions) approach to the treatment of 
osteoarthritis.  
In the future evermore measures of the patients’ general wellbeing and daily 
activities can be, and will be, collected; more wearables and apps are designed to 
monitor the patient’s health, but also its shift from normality (which has to be 
defined).32-34 Also, specific questionnaires which are part of cohort studies can be 
admitted to patients by means of apps, leading to a reduction of questions, thus 
saving time and costs and increase efficiency.35 
Virtually every smartphone includes an accelerometer (e.g. pedometer), which 
keeps track of the number of steps, but also quality of walking (e.g. fast, slow or 
uphill) and heartbeat in relation to the activity. Currently, a systematic review is 
conducted on the use of apps in mobile devices as a measure to assess physical 
activity and sedentary behavior.36 Besides monitoring, apps have also potential as 
motivating tools to coach individuals into a more active lifestyle. A good example of 
the potential of stimulating physical activity was the Pokémon-GO rage which urged 
sedentary people to use their musculoskeletal system.37 The SMART-MOVE study 
demonstrated that besides increasing the physical activity levels of the participant, 




Skrepnik et al39 report that the use of a smartphone app (OA GO) which is focused 
on increasing mobility in knee OA patients actually lead to more steps per day. 
Patients who were randomized to follow the application performed better on the six-
minute walking test. With up to 80.2% of the patients following the program for 180 
days and 67.3% of the physicians reporting to be likely or very likely to recommend 
the use of this application, it is a very feasible method to motivate patients with knee 
OA.  
Besides motivating patients during the course of their disease to be physically active, 
prevention is an even more important issue to be addressed in earlier stages of 
health decline. By collecting handgrip strength measurements during lifetime, assess 
frailty every once in a while by means of validated assessments and check the 
metabolic profile of elderly regularly, the patients might be motivated to action 
themselves if data are presented in an accessible, understandable and 
comprehensive way, such as a personal story-board within an app, seems to have 
positive results.40 The person, not-patient-yet, may take action and/or preventative 
measures when a gradual increase of vulnerability is detected, before a person gets 
actually sick. However, any action on presented data should be taken by persons 
themselves and not by an overall controlling system, human integrity of taking 
actions should be safeguarded. 
Such long-term monitoring may prevent disease, lead to earlier detection of disease 
and prevent severe outcomes. Also, by having a clear overview of the patient’s basic 
levels of resistance and vulnerability over time, the final outcomes of an intervention 
such as arthroplasty may be more predictable. Long term monitoring may improve 
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Artrose is een progressieve ziekte die de gewrichten aantast. Door artrose slijt het 
kraakbeen in het gewricht waardoor uiteindelijk bot-op-bot contact ontstaat. 
Bewegen wordt steeds pijnlijker en de patiënt functioneert steeds minder goed in het 
dagelijks leven. De diagnose ‘artrose’ is lastig te stellen omdat er weinig samenhang 
zit tussen de radiologische en de klinische symptomen. Er zijn patiënten met veel 
radiologische schade die weinig pijn ervaren, terwijl er ook patiënten zijn met heel 
veel pijn maar die erg weinig radiologische schade hebben. Op het moment is er nog 
geen genezing mogelijk voor artrose. Medicatie is gericht op symptoombestrijding 
terwijl de ziekte progressief doorgaat met het aantasten van de gewrichten. 
Uiteindelijk zal, als de pijn te erg wordt, een gewrichtsvervangende operatie worden 
uitgevoerd. Deze operaties (totale heup arthroplastiek (THA) voor de heup en totale 
knie arthroplastiek (TKA) voor de knie) worden erg vaak uitgevoerd en 95% van de 
geplaatste protheses blijven tot 15 jaar na de operatie goed zitten. 
Ondanks deze goede prognoses, is toch 15 tot 20% van de mensen die een 
gewrichtsvervangende operatie ondergaan, na afloop niet tevreden. Er zijn vele 
verklaringen te bedenken voor deze slechte uitkomsten zoals operatieve factoren 
(bijv. chirurgische technieken), gewrichtsstatus (bijv. mate van artrose) maar ook 
patiënt gerelateerde factoren zoals verwachtingen, patiënt selectie en preoperatieve 
functionele status. De preoperatieve functionele status van de patiënt is gelinkt aan 
de metabole staat van de patiënt, welke ook invloed heeft op de mate waarop een 
patiënt kan herstellen en revalideren na een operatie. Daarnaast kan de uitkomst 
van een gewrichtsvervangende operatie worden beïnvloed door de prothese zelf, 
waarbij bijvoorbeeld deeltjes, die uit het gewrichtsvlak van de twee delen van de 
prothese slijten, kunnen lijden tot lichamelijke reacties. 
De invloed van de deeltjes die vrijkomen bij een metaal-op-metaal (MOM) 
heupprothese vergeleken met een niet-metal-op-metaal (non-MOM, bijvoorbeeld 
polyethyleen, keramiek of carbon) prothese op mortaliteit is bestudeerd in 
hoofdstuk 2 met behulp van een meta-analyse en systematische review.  
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Zevenenveertig artikelen met 4.000 patiënten uit gerandomiseerde studies en 
500.000 patiënten uit observationele studies werden samengevoegd. Bij een follow-
up van 10 jaar bestond er 8.5% risico verschil ten nadele van de mensen met een 
MOM-heupprothese vergeleken met mensen met een non-MOM heupprothese.  
Bij mensen die de prothese minder dan 10 jaar geleden hadden gekregen vonden 
we dit risico verschil niet. Dit suggereert dat er een dosis-effect relatie is tussen de 
Chroom-Kobalt deeltjes, die vrijkomen bij de MOM-protheses, en de uiteindelijke 
mortaliteit. Er is meer onderzoek nodig naar de exacte mechanismen, daarnaast is 
het belangrijk om de patiënten met een MOM-prosthese van dichtbij te volgen en 
indien nodig hun prothese te vervangen.  
Een goed functionerende prothese betekent dat je deze goed kunt gebruiken in het 
dagelijks leven. Om te kijken in hoeverre mensen met een nieuwe heup of knie 
bewegen in het dagelijks leven hebben we in hoofdstuk 3 de mate van fysieke 
activiteit van patiënten vergeleken met die van de algemene Nederlandse bevolking. 
De waardes van de Nederlandse bevolking worden door het CBS bijgehouden, de 
waardes van de mensen die een gewrichtsvervangende operatie hebben ondergaan 
werden verzameld middels een vragenlijst 6-22 maanden na operatie.  
Wanneer we tijd en intensiteit van beweging per week tussen de groepen vergeleken 
en corrigeerden voor verschil in leeftijd, geslacht, BMI en opleidingsniveau zagen 
we dat mensen met een nieuwe heup of knie vaker voldoen aan de Nederlandse 
Norm Gezond Bewegen (5 dagen per week 30 minuten matig bewegen). Daarnaast 
bewogen mensen met een nieuwe heup zelfs 13.8% meer als we beweging in 
absolute minuten uitdrukten.  
Er zijn verschillende verklaringen te bedenken voor deze vindingen. Zo krijgen 
mensen met een nieuwe heup of knie fysiotherapie tijdens hun revalidatie, wat kan 
leiden tot een verandering van leefstijl. Daarnaast zijn deze mensen meer gefocust 
op de mate waarin zij bewegen, waardoor er een (te) optimistische inschatting 
gemaakt kan worden van de mate van bewegen. 
Ongeveer 80% van de mensen die een gewrichtsvervangende operatie ondergaan 
zijn ouder dan 60 jaar. Het verouderingsproces binnen deze leeftijdsgroep verloopt 
 
144 
heel verschillend. De ene persoon veroudert sneller dan de ander, een proces dat 
gereflecteerd wordt in het concept van “frailty”, oftewel “kwetsbaarheid”.  
Kwetsbaarheid behelst een lagere weerstand tegen ziektes, en weerspiegelt de 
reserves die een patiënt heeft om stressors, zoals een gewrichtsvervangende 
operatie, op te vangen. Zou het zo kunnen zijn dat de mensen met een slechte 
uitkomst een lagere weerstand hebben?  
Om de weerbaarheid van ouderen te meten zijn er verschillende vragenlijsten 
ontworpen. Een van deze vragenlijsten, de Groningen Frailty Indicator (GFI), hebben 
we in hoofdstuk 4 gevalideerd voor artrose patiënten die op de wachtlijst staan om 
een gewricht vervangende operatie te ondergaan. Nadat we hadden aangetoond dat 
de GFI gebruikt kan worden in onze populatie, vonden we dat 33% van de heup- en 
24% van de knie artrose patiënten die binnenkort een gewrichtsvervanging 
ondergaan kwetsbaar zijn.  
In hoofdstuk 5 hebben we gekeken of de uitkomst van een gewrichtsvervangende 
operatie voor deze kwetsbare patiënten verschilt van de niet-kwetsbare patiënten. 
De functionele uitkomsten verbeterden met een vergelijkbare maat in de kwetsbare 
en niet-kwetsbare patiënten, maar omdat de kwetsbare patiënten een slechtere 
functionele score hadden voor de operatie was hun uiteindelijke functionaliteit een 
jaar na de operatie slechter vergeleken met niet-kwetsbare patiënten. 
Het kan dus zo zijn dat het, in het belang van de patiënt, belangrijk is om 
voorafgaand aan de operatie de functionele score te verbeteren door middel van 
bijvoorbeeld pre-operatieve fysiotherapie. Of dat er niet te lang gewacht moet 
worden met het uitvoeren van een gewrichtsvervangende operatie, zodat de patiënt 
niet teveel van zijn/haar functionaliteit verliest. Op dit moment zijn er nog geen vaste 
richtlijnen wanneer een patiënt onder het mes gaat, mede doordat artrose zo’n 
heterogeen ziekte beeld heeft. Meer onderzoek naar het optimale moment voor het 
uitvoeren van een gewrichtsvervangende operatie is nodig. 
Omdat een vragenlijst misschien geen goede reflectie is van kwetsbaarheid, hebben 
we in hoofdstuk 6 gekeken naar een meer objectieve maat: handknijpkracht. Het is 
aangetoond dat handknijpkracht gerelateerd is aan de algemene spierkracht, 
 
145 
gezondheid en mortaliteit. Toegepast in patiënten die een gewrichtsvervangende 
operatie ondergaan, voorspelt handknijpkracht de uitkomst op enkele onderdelen 
van functionele vragenlijsten, namelijk ‘sport & recreatie’ en, voor heup patiënten, 
‘symptomen’ .  
Doordat handknijpkracht een makkelijk te meten maat is, en het iets kan zeggen 
over de te verwachten effecten van de gewrichtsvervangende operatie, kan het 
geïmplementeerd worden in het “shared decision making proces” voorafgaand aan 
de operatie.  
Epidemiologische studies hebben aangetoond dat er een verband is tussen artrose 
en ongezonde metabole parameters zoals hoog BMI, een hoge heup-taille ratio en 
een hoge proportie van vetmassa. Daarnaast is aangetoond dat wanneer een 
artrose patiënt gewicht verliest hij/zij minder last heeft van de symptomen van 
artrose. Dit verband lijkt verklaart te kunnen worden door de mechanische belasting 
van het lichaam op de heup en knie, maar het feit dat dit verband ook is aangetoond 
voor hand-artrose betekent dat er misschien meer aan de hand is. Studies hebben 
aangetoond dat ook klassieke markers voor een slechte metabole status, zoals lage-
dischtheid cholesterol (LDL-cholesterol), gelinkt zijn aan artrose. Zo worden er 
steeds meer aanwijzingen gevonden dat artrose een onderdeel is van het metabool 
syndroom. 
Metabolieten zijn de producten van verschillende lichamelijke processen die 
plaatsvinden op het snijvlak van het genoom en de omgeving. Een metabool profiel 
van een persoon kan een indicatie geven van de metabole status van een patiënt, 
waarbij een slechte metabole staat kan betekenen dat een patiënt meer vatbaar is 
voor de ontwikkeling van allerlei zieken zoals artrose. Daarnaast zou dit metabool 
profiel misschien op de lange termijn een indruk kunnen geven van de 
‘kwetsbaarheid’ van een patiënt en op die manier patiënten met slechte uitkomsten 
pre-operatief onderscheiden van patiënten met een goeie uitkomst.  
Daarom hebben we in hoofdstuk 7 gekeken of er bepaalde metabolieten zijn die 
gerelateerd zijn aan artrose en aan de progressie van artrose. Uiteindelijk hebben 
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we 231 verschillende metabolieten gemeten en deze teruggebracht naar 23 
samengestelde scores van groepjes gecorreleerde metabolieten. Van deze 
metabolieten-groepen lieten er drie interessante associaties zien met zowel 
prevalente artrose als de progressie van artrose.   
Allereerst was er de score die bestond uit histidine en glutamine, welke een 
negatieve associatie liet zien met prevalente heup en knie artrose en met de 
progressie van knie artrose. Daarnaast was een score van de opbouw van vetzuren 
positief geassocieerd met prevalente heup en knie artrose en met progressie van 
heup artrose. Deze score bestond uit de lengte van het vetzuur en de mate waarin 
deze vetzuren verzadigd zijn. Langere verzadigde ketens zijn geassocieerd met 
artrose, daarnaast is al bekend dat deze ook geassocieerd zijn met het metabole 
syndroom. Ten slotte vonden we ook een associatie met een score die bestond uit 
alanine, lactaat en pyruvaat. Alle drie deze metabolieten zijn gelinkt aan de 
energiehuishouding. Deze ‘energie’-score had een positieve associatie met 
prevalente heup en knie artrose en een negatieve associatie met de progressie van 
artrose. Het zou kunnen zijn dat we dit op het oog tegenstrijdige resultaat vinden 
doordat de verbranding van de cel kan omslaan van aëroob naar anaëroob.  
Deze drie scores zullen verder moeten onderzocht om duidelijk te maken hoe deze 
mechanismes werken en hoe ze verband houden met artrose. Desondanks is het 
een aanwijzing dat artrose waarschijnlijk een onderdeel is van het metabole 
syndroom. Misschien zal het hebben van hoge waardes voor deze metabolieten niet 
direct leiden tot de ontwikkeling van artrose, maar waarschijnljk wel tot meer kans 




Riassunto in italiano 
L'osteoartrosi è una malattia progressiva che colpisce le articolazioni. Essa causa 
l'usura della cartilagine nell'articolazione, con il conseguente contatto osso-osseo. 
L'esercizio fisico diventa sempre più doloroso con crescente disabilità per il  
paziente. La diagnosi di osteoartrosi è difficile da stabilire perché c'è poca 
correlazione tra sintomi radiologici e clinici. Ci sono pazienti con molti danni 
radiologici e deformità ossee che sperimentano poco dolore, mentre ci sono anche 
pazienti con molto dolore ma che hanno pochissimi danni radiologici. 
Al momento non esiste una cura per l’osteoartrosi. I farmaci sono mirati al controllo 
dei sintomi mentre la malattia progredisce progressivamente con l'affezione delle 
articolazioni. Se il dolore è troppo grave, viene eseguita un'operazione di 
sostituzione dell'articolazione. Queste operazioni vengono eseguite molto spesso e 
il 95% delle protesi posizionate rimane in sede per più di 15 anni dopo l'operazione. 
Ciò nonostante, il 15-20% delle persone che si sottopongono a un intervento di 
sostituzione dell'anca o ginocchio non sono soddisfatte. I motivi degli esiti avversi 
sono molteplici: fattori chirurgici (ad es. le tecniche chirurgiche), lo stato comune (o 
deformazione grado di osteoartrosi), come fattori correlati al paziente (quali le 
aspettative, la selezione dei pazienti) e lo stato funzionale preoperatorio. Lo stato 
preoperatorio del paziente è legato allo stato metabolico del paziente, che ha anche 
un'influenza sulla misura in cui un paziente può recuperare e riabilitarsi dopo 
un'operazione. Inoltre, il risultato della protesi articolare chirurgico è influenzato dalla 
protesi stessa. Per esempio, le particelle del materiale in cui le due parti della protesi 
è fatta, possono usurarsi e portare a reazioni fisiche. 
L'influenza delle particelle che vengono rilasciati dalle protesi dell’anca metal-on-
metal (MOM) sulla mortalità rispetto a un non-metal-on-metal (non-MOM, ad 
esempio, polietilene, ceramica, o fibra di carbonio) è stato studiato nel Capitolo 2 
usando una meta-analysis e systematic review. Sono stati combinati un totale di 47 
articoli con 4000 pazienti in studi randomizzati e 500.000 pazienti in studi 
osservazionali. Abbiamo scoperto che con al meno 10 anni di follow-up, c'è una 
differenza di rischio dell'8,5% a scapito delle persone con una sostituzione dell'anca 
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MOM rispetto a persone con un diverso tipo di protesi d'anca. Nelle persone che 
avevano ricevuto la protesi meno di 10 anni fa, non abbiamo riscontrato questa 
differenza di rischio. Ciò suggerisce che esiste una relazione dose-effetto tra le 
particelle di cromo-cobalto, rilasciata dalle protesi della MOM, e la mortalità finale. 
Sono necessari ulteriori studi sui meccanismi esatti, inoltre è importante seguire da 
vicino i pazienti che hanno impiantato una protesi MOM e, se necessario, sostituire 
le loro protesi. 
Una protesi correttamente funzionante significa che può essere usata nella vita 
quotidiana. Per vedere fino a che punto le persone con una nuova anca o ginocchio 
si muovono nella vita quotidiana, nel Capitolo 3 abbiamo confrontato il grado di 
attività fisica dei pazienti con quello della popolazione generale olandese. I valori 
della popolazione olandese sono gestiti dalla CBS. I valori delle persone che hanno 
subito un'operazione di sostituzione dell'articolazione sono stati raccolti per mezzo 
di un questionario 6-22 mesi dopo l'intervento chirurgico. I minuti di esercizio a 
settimana sono stati corretti per le differenze di età, sesso, BMI e livello d’istruzione 
e abbiamo osservato che le persone con una protesi dell'anca o del ginocchio hanno 
un livello di attività fisica maggiore rispetto alla popolazione olandese. 
Ci sono diverse spiegazioni per questi risultati. Ad esempio, le persone con una 
nuova anca o ginocchio sono sottoposti a fisioterapia durante la riabilitazione, che 
può portare a un cambiamento dello stile di vita. Inoltre, queste persone sono più 
focalizzate sulla importanza dell’attività fisica e quindi tendono a fare una valutazione 
(troppo) ottimistica del grado di esercizio. 
Circa l'80% delle persone che si sottopongono a un intervento di sostituzione 
dell'articolazione ha più di 60 anni. Il processo di invecchiamento all'interno di questo 
gruppo di età è molto diverso. Una persona invecchia più velocemente dell'altra, un 
processo che si riflette nel concetto di "frailty" o "vulnerabilità". La vulnerabilità 
comporta una minore resistenza alle malattie e riflette le riserve che un paziente ha 
per affrontare i fattori stressanti, come la chirurgia sostitutiva delle articolazioni. 
Potrebbe essere che le persone con esiti avversi abbiano una resistenza inferiore? 
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Per misurare la resistenza degli anziani, sono stati progettati diversi questionari. Uno 
di questi questionari, Groningen Frailty Indicator (GFI), è stato convalidato nel 
Capitolo 4 per i pazienti con osteoartrite in attesa di un intervento di sostituzione 
dell'articolazione. Dopo aver dimostrato che la GFI può essere utilizzata nella nostra 
popolazione, abbiamo scoperto che il 33% dei pazienti dell'anca e il 24% dei pazienti 
del ginocchio che presto subiranno una sostituzione dell'articolazione sono 
vulnerabili. 
Nel Capitolo 5 abbiamo esaminato se l'esito di un'operazione di sostituzione 
articolare per questi pazienti vulnerabili differisce dai pazienti non vulnerabili. I 
risultati funzionali sono migliorati in misura simile nei pazienti vulnerabili e non 
vulnerabili, ma poiché i pazienti vulnerabili avevano un punteggio funzionale 
peggiore prima dell'operazione, il loro punteggio finale rimane peggiore rispetto ai 
pazienti non vulnerabili. 
È quindi possibile che sia nell'interesse del paziente migliorare il punteggio di base 
prima dell'intervento mediante, ad esempio, la terapia fisica preoperatoria. Oppure 
che l'attesa non dovrebbe essere troppo lunga per eseguire un'operazione di 
sostituzione dell'articolazione, in modo che il paziente non perda troppo della sua 
funzionalità. Al momento non ci sono linee guida fisse riguardo a quando un paziente 
si sottopone ad un intervento, in parte perché l'osteoartrosi ha un quadro di malattia 
così eterogeneo. Sono necessarie ulteriori ricerche sul momento ottimale per 
eseguire un'operazione di sostituzione dell'articolazione. 
Poiché un questionario potrebbe non essere un buon riflesso della vulnerabilità, 
abbiamo esaminato una misura più obiettiva nel Capitolo 6: forza di presa della 
mano (FPM). È stato dimostrato che la FPM è correlata alla forza muscolare 
generale, alla salute generale e alla mortalità. Applicato in pazienti sottoposti a 
sostituzioni articolari, la FPM predice il risultato su alcune componenti degli esiti 
funzionali: "Sport e Ricreazione" e, per i pazienti con anca, anche la parte "Sintomi". 
Poiché la forza manuale è una misura facile da misurare e può dire qualcosa sugli 
effetti attesi dell'operazione di sostituzione dell'articolazione, può essere 
implementata nel "processo decisionale condiviso" prima dell'operazione. 
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Studi epidemiologici hanno dimostrato che esiste un legame tra l'osteoartrite e 
parametri metabolici malsani come un alto indice di massa corporea, un alto rapporto 
vita-fianchi e un'alta percentuale di massa grassa. Inoltre, è stato dimostrato che 
quando un paziente affetto da osteoartrite perde peso, soffre meno dei sintomi 
dell'osteoartrosi. Questa connessione sembra essere spiegata dall peso fisico che 
poggia sull'anca e ginocchio, ma il fatto che questa connessione sia stata dimostrata 
anche per l'osteoartrite della mano significa che potrebbe esserci di più. Gli studi 
hanno dimostrato che i marcatori classici per uno scarso status metabolico, come il 
colesterolo a bassa densità (colesterolo LDL), sono collegati all'osteoartrosi. Sono 
presenti in letteratura sempre più evidenze che indicano che l'osteoartrosi è parte 
della sindrome metabolica. 
I metaboliti sono i prodotti di vari processi fisici che avvengono all'intersezione tra il 
genoma e l'ambiente. Un profilo metabolico di una persona può dare un'indicazione 
dello stato metabolico di un paziente: uno scarso stato metabolico può significare 
che un paziente è più suscettibile allo sviluppo di alcuni i tipi di malattie, come 
l'osteoartrosi. Inoltre, questo profilo metabolico potrebbe dare un'indicazione a lungo 
termine della "vulnerabilità" di un paziente e in questo modo distinguere i pazienti 
con esiti negativi prima dell'intervento da pazienti con un buon esito. 
Ecco perché abbiamo esaminato nel Capitolo 7 se ci sono alcuni metaboliti correlati 
all'osteoartrosi e alla progressione dell'osteoartrosi. Infine, abbiamo misurato 231 
diversi metaboliti e li abbiamo ridotti a 23 diversi punteggi compositi di metaboliti 
correlati. Di questi 23 gruppi di metaboliti, tre hanno mostrato interessanti 
associazioni con l'osteoartrosi prevalente e la progressione dell'osteoartrosi. 
Il punteggio costituito da istidina e glutammina mostra un'associazione negativa con 
l'osteoartrosi prevalente dell'anca e del ginocchio e con la progressione 
dell'osteoartrosi del ginocchio. Inoltre, un punteggio composito di accumulo di acidi 
grassi è positivamente associato all'osteoartrosi dell'anca e del ginocchio prevalente 
e alla progressione dell'osteoartrosi dell'anca. Questo punteggio consiste nella 
lunghezza dell'acido grasso e nella misura in cui questi acidi grassi sono saturi. 
Catene saturate più lunghe portano più osteoartrite, è già dimostrato che queste 
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sono anche associate alla sindrome metabolica. Infine, abbiamo anche trovato 
un'associazione con un punteggio costituito da alanina, lattato e piruvato. 
Tutti e tre i punteggi compositi dovranno essere ulteriormente studiati per chiarire 
come funzionano questi meccanismi, ma è chiaramente un suggerimento che 
l'osteoartrosi sia parte della sindrome metabolica. Forse avere valori elevati per 
questi metaboliti non porterà direttamente allo sviluppo dell'osteoartrosi, ma 
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